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SUMMARY
Advances in genome engineering technology over the past four years have triggered
a renaissance for gene therapy prospects. But while researchers have “cured” numerous
single gene disorders in cellular models by repairing the underlying defect in the genome
[64, 103, 84, 70, 49, 133, 41], clinical translation of these findings has progressed much
more slowly. “Off-target” effects of gene therapy remain a major safety concern as the
negative outcomes of the X-SCID clinical trials [46] continue to haunt the field. However,
most researchers do not perform an analysis of the off-target effects of the nucleases they
use or design their nucleases to rationally limit potential off-target effects. This is primarily
attributed to the lack of user-friendly tools and methods that could be easily applied by
researchers who do not have particular expertise in genome-wide bioinformatics analysis.
Furthermore, efforts to optimize homology directed repair (a more versatile genome engi-
neering approach for gene therapy applications) in primary cells have been muted due to
the lack of sensitive assays which can detect incremental—but potentially clinically mean-
ingful—improvements in efficiency at endogenous loci. Therefore, there is a clear need to
develop tools that can be placed into the hands of eager experts in various genetic diseases
to help them translate cellular proof-of-concept studies into more clinically meaningful
results. To address this need, my research developed computational tools to accurately pre-
dict locations of off-target effects and novel DNA sequencing-based methods to sensitively
measure homology directed repair.
The goal of accurately predicting nuclease off-target activity through computational ap-
proaches (as opposed to experimentally examining a nuclease in order to predict off-target
activity) is not new. However, numerous previous attempts failed to uncover any off-target
sites through their computational approaches [54, 129, 26, 103, 66, 134]. To date, no study
xiv
has uncovered unexpected off-target activity of ZFNs or TALENs using computational pre-
dictive modeling apart from the work described in this thesis. We created more advanced
models of ZFN and TALEN binding guided by biological principles of the protein-DNA in-
teractions which allowed us to make the first report of ZFN and TALEN off-target activity
discovered through computational modeling (Fine EJ et al. [34]). Through this analy-
sis, we discovered that alternative ‘NK’ forms of TALENs can have substantially reduced
off-target activity. We then provided this model as an online webtool which allowed any
researcher to easily search for potential off-target sites of their nuclease in a wide variety
of different genomes.
Although our algorithms were able to accurately locate off-target activity, there was
ample room for improvement in the predictive power of the algorithms (particularly with
respect to false-positives). To achieve this, we investigated a large number of nucleases
for off-target activity, achieving an overall ∼230% increase in the number of ZFNs and
TALENs with known off-target sites from 2011 levels ([79, 1], and other manuscripts in
preparation). Through these analyses, we discovered that adding additional zinc finger
modules does not always reduce off-target activity, that rational design of TALEN bind-
ing sites can allow for enhanced discrimination between two similar sequences, that the
locations of off-target are similar between different cell types, and that the frequencies of
off-target activity are very consistent within the same cell type. With a larger training set
of data from which to construct more advanced algorithms, we applied machine learning
techniques to develop a robust framework for ZFN and TALEN off-target prediction and
achieved a ∼10% improvement in the predictive power of the algorithms. The large dataset
of nuclease off-target sites also allowed for the first comprehensive comparison of the ge-
nomic locations of off-target activity of engineered nucleases compared to lentiviral vectors
(Fine EJ and Bao G, submitted). Through this analysis, we discovered that while lentivi-
ral vectors tend to induce off-target activity within cancer-associated genes more frequently
than engineered nucleases, nucleases are much more prone to have off-target activity within
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exons.
Leveraging the long read lengths of SMRT sequencing, we developed a highly sen-
sitive DNA-sequencing based approach to simultaneously measure rates of homology di-
rected repair and non-homologous end-joining in any cell type, at any genomic locus, us-
ing any type of nuclease (Hendel A*, Kildebeck EJ*, Fine EJ* et al. [48]). We validated
the approach against the ‘gold standard’ of sequencing single cell clones and found our
new method to be both precise and accurate, with minimal variance introduced by the ex-
perimental processes and the bioinformatics analysis pipeline. We discovered substantial
variance in the ratios of the two DNA repair pathways at different genomic loci, an effect
that had previously been undiscovered because only artificial reporter constructs had been
able to measure both pathways [15]. We used the system to quantify low (<1%) rates of
homology directed repair occurring in primary human CD34+ and embryonic stem cells.
Furthermore, we demonstrated the use of our system in optimizing gene editing parame-
ters, including plasmid masses and ratios and the length of donor homology arms. We then
used the method specifically to investigate a wide variety of nucleases targeting the HBB
gene and found that CRISPR systems achieved the most favorable homology directed re-
pair rates. Finally, we observed rare cases of exogenous DNA (from sources such as bovine
and E. coli genomes) integrating at the nuclease target site—a phenomenon only observ-
able through the SMRT-based approach—that warrants caution when choosing reagents for
human therapeutic purposes.
Genome engineering has enormous potential to impact human health by curing ge-
netic disorders. However, limitations in available methods have slowed the translation of
this technology. Together, this project has established a toolkit of robust and user-friendly
methods that can be applied by researchers to tackle a wide variety of genetic diseases in





Single gene disorders have a global prevalence of 1/100 births and are estimated to account
for up to 40% of pediatric hospital care in developed countries [99]. While transplants are
curative for some diseases, the discovery that engineered nucleases could create targeted
modifications to the genomes of human cells [90] opened the possibility of curing genetic
disorders by correcting the underlying mutation in the DNA sequence of a patients cells.
Recent advances have made the design of these nucleases much easier [78, 72, 77], allowing
many new researchers to join the field and prompting a rapid increase in the number of ge-
netic diseases that have been corrected in cellular experiments [64, 103, 84, 70, 49, 133, 41].
However, progress in understanding nuclease off-target effects and increasing modification
efficiency in relevant cell types has been limited due to the complexity of current assays
required to obtain those types of data. This thesis aims to fill this gap by developing a user
friendly analysis toolkit that can be used by any lab along with basic molecular biology
techniques to answer questions about off-target effects and gene modification efficiency. I
hypothesized that nuclease off-target effects can be reasonably predicted by bioinfor-
matic modeling and that Single Molecule Real-Time (SMRT) sequencing can yield
sensitive gene modification rates without the use of specialized computing platforms
or complex experimental protocols.
Recent experiments in unbiased assessments of nuclease off-target effects [88, 44] and
analysis of DNA binding domains [78, 28] produced theories that formed the basis of my
new bioinformatic predictive models. Improvements made to the SMRT sequencing plat-
form now allow it to achieve sufficiently long read lengths to make measurement of gene
modification possible [117].
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The objective was accomplished and the central hypothesis was tested through comple-
tion of the following specific aims:
Specific Aim 1: Develop and validate an off-target prediction tool An online search
interface to allow exhaustive searching of a genome for potential nuclease off-target sites
was implemented. Previously discovered off-target sites were collated and ranking algo-
rithms developed that preferentially score validated off-target sites higher than other pre-
dictions. HEK-293T cells transfected with newly developed TALENs and ZFNs targeting
the beta-globin gene were analyzed at the off-target sites predicted by the tool.
Specific Aim 2: Expand off-target data set and refine off-target prediction algo-
rithms Many samples of genomic DNA from cells treated with different ZFNs and TAL-
ENs were analyzed for off-target effects to generate a greatly expanded training set of bona
fide off-target sites. Modifications to the off-target prediction algorithm parameters were
evaluated for improvement through Precision-Recall analysis and several other metrics.
Specific Aim 3: Develop a method to provide molecular data on gene editing events
An analysis pipeline was developed to process SMRT reads to simultaneously measure the
rates of different DNA repair mechanisms by directly examining the DNA sequences. K562
cells were transfected with different types of nucleases and donor repair templates in order
to optimize conditions for repairing the beta-globin gene.
This thesis addresses two issues inhibiting clinical translation of engineered nucleases:
off-target effects and gene editing efficiency. The impact of this work is significant be-
cause it will optimize nuclease treatment conditions for the repair of sickle cell anemia and,
through the development of easier methods, allow other laboratories to optimize nuclease-





This research was the first to accurately predict novel nuclease off-target sites using a
purely bioinformatics-based approach. While previous methods that used experimental
characterization of the nucleases to guide a bioinformatic search of the genome have suc-
cessfully found off-target sites [88, 44, 89, 37, 116, 51], previous purely bioinformatics-
based approaches have failed to locate any novel valid off-target sites [54, 129, 26, 103,
66, 134]. Current methods for experimental characterization of nucleases for off-target
prediction are extremely technically challenging and their use has therefore been effec-
tively limited to the originating laboratory. By accurately predicting potential off-target
sites purely in silico, the ability to investigate off-target activity is now extended to every
laboratory.
Limitations in next generation sequencing technologies and enzymatic assays have
thus far prevented direct molecular analysis of endogenous gene editing events in a high-
throughput manner. Although a fluorescent reporter system has been useful in examining
general aspects of the gene editing process [15], that system is unable to provide data for
editing endogenous gene targets and—while theoretically possible—has yet to be imple-
mented in clinically relevant cell lines due to the difficulty involved. The method developed
in this thesis using SMRT sequencing was the first to provide high-throughput molecular
data that can be used to optimize gene editing conditions using the exact reagents that
would be translated clinically.
At the onset of this work, only two TALENs [116, 51] (See section 2.3.2) and three
ZFNs [88, 44] (See section 2.3.1) had been successfully interrogated for off-target effects,
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uncovering a total of three and ∼120 off-target sites for TALENs and ZFNs respectively.
In order to more thoroughly understand nuclease off-target effects—and how to diminish
them for clinical applications—many more examples, especially for TALENs, needed to
be found in order to search for trends and build meaningful hypotheses. Multiple in sil-
ico prediction attempts were made to discover additional TALEN and ZFN off-target sites
[54, 129, 26, 103, 66, 134], but none were successful—possibly due to their use of only
simplistic bioinformatics models to predict potential off-target sites. This thesis dramati-
cally increased the total number of ZFNs and TALENs which have known off-target
sites which provided a data set to better train off-target predictive models. Better under-
standing of off-target effects will allow for selection of nucleases in pre-clinical stages with
minimal chances of inducing adverse events in patients.
As a whole, this work establish methods to easily interrogate nucleases for off-target
effects and to optimize gene editing conditions. These methods were used in this thesis
specifically to optimize nucleases that target the hemoglobin beta (HBB) gene for correction
of sickle cell anemia. While many high-throughput sequencing and bioinformatics anal-
ysis packages require specialized software or hardware systems that only highly trained
researchers can operate, this thesis developed an analysis toolkit consisting entirely of
user-friendly components that can be run on a standard Windows® machine. Insights
gained through the use of these new methods will lead to improved gene therapy applica-
tions for single gene disorders.
2.2 Sickle Cell Anemia
Sickle cell anemia was the first disease to have its molecular basis uncovered; an A→T
transversion in the sixth codon of the HBB gene creates a missense mutation substitut-
ing valine for glutamate[110]. This mutation causes polymerization of the hemoglobin
molecules under low oxygen tension which causes the red blood cells to adopt a “sickle”
conformation which can lead to vasooclusion. Acute and chronic pain, increased risk of
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stroke, and a drastically shorter life expectancy are hallmarks of the illness. Bone mar-
row stem cell transplants are currently the only cure, but suitable donors are only available
for ∼10% of patients and complications (fatal in some cases) arise during the transplant
process. Because of the simple molecular basis of the disease and the knowledge that allo-
geneic transplants are curative, sickle cell anemia has been a major focus of gene therapy
attempts [103]; by correcting the patient’s own hematopoietic stem cells ex vivo and per-
forming an autologous transplant, the limitations of current allogeneic transplants could be
overcome.
2.3 Engineered Nucleases
Restriction enzymes are common tools in molecular biology due to their ability to recognize
and cleave a specific sequence of DNA. Since DNA is a nucleic acid, these enzymes fall
into the broad class of “nucleases”. While restriction enzymes commonly recognize a
short 6 bp sequence, engineered nucleases expand the concept by targeting an 18-50 bp
sequence. The longer recognition sequence ensures that, even in large genomes, there is
only a single site that perfectly matches the target sequence. There are a few naturally
occurring restriction enzymes that have long (≥ 18 bp) recognition sequences, but they
generally do not target near any region of interest in the human genome. The ability to
re-engineer the sequence that the nuclease targets so that it will recognize a location near a
gene of interest has driven a revolution in genetic studies and formed the basis of the new
field of “genome engineering”.
2.3.1 Zinc Finger Nucleases
Nearly two decades ago, the discovery was made that a DNA binding domain from a “zinc
finger” transcription factor could be fused to the cleavage domain from a restriction enzyme
to create a nuclease—which later became known as a zinc finger nuclease (ZFN)—with a
novel target sequence [60]. Three aspects of this work were critical to the subsequent
proliferation of ZFNs. Firstly, zinc fingers are a modular family of naturally occurring
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Figure 2-1: Protein-DNA interactions of ZFNs (a, b) and TALENs (c, d). Adapted from
Gaj et al.[38]
transcription factors with each subunit—the “finger”—specifying three nucleotides (Fig-
ure 2-1a) and these interchangeable subunits are able to be linked together to recognize
longer sequences.
2.3.2 Transcription Activator-Like Effector Nucleases
In 2009, it was discovered that the transcription activator-like effector (TALE) family of
proteins in pathogenic plant bacteria had a surprisingly simple pattern in its DNA binding
domains to determine what sequence it targeted [78]. The proteins consist of tandem re-
peats of 34 amino acid blocks where all amino acids except the 12th and 13th are constant in
each repeat. The 12th and 13th residues, termed repeat variable di-residues (RVDs), specify
the single nucleotide targeted by that repeat unit (Figure 2-1c). The most common RVDs
create a very simple system: Asparagine-Isoleucine (NI) to target adenosine, His-Asp (HD)
to target cytidine, Asn-Asn (NN) to target guanosine, and Asn-Gly (NG) to target thymi-
dine. Soon after the binding pattern was discovered, designed blocks of TALE repeats
were attached to the FokI cleavage domain to create a new class of engineered nucleases
that became known as TALE nucleases (TALENs) [77] (Figure 2-1d). TALENs have been
used to edit the genomes of rats [116], grasshoppers [129], human embryonic and induced
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pluripotent stem cells [51], and many other animals and cell lines.
Compared to ZFNs, TALENs have certain advantages and disadvantages. Due to the
simple RVD code, it is easy to design TALENs to target a new DNA sequence, and the ma-
jority of TALEN pairs meeting minimal design criteria are able to cut the intended genomic
target [97]. While ZFNs can theoretically target any sequence, using triplets with a motif
other than GNN (where “N” stands for any nucleotide) greatly reduce the chances that the
ZFNs will be able to function correctly in cells. Although studies of TALEN off-target
activity have so far been limited, initial findings suggest that they are more specific than
ZFNs in preferentially cutting their intended target sequence as opposed to other locations
in the genome [51, 116]. The major disadvantage of TALENs is their size—they are ∼4
times larger than ZFNs—which makes delivery into primary cells more difficult because
packaging them into viral delivery vectors has proved troublesome [52].
2.3.3 CRISPR/Cas9 Nucleases
In 2012, it was discovered that the clustered regularly interspaced short palindromic re-
peat (CRISPR) bacterial defense system—that operates by cleaving invading DNA se-
quences—could be co-opted to easily direct cleavage to any DNA sequence of interest
[56]. The combination of a short RNA sequence and the Cas9 protein is all that is required
to cause cleavage at the intended genomic locus. The first 20 bp of the single guide RNA
(sgRNA) strand can be customized to any desired sequence (Figure 2-2) to direct Cas9 to
cleave at the complementary matching site in the genome.
Although the sgRNA fragments are easy to design and construct, they do not confer a
high level of specificity. Many off-target sites with relatively high nuclease-induced muta-
tion rates were easily found for CRISPR/Cas9 systems using very simple search methods
[53, 21] but, counterintuitively, substantially less cytotoxicity is observed than with TAL-
ENs or ZFNs. The Cas9 from Streptococus pyogenes, the version of Cas9 used in nearly
all studies to date, is only one of many different proteins that can be paired with sgRNAs
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Figure 2-2: sgRNA architecture for the CRISPR/Cas9 nuclease system. The sgRNA
consists of a 20-nt guide sequence (blue) and scaffold (red). The scaffold was truncated at
various positions as indicated and the +85 bp scaffold was found to be optimal for achieving
NHEJ. Taken from Hsu, ...Fine et al., Nature Biotechnology 2013 [53].
to act as an engineered nuclease and as of yet Cas9 itself has not been studied for ways
to improve specificity. Because CRISPR systems are so efficient at inducing cleavage and
so simple to design, it is expected that attempts to re-engineer Cas9 to be more specific
or to adapt a different Cas protein will be forthcoming shortly in an effort to determine if
CRISPR could be a viable gene therapy option.
2.3.4 Paired CRISPR/Cas9 Nickases
A recent development to reduce CRISPR off-target effects are paired CRISPR nickases
[95]. While Cas9 normally causes a double strand break in the DNA, these nickases have
one catalytic domain inactivated (commonly through the D10A mutation but also through
H840A) which causes them to only cleave one of the phospho-diester bonds of the DNA
backbone, thereby creating a ‘nick’ rather than a double strand break. Because nicks are
repaired in an error-free manner much more frequently than double strand breaks, indi-
vidual CRISPR guide strands causing nicking at off-target sites in the genome is of less
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Figure 2-3: Paired CRISPR Nickases. A schematic detailing the double offset nicks
generated by a pair of CRISPR nickases. Taken from Ran et al. [95].
concern—reductions in mutation levels at off-target sites exceeded 1400 fold in some cases
for nickases compared to nucleases [95]. In order to promote on-target activity, two guide
strands are deployed that cause offset nicks in nearby sequences in order to create an effect
similar to a double strand break (Figure 2-3). Somewhat surprisingly, studies have found
that these paired nickases can cause on-target mutations at rates even higher than single
CRISPR nucleases [95].
2.4 DNA Repair Pathways
Of all types of DNA damage, breaks in the phosphodiester backbones of both strands of the
double helix in close proximity to each other—termed a double strand break (DSB)—are
the most dangerous to cells [55]. Inattention to these breaks will rapidly lead to genome
instability which can cause programmed cell death or transformation into a cancerous phe-
notype. To prevent this, cells have several different mechanisms to repair DSBs.
2.4.1 Non-Homologous End-Joining
The non-homologous end-joining (NHEJ) repair pathway is the most common DSB repair
pathway in higher eukaryotes [102]. In the case of a clean break—such as the type made
by engineered nucleases—where no DNA bases have been lost and compatible overhangs
are present, NHEJ can often result in an error free re-ligation of the two ends of DNA.
However, if the two strands have begun to diffuse away from each other, end-processing
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enzymes are not able to bind quickly enough, or other circumstances have interfered, NHEJ
can result in small (typically < 50 bp) insertions and deletions (indels) at the site of the
break in the process of re-joining the ends together. In rare cases, exacerbated if there are
a large number of DSBs being generated, NHEJ can re-join two pieces of DNA that were
not originally together, causing chromosomal translocations, gross deletions, or inversions.
2.4.2 Homology Directed Repair
The homology directed repair (HDR) pathway is a slower process than NHEJ, but typically
results in “error-free” repair whereas NHEJ is “error-prone”. Instead of simply re-ligating
the broken DNA ends together, complexes form in HDR to find a section of DNA with
high homology to the regions surrounding the DSB. Typically, the homologous template
is the sister chromatid and therefore HDR is restricted to the S and G2 phases of the cell
cycle (after chromosome replication has taken place), whereas NHEJ can occur at any
stage of the cell cycle. If a homolgous template is found, the broken strands are resected
a short distance, the broken strands then invade the region of homologous DNA, and DNA
polymerases use the homologous DNA as a template to fill in the gap in the original strands
where the DSB occurred.
2.5 Gene Therapy using Engineered Nucleases
While viral gene therapy is useful in many applications, there are several shortcomings.
Viruses cannot knock-out a specified gene, alter the status of the diseased allele, or regulate
the inserted healthy gene in the same manner as the full endogenous promoter. Addition-
ally, viruses integrate at random into the genomes of dividing cells, which can cause the
cells to become cancerous if a sensitive area of the genome is altered. By directly edit-
ing the genetic defect at the in situ location in the genome, engineered nucleases offer the
promise of curing genetic disorders at the most fundamental level: repairing the mutation
causing the disease.
Some potential gene therapy treatments using engineered nucleases involve the NHEJ
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repair pathway. The NHEJ pathway creates small indels during repair of the DSB. If the
DSB induced by the nucleases occurs in the coding sequence of a gene and the length of the
resulting indel is not a multiple of three (roughly 66% of the time), the reading frame of the
downstream sequence will be shifted. In most cases, this frameshift will cause a premature
stop codon which effectively knocks-out the gene; this strategy is used to treat HIV/AIDS
by knocking-out the CCR5 receptor that HIV requires for cell entry [89]. Alternatively, if
the original mutation that causes the disease is a short deletion or insertion that creates a
frameshift, the indels resulting from NHEJ repair can restore the correct reading frame; this
strategy is being developed to treat Duchenne muscular dystrophy by restoring the reading
frame of the dystrophin gene to allow cells to properly express the full length protein [85].
However, since the NHEJ pathway does not allow the exact nature of the DNA modi-
fication to be precisely specified, most potential gene therapy treatments utilize the HDR
repair pathway. While HDR normally uses the sister chromatid as a template to repair the
DSB by restoring the original sequence, if another DNA template with homology to the
region surrounding the DSB is introduced, the cell can use that as a template instead. For
precise genome editing, a plasmid can be constructed containing homologous sequences
stretching ∼400-800 bp upstream and downstream of the site of the DSB—typically called
“arms of homology”—and the desired DNA modifications placed in the region immediately
adjacent (within ∼200 bp) to the DSB between the two arms of homology (Figure 2-4). This
plasmid can then act as a template for HDR repair, “donating” the desired DNA sequence
into the genome at the location of the DSB to replace the endogenous sequence.
HDR-based engineered nuclease gene therapies have been validated in cell lines for
several diseases. The single point mutations causing sickle cell anemia [103], epidermol-
ysis bullosa [84], α1-antitrypsin deficiency [133], and inactive versions of the p53 tumor
suppressor protein [49] as well as the three bp deletion causing most forms of cystic fibro-
sis (∆508) [64] have all been repaired using ZFNs or TALENs. For diseases where a range
of mutations throughout the gene exists in the patient population, a healthy version of the
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Figure 2-4: Donor plasmid repair template for precise genome editing using HDR.
Adapted from Sigma Aldrich Biowire Fall 2010.
full length cDNA for the gene can be placed between the arms of homology and targeted
to the start codon of the gene; this approach has been used to insert healthy copies of the
IL2Rγ gene to correct severe combined immunodeficiency (SCID) [70]. The advantage
of the cDNA approach using engineered nucleases over viruses is that since the cDNA is
targeted to the endogenous location of the gene instead of randomly integrated, it will be
under the control of the entire endogenous promoter, including any distal elements, which
will encourage a more natural gene expression pattern.
2.6 Experimental-based Off-Target Prediction Methods1
Most previous studies of nuclease off-target activity have used experimental characteri-
zation of the specific nuclease in order to predict potential off-target sites. Although
experimental-based prediction methods are generally quite effective (nearly all publications
employing them have located at least one bona fide nuclease off-target site), they are very
1Modified from: Fine et al. (in press). Strategies to Determine Off-Target Effects of Engineered Nucle-
ases. Springer.
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technically challenging, costly, and time intensive. Because of the difficulty of implement-
ing these techniques, most have never been replicated outside of the original laboratories
in which they were developed.
2.6.1 SELEX
Systematic Evolution of Ligands by Exponential Enrichment (SELEX) is an established
technique for determining nucleic acid sequences that have high affinity for target molecules.
This approach has been used to ascertain nuclease specificity in works from the laborato-
ries of Sangamo Biosciences. SELEX has been used to determine the binding preference
of ZFNs [50, 89] and TALENs [77, 116, 51] and subsequently to guide bioinformatics
searches for potential genomic off-target sites. The general approach is to (i) genetically
tag the nuclease with an affinity molecule, such as hemagglutinin (HA), (ii) express the nu-
clease in vitro, (iii) incubate it with a semi-randomized library of oligonucleotides (usually
biased towards the expected binding site of the nuclease), (iv) capture the nuclease protein
using antibodies, and (v) PCR the bound DNA fragments to amplify them. Steps (iii)-(v)
are then repeated for multiple rounds of enrichment with the PCR products from step (v)
replacing the initial semi-randomized library in step (iii). After the desired number of se-
lection rounds, the PCR amplicons are sequenced to determine the identity of the selected
DNA. SELEX typically yields 20-50 unique sequences that were bound by the nucleases or
DNA binding domains [77]; if too few or too many unique sequences are found, amplicons
from prior rounds can be sequenced or additional rounds of selection can be carried out.
These sequences can be compiled to form position weight matrices (PWMs) indicating the
binding preferences of the nuclease at each position (Figure 2-5).
Once PWMs for each nuclease half-site have been established, the genome can be
searched bioinformatically and scores calculated for each position. Each potential bi-partite
nuclease off-target siteone half-site, separated by an appropriate length spacer sequence,
and the other half-sitecan be given a score by calculating the product of the values of the
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Figure 2-5: SELEX characterization of zinc finger binding domains. The positive y-
axis represents a preference for the intended base at that binding position. The negative
y-axis represents preferences for alternative bases at that position. Adapted from Perez et
al. [89]
PWM for each nucleotide comprising the potential off-target site (Note: the authors from
Sangamo did not publish their formula for generating a score from the PWMs, but calcu-
lating the product of all positions provides a close approximation [20]). All sites in the
genome can then be ranked and a subset can be chosen for further investigation.
This technique has faced several criticisms, but has proven remarkably robust at finding
off-target sites for both ZFNs and TALENs. Drawbacks of this technique include the fact
that it only provides information about the binding preferences of each nuclease half-site,
therefore ignoring interactions between the two half-sites required for nuclease cleavage.
Another limitation is that it is performed completely in vitro, therefore ignoring changes
that may occur to the protein in the cellular environment as well as ignoring any factors that
may affect the genomic DNA at the potential off-target sites in the cells, such as chromatin
structure, accessibility, and methylation status. Finally, because the starting oligonucleotide
library is only semi-randomized, this method is biased towards finding sites with relatively
high homology to the intended nuclease target. Nevertheless, this has been the most pub-
lished experimental characterization technique for successfully finding nuclease off-target
sites and is one of only two experimental-based prediction technique thus far published that
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has found bona fide TALEN off-target sites [116, 51].
2.6.2 Bacterial One-Hybrid
The bacterial one-hybrid (B1H) approach is similar to SELEX in that it analyzes the bind-
ing preferences of nuclease monomers. To begin, a library of reporter plasmids is generated
with a semi-randomized (biased towards the intended nuclease target) region upstream of
the reported gene. This library is co-transformed into bacteria along with a plasmid en-
coding the nuclease DNA binding domain fused to a transcriptional activator [44]. E. coli
colonies expressing the reporter gene, due to the nuclease DNA binding domain having suf-
ficient affinity for the sequence in the plasmid to be able to activate the gene, are selected
and the plasmid is sequenced to determine the sequence of the semi-randomized binding
site. All sequences recovered from the E. coli colonies are compiled to create a PWM that
can be used to screen the genome for potential off-target sites in the same way as the SE-
LEX method. Using B1H for nuclease off-target prediction was developed by Scot Wolfe’s
laboratory which has been the only group to employ this method so far, and only for pre-
dicting off-target activity of ZFNs [44]. This approach faces many of the same criticisms
as SELEX relating to the analysis of single monomers, but it has the advantage of being
performed in a cellular (albeit bacterial and not eukaryotic) environment which may better
model protein-DNA interactions than a completely in vitro analysis.
2.6.3 In vitro cleavage
Unlike the previous two prediction methods that separately characterize the DNA binding
abilities of each monomer, in vitro cleavage assays explicitly investigate which DNA se-
quences in a random pool can be cut by a nuclease [88]. This approach has been applied
to ZFNs [88], TALENs [43], and CRISPRs [87], but has only been in studies published
by David Lius laboratory. In this approach, a semi-randomized oligonucleotide library is
synthesized that consists of the full nuclease recognition site. For paired nucleases (such
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as ZFNs, TALENs, or paired CRISPR nickases), the half-sites of both monomers are in-
cluded, separated by appropriate length spacer sequences. The nuclease is then expressed
in vitro, and incubated with the oligonucleotide library. Several enzymatic and gel isolation
steps allow separation of sequences cleaved by the nuclease. Libraries are deep sequenced
before and after nuclease incubation to identity the sequences cleaved by the nuclease. A
bioinformatics search is then performed to determine if any of the sites that were cleaved
in vitro also exist in the genome of interest. These sites can then be assayed for off-target
activity.
There are several advantages and limitations of this technique. By examining nuclease
cleavage instead of merely binding, insights were gained in the original study [88] that
led to the hypothesis of an “energy compensation” model of dimeric ZFN interactions
where larger numbers of mismatches in one half-site can be compensated by few or no
mismatches in the other half-site. However, as this technique is performed entirely in vitro,
effects of the cellular environment on the nuclease and genomic DNA are not accounted for.
Furthermore, since the oligonucleotide library is semi-randomized, the analysis is biased
towards finding sites with higher levels of homology to the intended nuclease target site.
An extension to this approach was recently developed to make better use of the large
amount of data generated [101]. The original applications of this method searched through
genomes to find exact matches to sequences that had been cleaved [88, 87], but those
sequences that matched the genome were only a small fraction of the total sequences that
the nuclease was shown to be able to cleave. By applying a Bayesian machine learning
algorithm to the full list of sequences that the CCR5 and VEGF ZFNs were confirmed to
cleave in the original study, classifiers were developed for each nuclease that could generate
a score for any given sequence predicting the likelihood of cleavage. The full genome was
then screened bioinformatically—in a similar manner to the PWM screening in the SELEX
and B1H methods—for sites that scored highly by the classifier. The analysis of off-target
activity at the sites predicted by this method demonstrated that it could locate bona fide
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off-target sites with relatively low sequence homology and sites that have low activity.
Impressively, this method also appears to have a fairly low false discovery rate that resulted
in the analysis locating a large number of new bona fide off-target sites for both the CCR5
and VEGF ZFNs [101] and two TALENs targeting CCR5 and ATM [43]. Unfortunately,
the incredibly difficult and time consuming nature of this approach that must be performed
for each nuclease to be studied—conducting the in vitro cleavage experiments and then
subsequently building a Bayesian classifier using machine learning—will likely severely
limit the number of nucleases that are studied using this method.
2.6.4 IDLV LAM-PCR
Integrase-Deficient Lentiviral Vector Linear Amplification Mediated Polymerase Chain
Reaction (IDLV LAM-PCR) is one of the two off-target prediction methods that is per-
formed in the full intracellular environment. This approach was developed by Christof von
Kalle’s laboratory [37] and thus far, they have the only publications using this method. In
this approach, the cells are transduced by an IDLV encoding a selectable marker, such as
green fluorescent protein (GFP). Because the virus is integrase deficient, its ability to inte-
grate into the genome is severely limited. Therefore, cultured dividing cells would rapidly
dilute the IDLV gene sequence after several weeks, as it is not replicated during cell di-
vision. If nucleases are added, the resulting DSB can lead to a much higher efficiency of
IDLV integration into the cellular genome. In this case then, after culturing dividing cells
for several weeks, a larger fraction of nuclease treated cells express the selectable marker
compared to control cells. These cells are then selected and viral integration site analysis
is performed. Briefly, their approach was to use LAM-PCR on the genomic DNA using
primers that bind to the long terminal repeat (LTR) regions of the IDLV. The amplicons re-
sulting from LAM-PCR include a portion of the genomic sequence flanking the LTR, and
therefore the location of the integration site of the IDLV can be deduced by high-throughput
sequencing of the amplicons. Clustered integration site (CLIS) analysis is performed to
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filter out much of the random integration by imposing a criteria that two independent in-
tegration sites must be observed within 500 bp of each other in order for that locus to be
considered a potential site of nuclease activity (although fragile sites in the genome are
also prone to clustered integration sites). The next step is to search the sequence space
surrounding the CLIS locus for a region with homology to the intended nuclease target that
might be a location of bona fide nuclease cleavage activity; random sequence space has an
expected level of ∼45% homology to the nuclease target [37], so sequences with > 60%
homology to the nuclease target are likely candidates. The predicted off-target sites can
then be interrogated in cells treated with nucleases without the IDLV.
The major limitation of this approach is its lack of sensitivity. This drawback is an
inherent part of the method since the underlying process relies on the relatively rare event
of the IDLV being captured during the repair of a DSB. Consequently, many off-target
sites, especially those with lower activity, are overlooked; the IDLV LAM-PCR analysis
of the hetero-obligate CCR5 ZFNs [37] predicted only four of the 38 known off-target
sites [101, 34]. This method has thus far only been successfully used to locate ZFN off-
target sites; an attempt was made using it to locate TALEN off-target sites, but very few
cases of CLIS were observed and no attempt was made to validate off-target activity at the
predicted loci [84]. However, this approach does provide an unbiased survey of any highly
active off-target sites in the full intracellular environment with the cells genome in its native
structure. Because it is not biased by oligonucleotide selection libraries, this method was
able to locate bona fide off-target sites with extremely low (66%) homology to the intended
nuclease target [37]. As this method lacks sensitivity, it may not be optimal for testing
nucleases for potential use as human therapeutics—or other applications where even rare
off-target cleavage could cause adverse events—but it remains a highly useful research tool
because its unbiased nature allows it to uncover sites that might not fit standard models




Chromatin immunoprecipitation followed by deep sequencing (ChIP-Seq) is a well-established
method for determining what sequences in a genome a certain protein binds. ChIP-Seq in-
volves genetically tagging the nuclease with an affinity epitope (commonly hemagglutinin)
and catalytically inactivating the nuclease (so that it binds but does not cleave DNA), ex-
pressing the modified nuclease in cells, cross-linking the protein and DNA together, shear-
ing the genomic DNA into smaller fragments, purifying the nuclease (and the DNA frag-
ments to which it is cross-linked) using antibodies (immunoprecipitation), sequencing the
DNA fragments bound to the nuclease, and then mapping those sequences to the genome.
In early 2013 it was noted how well the idea of ChIP-Seq seemed to be suited to facilitating
an unbiased genome-wide survey of nuclease off-target activity in living cells [104], but
the results of recent studies thus far have not been as promising as initially hoped.
Dimeric nucleasessuch as ZFNs, TALENs, RFNs, and paired Cas9 nickasespresent spe-
cial challenges for ChIP-Seq. As noted in an unsuccessful attempt in late 2013 to use ChIP-
Seq to identify off-target sites of the CCR5 ZFNs: “thousands of high affinity monomeric
target sites may exist in the genome, however a monomer is not sufficient to generate a
lesion. Alternatively, dimeric ZFN sites that are bound weakly by both monomers may be
sufficient to cleave DNA at a low frequency but may not bind stably enough to be detected
reliably via ChIP” [101].
Because Cas9 can act as a monomeric nuclease, three groups attempted to use ChIP-Seq
to locate CRISPR/Cas9 off-target sites in early 2014. While Cas9 binding was observed at
many (up to thousands, depending on the gRNA used) sites throughout the genome other
than the intended target site, off-target nuclease activity (NHEJ) was only found at a tiny
fraction of the sites interrogated by two of the groups [130, 82], indicating that this method
has a very high false positive rate as a method of discovery of off-target nuclease activity.
In summary, ChIP-Seq has not yet become a reliable method to predict off-target nucle-
ase activity. Although it identifies the on-target site with reasonably accuracy , ChIP-Seq
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may be fundamentally ill-suited to identifying off-target sites of nuclease activity. Emerg-
ing evidence into the mechanism of Cas9 shows that it uses a multi-step approach to DNA
cleavage [130, 111]: binding to many points along a chromosome as it pauses in the search
for a target matching the gRNA but only cleaving when a good match is found. ChIP-Seq
detects all binding events which leads to very high false positive prediction rates of nu-
clease activity. Without a method to discriminate between binding and cleavage events,
ChIP-Seq may be incapable of detecting sites of low frequency off-target cleavage because
the ChIP-Seq signal at those sites may not rise above the background noise.
2.7 SMRT Sequencing
Single molecule real-time (SMRT) sequencing is a recently developed “third-generation”
sequencing platform with different strengths and weaknesses compared to the “next-generation”
sequencing (NGS) platforms such as Illumina and Ion Torrent. Chief among these tradeoffs
is throughput versus read length. While NGS platforms can sequence millions of pieces of
DNA in parallel, they cannot provide reliable information about sequences longer than
∼400 bp [93]. In contrast, SMRT sequencing has lower throughput—providing information
about tens of thousands of pieces of DNA instead of millions—but can provide highly ac-
curate information about much longer pieces of DNA; when sequencing 900 bp samples,
nearly half of the reads have an average QV score of > 40, meaning that the error rate is
less than one in ten thousand bases. Examining longer pieces of DNA (> 600 bp) is critical
to gaining a full understanding of the different types of DNA repair events occurring after a
nuclease induced DSB. SMRT sequencing achieves this high accuracy by having the DNA
polymerase iteratively loop around the amplicon multiple times (Figure 2-6).
Beyond the technical differences between SMRT and NGS sequencing, there are sev-
eral aspects that make SMRT a more favorable choice for a system designed to be user-
friendly and accessible to any lab. The average cost per sequenced DNA base is substan-
tially cheaper for NGS systems than for SMRT [93], however the cost per sequencing
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Figure 2-6: SMRT sequencing process. Adapted from Hendel*, Kildebeck*, Fine* et al.
[48]
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reaction is much lower for SMRT. This is because each NGS run provides a much larger
amount of data than each SMRT run. For a core facility analyzing dozens of different nu-
cleases on a regular basis, NGS platforms would hold a strong price advantage. But for a
single lab that wants to analyze just a few experiments, an NGS run would cost much more
than a SMRT run and would generate an amount of sequencing data far in excess of what
would be needed to answer their questions. Additionally, there are various restrictions and
requirements for the sizes of amplicons and adapter sequences that must be used for NGS
platforms that can make the process difficult for novice users, whereas SMRT only requires
that within each sequencing run the amplicons are of roughly the same length (±100 bp).
For this proposal, the only effect of that SMRT requirement is that off-target and gene edit-
ing investigations are sequenced separately, which makes SMRT much more user-friendly
for a lab without extensive sequencing experience.
2.8 Machine Learning
Machine learning involves looking for predictive patterns in large datasets. Each item in
the dataset is accompanied by a list of attributes—also known as ‘features’—which can be
readily observed which the machine uses an inputs into its algorithm in order to predict
an unknown attribute. How each feature is weighted and other features of the algorithm
are customized to the question at hand by ‘training’ the algorithm on a dataset where the
desired attribute is known. In this manner, the machine can select parameters which result
in a close fit between the predictions of the algorithm and the known results.
2.8.1 Feature Extraction
Most machine learning algorithms work best when the ‘features’ of the dataset are numeri-
cal values, however many experimental attributes do not naturally exist in that state. While
percentages, concentrations, and temperatures can easily be formatted into machine learn-
ing features, other types of data (such as diverse lengths of DNA sequences representing
potential nuclease off-target sites) present more of a challenge. The process of creating
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numerical representations of complex data that can be used as machine learning input is
known as ‘feature extraction’ and is as much an art as a science, analogous to determining
how best to quantify microscopy images.
2.8.2 Learning Algorithms
Most machine learning algorithms fall into the following three categories:
Classification Predicting an item’s category based on other available attributes
Regression Predicting a quantitative value for an item based on other available attributes
Clustering Determining groups of items which are similar to each other based on available
attributes
For the purposes of predicting off-target activity, clustering algorithms are not as relevant
because it is known (for the sites in the algorithm development dataset) whether a site
is or is not a bona fide off-target site. Additionally, while using regression algorithms to
accurately predict exact levels of off-target activity would be extremely useful, with current
available datasets it is not yet feasible (for reasons discussed further in Section 5.3.3).
Understanding how classification algorithms work can be facilitated using the following
model. Consider a case where there are only two ‘features’ of a datapoint; all datapoints can
then be plotted on a simple plot with one feature on the x and y axes respectively. The goal
of the classification algorithm is to find a line which can divide the data such that the two
different classes fall on opposite sides of the line while the relative emphasis placed on false
positives and false negatives is given through tuning the algorithm parameters (Figure 2-7).
As the model becomes more complex, the dataset is plotted in multi-dimensional space and




Figure 2-7: Classification Algorithm Model. Two different dataset classes (red circles
and blue pluses) are plotted according to their two features (x- and y-axes). A line sep-
arating the two classes is determined by the classification algorithm. Different algorithm
parameters can result in lower false positive (left) or false negative (right) rates. Figure
modified from Ben-Hur and Weston [6]
.
In a binary classification problem, performance metrics are based on the values of the
‘confusion matrix’ (Table 2-1). Three commonly used attributes of the confusion matrix
are:
‘True Positive Rate’ or ‘Recall’: When it’s actually yes, how often does it predict yes?
• True Positives divided by the number of positives in the dataset (‘Actual Yes’)
– Method 1: 9
10
= 0.9
– Method 2: 9
10
= 0.9
False Positive Rate: When it’s actually no, how often does it predict yes?
• False Positives divided by the number of negatives in the dataset (‘Actual No’)
– Method 1: 1
99990
= 1 ∗ 10−5
– Method 2: 191
99990
= 191 ∗ 10−5
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Precision: When it predicts yes, how often is it correct?
• True Positives divided by the number of predicted positives (‘Predicted Yes’)
– Method 1: 9
10
= 0.900
– Method 2: 9
200
= 0.045
The most frequently used performance metric is known as the “Receiver Operating Charac-
teristic” (ROC). ROC is based on the True Positive Rate and the False Positive Rate. While
ROC is a informative metric for many cases, it is not as useful in datasets where the pos-
itives are greatly outnumbered by the negatives (as in the case of a small number of bona
fide nuclease off-target sites mixed in with a very large number of additional sites in the
genome with some homology to the intended nuclease target). For example, compare the
two methods in Table 2-1; both classifiers retrieve the same number of true positives (and
therefore have the same ‘True Positive Rate’ / ‘Recall’), but method 2 has a much higher
number of false positives and is therefore clearly inferior. Using the False Positive Rate
component of the ROC metric, the two rates have only a small difference of 0.0019 (see
above definition of False Positive Rate) which masks the performance difference.
An alternative to the ROC that is particularly well-suited to cases with large numbers
of negatives in the dataset is “Precision-Recall”. The Precision measurements of these two
methods show a large difference of 0.855 (see above definition of Precision), accurately
capturing the considerable difference in the performance of the two classifiers.
The examples above calculated precision and recall for a specific data point, but in eval-
uating algorithm performance, precision is evaluated for all possible recalls to form a two
dimensional curve (Figure 2-8). Precision-Recall curves typically trend from the upper left
(high precision, low recall) to the bottom right (low precision, high recall), signifying that
an algorithm becomes less precise as it is required to recovers more of the true positives.
The overall performance of the algorithm is quantified by calculating the area under the
curve (AUC) and is termed the ‘average precision’. Precision-Recall curves often exhibit a
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Table 2-1: Sample Confusion Matrix. Categorization of classifier predictions for a sam-
ple dataset. TN–True Negative. FN–False Negative. FP–False Positive. TP–True Positive.











NO 99,989 (TN) 1 (FP) 99,799 191
Actual:
YES 1 (FN) 9 (TP) 1 9
99,990 10 99,800 200
jagged ‘sawtooth’ like appearance due to the fact that finding several true positives in quick
succession can actually cause an increase in the measured precision even at a higher recall
value.
2.8.4 Cross-validation
In order to mitigate the possibility of over-fitting the model to the training data, cross-
validation approaches are typically employed. Cross-validation (Figure 2-9) consists of
randomly dividing a training set into several equal parts, using all but one subset of those
parts as a training set, and then testing the model’s predictive abilites on the “hold-out” data
set (also known as the “test-set”). The process is then repeated choosing different subsets
as the “hold-out” data set and the performance is averaged across all of the tested subsets.
Additional cross-validation can be performed by iteratively repeating the whole previously
described process with different randomized divisions of the dataset.
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Figure 2-8: Precision-Recall Curve. Figure obtained from Davis and Goadrich [25].
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Figure 2-9: Cross Validation. A dataset consisting of two different classes (red cir-
cles and green circles) is broken up into a test set and a training set for each fold of




DEVELOPMENT OF AN ONLINE BIOINFORMATICS TOOL TO
PREDICT ZFN AND TALEN OFF-TARGET SITES1
3.1 Abstract
Although engineered nucleases can efficiently cleave intracellular DNA at desired target
sites, major concerns remain on potential off-target cleavage that may occur throughout the
genome. We developed an online tool: Predicted Report Of Genome-wide Nuclease Off-
target Sites (PROGNOS) that effectively identifies off-target sites. The initial bioinformat-
ics algorithms in PROGNOS were validated by predicting 44 of 65 previously confirmed
off-target sites, and by uncovering a new off-target site for the extensively studied zinc
finger nucleases (ZFNs) targeting C-C chemokine receptor type 5. Using PROGNOS, we
rapidly interrogated 128 potential off-target sites for newly designed transcription activator-
like effector nucleases containing either Asn-Asn (NN) or Asn-Lys (NK) repeat variable
di-residues (RVDs) and 3- and 4-finger ZFNs, and validated 13 bona fide off-target sites
for these nucleases by DNA sequencing. The PROGNOS algorithms were further refined
by incorporating additional features of nuclease-DNA interactions and the newly confirmed
off-target sites into the training set, which increased the percentage of bona fide off-target
sites found within the top PROGNOS rankings. By identifying potential off-target sites in
silico, PROGNOS allows the selection of more specific target sites and aids the identifica-
tion of bona fide off-target sites, significantly facilitating the design of engineered nucleases
for genome editing applications.
1Modified from: Fine EJ et al. (2013). An online bioinformatics tool predicts zinc finger and TALE
nuclease off-target cleavage. Nucleic Acids Research [34]
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3.2 Introduction
The efficiency of genome editing in cells is greatly increased by specific DNA cleavage with
zinc finger nucleases (ZFNs) or transcription activator-like (TAL) effector nucleases (TAL-
ENs), which have been used to create new model organisms [54, 66, 134, 129, 116, 44],
correct disease-causing mutations [103], and genetically engineer stem cells [51]. How-
ever, both ZFNs [44, 88, 37, 101] and TALENs [116, 51] have off-target cleavage that can
lead to genomic instability, chromosomal rearrangement, and disruption of the function
of other genes. It is vitally important to identify the locations and frequency of off-target
cleavage to reduce these adverse events, and ensure the specificity and safety of nuclease-
based genome editing. Although the emerging systems utilizing clustered regularly in-
terspaced short palindromic repeats (CRISPR) and CRISPR associated (Cas) proteins are
highly active at their intended target sites, recent publications indicate that they likely have
much greater levels of off-target cleavage than ZFNs or TALENs [53, 21, 35].
Experimental identification of ZFN and TALEN off-target sites is a daunting task be-
cause of the size of genome and the large number of potential cleavage sites to assay.
Previous attempts to identify new off-target sites based entirely on bioinformatics search
methods have all failed to locate any off-target cleavage sites [54, 129, 26, 103, 66, 134],
which has led to the belief that identifying off-target activity based on sequence homology
alone would not be fruitful [37]. In contrast, efforts using experimental methods to char-
acterize the specificity of nucleases have successfully identified several off-target cleavage
sites for ZFNs [44, 88, 37, 101] and TALENs [116, 51]. While most of these characteri-
zation methods incorporate a bioinformatics component to search through the genome, the
final decision of what sites to investigate is dictated by the experimental data; for example,
Perez et al. applied a classifier based on their characterization of the nucleases to narrow
the full list of 136 genomic sites with two or fewer mismatches in each ZFN down to the top
15 sites they chose to interrogate [89].However, these experimental characterization meth-
ods, including SELEX [89, 50, 51, 116], bacterial one-hybrid [44], in vitro cleavage [88],
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or IDLV trapping [37], can be very time consuming, costly, and technically challenging.
This has severely limited the number of laboratories undertaking these experiments and the
number of nucleases characterized for off-target effects. There is a clear unmet need for a
rapid and scalable online method that can predict nuclease off-target sites with reasonable
accuracy without requiring the user to have specialized computational skills, especially for
application of nucleases in disease treatment.
3.3 Methods
3.3.1 Major Features of PROGNOS Ranking Algorithms
All PROGNOS algorithms only require the DNA target sequence as input; prior construc-
tion and experimental characterization of the specific nucleases are not necessary. Based
on the differences between the sequence of a potential off-target site in the genome and
the intended target sequence, each algorithm generates a score that is used to rank poten-
tial off-target sites. If two (or more) potential off-target sites have equal scores, they are
further ranked by the type of genomic region annotated for each site with the following
order: Exon > Promoter > Intron > Intergenic. A final ranking by chromosomal location
is employed as a tie-breaker to ensure consistency in the ranking order.
The average 5’ base and RVD-nucleotide frequencies for engineered TALEs were cal-
culated by compiling previously published SELEX results of nine engineered TALEs [77,
51, 116] and calculating frequency matrices (Table 3-1).
The PROGNOS algorithm operates in three stages. First, all potential off-target sites
that meet the search criteria (spacing distances, number of mismatches, etc.) are located.
Second, these sites are all assigned a score according to the different algorithms. Finally,
these sites are ranked by their scores and PCR primers are designed for top ranking sites.
3.3.2 PROGNOS Homology, RVDs and Conserved G’s Algorithms
The ‘Homology’, ‘RVDs’, and ‘Conserved G’s’ algorithms in PROGNOS all apply the “en-
ergy compensation” model of dimeric nuclease cleavage [88] to account for the interactions
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Table 3-1: Comparisons of SELEX studies of engineered TALs to TALE-NT fre-
quency matrix. The frequencies of RVD-nucleotide binding derived from natural TAL
Effectors in Supplementary Table 1 from Doyle et al. [28] were subtracted from the aver-
ages of SELEX data from engineered TALs. A positive number implies that the RVD is
predicted to be more likely to associate with that nucleotide in engineered TALs compared
to naturally occurring TAL Effectors.
SELEX Averages from all TAL domains
Count A C G T
5’ Base 9 0.053333 0.037942 0.008889 0.900947
NI 23 0.825696 0.077411 0.072375 0.024517
HD 52 0.075316 0.882704 0.009886 0.031709
NK 6 0.058025 0.012346 0.9 0.02963
NN 21 0.225663 0.04575 0.661518 0.068498
NG 37 0.092757 0.060536 0.043682 0.803835
Comparison to TALE-NT Frequency Matrix
A C G T
NI -0.0153 -0.03159 0.047375 -0.00048
HD -0.00868 0.024704 -0.01511 -0.00129
NK 0.033025 -0.01265 -0.025 0.00463
NN -0.13134 -0.10525 0.225518 0.011498
NG -0.00924 -0.04146 0.005682 0.045835
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between the two half-sites, but the scores for each half-site are calculated in different ways.
The Homology algorithm can be applied to both ZFNs and TALENs and is based largely
on the number of mismatches relative to the intended target sequence. The RVDs algorithm
is designed for use with TALENs and utilizes the RVD-nucleotide binding frequencies of
natural TAL Effectors [28]; alternate “5T”and “5TC” versions require either a thymidine
or a pyrimidine to be in the 5’ position of each half-site. The Conserved G’s algorithm is
designed for use with ZFNs and applies a weighting factor to the Homology algorithm that
biases the rankings towards sites where intended guanosine contacts are maintained.
3.3.2.1 Homology Algorithm
If M represents the maximum number of mismatches allowed per nuclease half-site in a
given PROGNOS search, a homology score for a potential off-target site is calculated by
Equation 1:
S coreH = (M + 1 − L)
2 + (M + 1 − R)2 (1)
where L and R are the number of mismatches in the left and right half-sites, respectively.
A higher score indicates a more likely off-target site. The squared factor captures some of
the energy compensation effects observed in previous work [88]. L and R must be less than
or equal to M as defined by the original search criteria.
3.3.2.2 Conserved G’s Algorithm
Ranking ZFN off-target sites by counting the number of guanine residues—the “G’s”—has
proven useful because many ZFNs, especially those using canonical frameworks, bind to
guanosine residues more strongly than other nucleic acids. The Conserved Gs ranking
system adds a weighting factor to the homology score based on the number of guanosine
residues in the intended target sequence (Gtotal) and the number of guanosine residues
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matching the target sequence at potential off-target sites (Gconserved) according to Equa-
tion 2:




A higher score indicates a site more likely off-target cleavage site. The weighting factor
of 2.5 was developed by varying the weighting factor in order to optimize the number of
previously published off-target sites for the CCR5, VEGF, and kdrl ZFNs identified in the
top rankings [44, 88].
3.3.2.3 RVD Algorithm
The repeat variable di-residue (RVD) ranking system is intended for ranking TALEN off-
target sites and uses the previously published method for ranking single TAL effector sites
based on RVD nucleotide preferences observed in natural TAL effectors [28, 78]. Given
RVDLmin, and RVDRmin as the scores for the left and right TALs binding to their intended
target sites, and RVDL and RVDR as the scores for the TALs binding to a potential off-target












A lower score indicates a more likely off-target site. The exponent is an attempt to cap-
ture the “energy compensation” effects observed for the interaction between ZFN dimers
[88]. Although there has been no direct testing of the energy compensation model with
TALENs, the similarities between the nucleases (both use FokI cleavage domain, both bind
in pairs) led us to include this model in our original algorithm. However, the optimization
of the parameter in the TALEN v2.0 algorithm found a slight preference for an “energy
distribution” model for TALENs instead of energy compensation. If no RVDs are specified
by the user in the PROGNOS online input form, RVDs are assumed to follow the standard
code based on the intended target sequence: NI→A, HD→C, NN→G, NG→T.
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3.3.3 PROGNOS “ZFN v2.0” and “TALEN v2.0” Algorithms
The weightings of the parameters for the refined PROGNOS algorithms “ZFN v2.0” and
“TALEN v2.0” were developed by training the algorithms to maximize recovery of previ-
ously confirmed off-target sites, as well as the novel off-target sites found using the initial
algorithms developed in this study. For each algorithm, approximately 105 randomly as-
signed parameter sets (within a constrained range) were analyzed for their performance
using the Perl off-target ranking script. The top performing parameter sets were further
optimized by running further analyses allowing each parameter to vary slightly from the
original value.
3.3.3.1 ZFN v2.0 Algorithm
The ZFN v2.0 algorithm was constructed based on the binding of individual zinc finger
subunits rather than treating all mismatches equally. Previously, it had been hypothesized
that each zinc finger subunit contributed a certain amount of overall binding energy and
that if one nucleotide contact in the zinc finger were disrupted, further disruptions in that
zinc finger were less detrimental. To model this, we analyzed each zinc finger subunit sep-
arately rather than considering all mismatches as equal (as was the case with the original
“Homology” algorithm). To model the increased affinity most zinc fingers have for guano-
sine residues, a parameter for binding a guanosine at the intended position was included.
Because many zinc fingers bind especially well to the “GNN” motif, if a guanosine was at
the 5’ position of a finger’s triplet, the parameter was doubled.
Each finger was therefore analyzed as follows:
i) An initial score of 100 was given as a starting point.
ii) If there was at least one mismatch, “First Penalty” was subtracted
iii) If there were additional mismatches, “Additional Penalty” was subtracted for each
additional mismatch
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iv) If a guanosine was the intended base at position 2 or 3 and it matched, “G Bonus” was
added
v) If a guanosine was the intended base at position 1 and it matched, “G Bonus”∗2 was
added
vi) If the resulting score was less than zero, it was set to zero
Because mismatches further from the FokI domain were better tolerated by zinc fingers in
previous bona fide off-target sites, we introduced parameters weighting the impact of each
of the 2nd-4th nucleotide triplets away from the FokI domain to model these polarity effects.
The 1st triplet weighting was arbitrarily set to 1 and there were no published bona fide off-
target sites at the time for ZFNs containing more than four zinc fingers to use to establish
weightings of additional fingers. In the online implementation, all fingers past the fourth
use the weighting parameter of the fourth finger.
The score for each zinc finger subunit is multiplied by the corresponding polarity pa-
rameter and all scores for the half-site are summed together. The sum is then divided by
the score of a perfect match to the intended target sequence of that half-site and multiplied
by 100 to generate a score from 0-100 (100 being a perfect match).
To allow for compensation effects between the two ZFN dimers, the score for each half-
site was raised to the power of “Dimer Exponent” before being summed together, divided
by two, and multiplied by 100 to generate a score from 0-100 (100 being a perfect match).
The final optimized parameter values are given in Table 3-2. The formal definition of
how to arrive at the scores of each ZFN half-site is as follows:
The score of a ZFN/DNA alignment of l consecutive DNA bases in a 5’→3’
orientation starting at the FokI junction, with b1 being the first base in the DNA
helix and z1 being the first intended base of the zinc finger helix, is calculated
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using the following formula:








The score of the “Intended” half-site is calculated by setting b to equal z at all
positions.
The formula utilizes the following functions:
• NN(x) ensures that the value is not negative by returning x if x ≥ 0 and
returning 0 if x < 0
• MC(start) returns the mismatch count (an integer from zero to three), for
the zinc finger beginning at start, between the intended target sequence
and the DNA bases according to the formula:




(zk == bk) (5)
• PC(position) returns the polarity coefficient algorithm parameter for that
position according to the following:
1 ≤ position ≤ 3 : 1.0
4 ≤ position ≤ 6 : Polarity 2
7 ≤ position ≤ 9 : Polarity 3
10 ≤ position : Polarity 4
• MS (start) returns the mismatch score for the zinc finger beginning at
start according to the rules:
If MC(start) == 0, return 0
If MC(start) == 1, return First Penalty
If MC(start) == 2, return (First Penalty + Additional Penalty)
If MC(start) == 3, return (First Penalty + Additional Penalty ∗ 2)
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Table 3-2: ZFN v2.0 Algorithm Parameters
Parameter Name Training Range Optimized Value
First Penalty 30–90 70
Additional Penalty 10–80 65
G Bonus 0–35 17.5
Polarity 2 0.4–1 0.85
Polarity 3 0.4–1 0.8
Polarity 4 0.4–1 0.7
Dimer Exponent 0.2–2.8 1.75
• GS (start) returns the guanosine score for the zinc finger beginning at
start according to the rules:
Initialize gS um = 0
If (zstart == “G” AND bstart == “G”): gS um = gS um +G Bonus ∗ 2
If (zstart+1 == “G” AND bstart+1 == “G”): gS um = gS um +G Bonus
If (zstart+2 == “G” AND bstart+2 == “G”): gS um = gS um +G Bonus
return gS um
Once the scores for each ZFN half-site have been calculated, then full off-target
score can be calculated according to Equation 6:
ZFN v2.0 S core =
(
O f f Target Le f t S core




O f f Target Right S core





Several interesting points emerged from the optimization of the ZFN algorithm:
a) The polarity parameters did form a decreasing trend away from the FokI domain as
hypothesized despite the possibility of remaining flat given their training range.
b) The dimer exponent was optimized at a value > 1, supporting the “energy compensa-
tion” model of dimeric nuclease interactions [88], despite the possibility of being equal
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to or less than 1 given its training range.
c) The First Penalty parameter optimized at a relatively high value (70% of the default
starting energy of 100), implying that most of the binding energy of a zinc finger can be
disrupted by a single mismatch.
d) The Additional Penalty parameter also optimized at a relatively high value which brings
the score for that finger close to zero in the case of two mismatches even with a high
guanosine composition in the binding site, implying that nearly all remaining binding
energy is disrupted by the second mismatch and that a third mismatch has negligible
effect. However, there were limited examples of fingers with all three nucleotides dis-
rupted in the training set of bona fide off-target sites, decreasing the significance of this
observation.
3.3.3.2 TALEN v2.0 Algorithm
A score for each RVD-nucleotide interaction is calculated using the same formula as in
TALE-NT [28] (and the original RVDs algorithm) except that the RVD-nucleotide fre-
quencies used were derived from engineered TAL domains instead of naturally occurring
TAL Effectors (Table 3-1). A value for the 5’ base is also able to be calculated using the
values derived from engineered TAL domains. Although there is no SELEX data for other
RVDs, a user may enter any of the RVDs allowed by TALE-NT and the RVD-DNA bind-
ing frequency from TALE-NT will be utilized for that interaction; however, we make no
claims as to the accuracy of predictions employing these alternate RVDs and it should be
noted that substituting the TALE-NT frequencies into the TALEN v2.0 algorithm resulted
in worse overall performance (Figure 3-9). If no RVDs are specified by the user in the
PROGNOS online input form, RVDs are assumed to follow the standard code based on the
intended target sequence: NI→A, HD→C, NN→G, NG→T.
Streubel et al. found that the presence of the “strong” RVDs NN and HD are key to TAL
binding [112]. We hypothesized that these RVDs may impart excess binding energy that
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could compensate for local effects of adjacent RVD-nucleotide mismatches. Accordingly,
we developed two parameters, “Single Strong” and “Double Strong” that were applied to
the score of RVDs that were flanked on one or both sides by NNs or HDs correctly bound
to their respective intended bases (guanosines or cytidines). If these criteria were met, a
fraction (defined by the parameter) of the difference between the mismatched RVD binding
to its intended base and the base at the potential off-target site was subtracted from the score
for that RVD-nucleotide interaction; subtraction is used because the base formula [28] uses
a negative logarithm indicating lower scores as more likely binding sites.
In accordance with the findings that a polarity effect exists in TAL-DNA binding where
mismatches further from the N-terminus have a less disruptive effect [75], the scores for the
14th RVD (including score modifications relating to strong RVDs) and any RVDs further
towards the C-terminus are all multiplied by the “Polarity” parameter.
The scores of all positions in each half-site are summed together to create the “Off Target”
score for that half-site and the full score for the potential off-target sites is computed using
the “Dimer Exponent” parameter and the score for a complete match between the RVDs
and their intended target bases to yield a score from 0 to 100 (a perfect match) according
to Equation 7.
T ALEN v2.0 S core =
(
Intended Le f t S core




Intended Right S core





The formal definition to calculate the score of a TALEN half-site is as follows:
The score of a TALEN/DNA alignment of l consecutive RVDs (rl at each po-
sition with r0 representing the N-terminal sequence that binds to the 5’ base)
aligned to DNA bases (bl at each position with b0 representing the 5’ base) is
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calculated using the following formula:




(PC(k) ∗ (Prn(rk, bk) − ((S FS (k) + DFS (k)) ∗ (Prn(rk, bk) − Prn(rk, I(rk))))))
(8)
The score of the “Intended” half-site is calculated by setting b to equal I(r) at
all positions.
The formula utilizes the following functions:
• A formula for the probability of an RVD-nucleotide interaction of the
identical form as used in Doyle et al. [28]:
Prn(RVD, base) = − log(0.9 ∗ S ELEX(RVD, base) + (1 − 0.9) ∗ 0.25)
• S ELEX(RVD, base) returns the frequency of that RVD (or the N-terminal
sequence that binds to the 5’ base) binding to that DNA base according
to the SELEX data in Table 3-1.
• PC(position) determines the polarity coefficient by returning 1.0 for all
position ≤ 14 and returning the Polarity algorithm parameter for all
position ≥ 15.
• I(RVD) returns the intended DNA base most frequently associated with
RVD according to the SELEX analysis: NI→A, HD→C, NN→G, NK→G,
NG→T
• S FS (position) determines if that position has a single flanking strong
RVD by returning the S ingle S trong algorithm parameter if the follow-
ing statement is true, and 0 if it is false:
((rposition−1 ==“NN” OR rposition−1 == “HD”) AND bposition−1 == I(rposition−1))
XOR ((rposition+1 ==“NN” OR rposition+1 == “HD”) AND bposition+1 ==
I(rposition+1))
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Table 3-3: TALEN v2.0 Algorithm Parameters
Parameter Name Training Range Optimized Value
Single Strong 0–0.4 0.10
Double Strong 0–0.5 0.15
Polarity 0.4–1.9 0.9
Dimer Exponent 0.2–2.8 0.6
• DFS (position) determines if that position has double flanking strong
RVDs by returning the Double S trong algorithm parameter if the fol-
lowing statement is true, and 0 if it is false:
((rposition−1 ==“NN” OR rposition−1 == “HD”) AND bposition−1 == I(rposition−1))
AND ((rposition+1 ==“NN” OR rposition+1 == “HD”) AND bposition+1 ==
I(rposition+1))
Several interesting points emerged from the optimization of the TALEN algorithm:
a) The polarity parameter was optimized to a value less than one, supporting the hypothesis
that TAL binding in off-target locations exhibits polarity effects.
b) The dimer exponent was optimized at a value < 1, which is contrary to the “energy
compensation” model of dimeric interactions for that was proposed for ZFNs and ap-
proximates a more “distributed energy” model where mismatches are preferred to be in
equal numbers in each half-site rather than concentrated in one half-site. However, this
finding is based on a relatively small number of bona fide off-target sites and it should
be noted that several parameter sets with exponents > 1 performed fairly well, but not
quite as well as the top performing sets with exponents < 1.
c) The Double S trong and S ingle S trong parameters were optimized at values greater
than 0, indicating that there are some compensatory effects of flanking strong RVDs,
supporting our hypothesis. Moreover, the double flanking strong RVD optimized to a
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higher value than a single flanking strong RVD supporting the hypothesis that a second
strong RVD has an additive effect over only a single flanking strong RVD.
3.3.4 Nuclease Construction
Four novel TALEN pairs and two novel ZFN pairs were designed to target sequences near
the A→T mutation that causes sickle-cell anemia in the human beta-globin gene. TAL-
ENs were assembled using the Golden Gate method [14] and cloned into a mammalian
expression destination vector containing the wild-type FokI domain. ZFNs were rationally
designed to target overlapping sites. As these ZFNs target the same site, the activity and
specificity of the 3-finger (3F) and 4-finger (4F) ZFNs can be directly compared. ZFN1-
4F contains an additional finger added to ZFN1-3F, extending the target site from 9 bp to
12bp. ZFN2-4F shares two proximal fingers with ZFN2-3F, and uses a long linker between
fingers two and three, extending the target site from 9bp to 13bp (Figure 3-1). The coding
sequences for the ZFNs were ordered (IDT) and cloned into a wild-type FokI expression
vector.
3.3.5 Cellular Transfection of Nucleases
HEK-293T cells were cultured under standard conditions (37°C, 5% CO2) in Dulbecco’s
Modified Eagle’s Medium (Sigma Aldrich), supplemented with 10% FBS. Plates were
coated with 0.1% gelatin. Passaging was performed with 0.25% Trypsin-EDTA. For TAL-
ENs, 2 ∗ 105 cells/well were seeded in 6-well plates 24 hours prior to transfection with
FuGene HD (Promega). 3.3 µg of each nuclease plasmid along with 80 ng of an eGFP
plasmid were transfected with 19.8 µL of FuGene reagent. Media was changed 24 and
48 hours after transfection. 72 hours after transfection, cells were trypsinized and the ge-
nomic DNA extracted using the DNeasy Kit (Qiagen). A small fraction of the cells were
analyzed with the Accuri C6 flow cytometer to determine transfection efficiency by GFP
fluorescence. For ZFNs, 8∗104 cells/well were seeded in 24-well plates and 100 ng of each
ZFN was transfected using 3.4 µL of FuGene HD along with 10 ng of eGFP and 340 ng of
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Figure 3-1: Binding sites of novel nucleases in the beta-globin gene. The binding sites
of the novel ZFNs (a) and TALENs (b) designed to target the beta-globin gene mutation
that causes sickle cell anemia. The start codon of beta-globin is underlined in bold. HEK-
293T cells contain a T→C SNP relative to the reference genome in the middle of the S1
and S2 binding sites, which is underlined. The S2 TALEN is designed to target the sickle
allele, which has an A→T mutation (underlined) at the 3’ position of the TALEN binding
site. This mutation is not present in HEK-293T cells. (c) The RVDs of the TALENs are
shown. In “NK” versions of the TALENs, all guanosines are targeted by the NK RVD.
In “NN” versions of the TALENs, all guanosines are targeted by the NN RVD: the other
RVDs remain the same. The differences between the TALEN versions are underlined.
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a Mock vector containing FokI but no DNA binding domain. 72 hours after transfection,
cells were harvested and the genomic DNA extracted using 100 µL of QuickExtract (Epi-
Centre). Mock transfections were performed similarly to the TALEN transfections, except
that 6.6 µg of the mock FokI vector was transfected instead of TALEN plasmid.
3.3.6 Implementation of PROGNOS Search Algorithm
PROGNOS exhaustively searches for matches to queries by moving the query mask itera-
tively across the sequence of an entire genome, base by base. To optimize search time, the
sequence comprising the length of the 5’ binding site is first examined to determine if the
number of mismatches does not exceed the query maximum. If that requirement is met, the
sequences comprising potential 3’ binding sites (separated by allowed spacing distances)
are examined. PROGNOS was implemented in Strawberry Perl 5.12 and can be run in par-
allel on different processors. We found that scale up to 8 parallel processors with minimal
efficiency losses was possible for most genomes.
3.3.7 PCR Amplification of Regions of Interest
3.3.7.1 Automated Design of PROGNOS PCR Primer Sequences2
An automated primer pair design process was included in PROGNOS to design primers
appropriate for off-target validation assays, matching user input criteria. This greatly sim-
plifies the standard method for primer design that requires iterative steps of primer design
and verification of the resulting fragment sizes. In addition to speeding the primer design
throughput, this automated design process allows the primers to be custom designed for the
downstream assays or sequencing, and to be matched for high-throughput, full-plate PCR
amplification.
For Surveyor assays, the primer design parameters can be specified to ensure that the
nuclease site is placed in an optimal position within the amplicon to yield cleavage bands
2This automated primer design algorithm was also incorporated into the COSMID tool. Cradick TJ, Qiu P,
Lee CM, Fine EJ, Bao G. (2014). COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas
Off-target Sites. Molecular Therapy—Nucleic Acids [22]
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that can be easily distinguished on gels from the parental band and each other. For res-
olution on a 2% agarose gel, the recommended parameters are: Minimum Distance Be-
tween Cleavage Bands—100, Minimum Separation Between Uncleaved and Cleaved Prod-
ucts—150.
To optimize amplicons for different sequencing platforms, the minimum distance from
the edge of the amplicon to the nuclease site can be specified. For SMRT sequencing, the
recommended parameters are: Minimum Distance Between Cleavage Bands—0, Minimum
Separation Between Uncleaved and Cleaved Products—125.
The design process implemented by PROGNOS uses the following steps and consider-
ations to yield primer pairs suitable for high-throughput PCR:
Each possible position in the sequence 5’ of the nuclease binding sites is con-
sidered as a possible 5’ base for a primer (beyond the minimum distance spec-
ified between the edge of the amplicon and the nuclease site). For a given 5’
starting position, the first 18 bases in the 3’ direction are taken as an initial
sequence for the primer. Then the following design loop begins:
1) Check for potential secondary structure that could result from the 3 end
folding back.
Check that the sequence of the primer up to the 4th most 3’ base does not
contain any exact matches to the reverse complement of the three most 3’
bases.
Example: For the potential primer sequence 5’-ACATTGAGGCACTACTTG-
3’, check that the sequence ‘CAA’ does not appear in ‘ACATTGAG-
GCACTA’.
If there is a match, lengthen the primer by one base in the 3’ direction
and repeat the loop.
2) Check the predicted melting temperature of the primer and GC content.
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Let Length be the number of nucleotides in the primer sequence
Let %GC be the percentage of guanosine and cytidine residues in the
primer sequence
Calculate the melting temperature of the primer according to the equa-
tion:




If Tm < 58 or %GC < 0.33 or %GC > 0.63 then lengthen the primer by
one base in the 3’ direction and repeat from Step 1.
3) If the primer length is > 30 bp, then exist the design loop unsuccess-
fully—no primer for this position.
4) Check for high self-complementarity by comparing all 7 bp sequences
within the primer to the reverse-complement sequence of the primer.
If any exact matches are found, then exit the design loop unsuccess-
fully—no primer for this position.
5) If all requirements are met, then exit the design loop successfully and
record the primer for this position.
After attempts to generate primers for all forward positions and all reverse
positions are complete, pairs are made with each forward pair to each possible
reverse pair. This list of pairs is then pruned to remove any that would result
in products where the distances between nuclease sites and the ends of the
amplicon fall outside of the specified ranges. This list is further pruned to
remove any primer pairs that could potentially form primer dimers as defined
by having the final 3’ bases of one primer match the reverse complement of the
final 3’ bases of the other primer.
All primer pairs are then sorted by how close their melting temperature is
to the target melting temperature (the default is 60°C) by computing Tdi f f =
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(Tm f orward − 60)
2 + (Tmreverse − 60)
2
All pairs where Tdi f f < 2 are then further sorted according to the following
criteria (in order of priority):
1. Prefer shorter amplicon length
2. Prefer a shorter length of the longer primer sequence in the pair
3. As a final tie-breaker, sort the primer sequences alphabetically
If no primer pairs are found acceptable under this optimal set of criteria, the
primer design constraints are iteratively relaxed and the primer search repeated.
The most lenient set of criteria still require a minimum %GC of 0.25, a max-
imum %GC of 0.70, a maximum Length of 38, and a minimum melting tem-
perature of 55°C.
3.3.7.2 PCR Experimental Conditions
The primers designed by PROGNOS (ordered from Eurofins-MWG-Operon) were used in
a high-throughput manner to amplify genomic regions of interest in a single-plate PCR
reaction. Each 25 µL reaction contained 0.5 units of AccuPrime Taq DNA Polymerase
High Fidelity (Invitrogen) in AccuPrime Buffer 2 along with 150 ng of genomic DNA or
0.5 µL of QuickExtract, 0.2 µM of each primer, and 5% DMSO vol/vol. Touchdown PCR
reactions were found to yield the highest rate of specific amplification. Following an initial
2-minute denaturing at 94°C, 15 cycles of touchdown were performed by lowering the
annealing temperature 0.5°C per cycle from 63.5°C to 56°C (94°C for 30 seconds, anneal
for 30 seconds, extend at 68°C for 90 seconds). After the touchdown, an additional 29
cycles of amplification were performed with the annealing temperature at 56°C before a
final extension at 68°C for 10 minutes. Reactions were purified using MagBind EZ-Pure





Amplicons from each transfection were pooled in roughly equimolar ratios and SMRT
sequenced using the C2/C2 Chemistry and Consensus Sequencing options, according to
the manufacturer’s protocol (Pacific Biosciences).
3.3.8.2 Sequencing Analysis
There are three main processing steps of the raw SMRT sequencing reads to detect nuclease-
induced non-homologous end joining (NHEJ). First, because many amplicons are pooled
into a single SMRT sequencing cell, sequencing reads must be mapped to the amplicon
from which they were generated. Second, because the processivity of the polymerase used
in SMRT sequencing is a stochastic factor, the quality of the sequencing reads ranges over
a distribution. However, for detecting the small insertions and deletions characteristic of
NHEJ, sequencing artifacts that would yield false positives must be eliminated. Therefore,
the sequencing reads must be filtered to obtain only the higher quality sequencing reads.
Third, the high quality sequencing reads need to be analyzed to determine if they show
mutations consistent with nuclease-induced NHEJ.
To address these issues, we created a sequencing processing pipeline based in Perl
and also utilizing the BLAST and Needle software packages for sequence alignment. All
aspects of the pipeline were implemented on a Windows machine and the source code is
available on the PROGNOS website http://bit.ly/PROGNOS.
Sequence Mapping
1. Create a BLAST database of all expected amplicons obtained from the reference
genome
2. BLAST each consensus SMRT sequencing read against the BLAST database using
the parameters: gapopen 2, gapextend 1, reward 1, penalty -1.
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3. Remove from further processing any reads that failed to make a significant BLAST
alignment to any sequence in the database.
Pairwise Alignment
1. Use the Needleman-Wunsch algorithm [81] to align each sequence read with the
expected amplicon to which it was mapped. Needle parameters: gapopen 10,
gapextend 1.
2. If the alignment of the sequencing read extends more than 65 bp past the end of the
reference sequence, remove it from further processing.
Sequence Quality Filtering
1. Calculate the average Phred score of each consensus SMRT read from the FASTQ
data.
2. Remove from further processing any reads that have an average Phred score lower
than 40.
3. Scan the region of the pairwise alignment extending 100 bp out from the edge of the
nuclease binding sites for “indels”. Define “indels” as a stretch of deleted, inserted,
or mismatched bases in the sequencing read relative to the reference sequence.
4. If an indel is found that does not overlap the nuclease target site (the region encom-
passing the binding site of the left nuclease, the spacer region, and the right nuclease
in the reference sequence), add the square of its length to a running total errorCount.
5. If errorCount
Length o f scanned sequence
> 0.005, remove that sequencing read from further process-
ing.
Identifying Events of Non-Homologous End-Joining (NHEJ)
1. Scan the pairwise alignment extending 100 bp out from the edge of the nuclease
binding site for indels.
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2. Check if the observed indel overlaps the spacer region in the reference sequence.
3. If the indel overlaps the spacer and is of length 5 or greater, classify as NHEJ.
4. If the indel overlaps the spacer, is 4 or 4 bp, and is either composed entirely of a
deletion or entirely of a tandem repeat of flanking sequence, classify as NHEJ.
5. Manually verify suspected NHEJ events by hand to confirm true cases of NHEJ.
3.3.9 Statistical Analysis
P values for off-target cleavage in Table 3-4 were calculated exactly as previously described
[88]. Briefly, the t-statistic was calculated based on the fraction of mutated reads in the
nuclease-treated sample compared to the fraction of mutated reads in the mock-treated
sample and the number of sequencing reads was given as the degrees of freedom. In a
similar manner, 90% confidence intervals were calculated by determining the upper and
lower bounds of the fractions of mutated sequences that would yield P values of 0.05.
3.4 Results
3.4.1 Construction of initial bioinformatics ranking algorithms
The initial PROGNOS algorithms codified several established factors influencing nucle-
ase specificity, including sequence homology, zinc fingers’ preference for binding guanine
residues [44], and RVD-nucleotide binding frequencies of natural TAL effectors [78]. To
improve upon simple “mismatch counting”, we incorporated the recently proposed “en-
ergy compensation” model of dimeric nuclease interactions [88]. Using these factors, three
different algorithms were initially developed. The “Homology” algorithm, which could
be used for both ZFNs and TALENs, generates a score based primarily on sequence di-
vergence from the intended target site, including the number of mismatches in the left
and right nuclease half-sites, and the maximum number of mismatches allowed per half-
site. The “Conserved G’s” algorithm (for ZFNs only) ranks ZFN target sites by counting
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the number of guanine bases and adding a weighting factor to the homology score ac-
cordingly. The “RVDs” algorithm (for TALENs only) weighs mismatches based on RVD
nucleotide preferences observed in natural TAL effectors and then applies the energy com-
pensation model. Since all three of the TALEN off-target sites discovered previously using
experimental-based off-target prediction methods contained a pyrimidine at the 5’ position,
a “5TC” version of the “Homology” and “RVDs” algorithms was also applied to TALEN
rankings that required a thymidine or cytidine in the preceding 5’ position of each half-site.
For any given potential off-target site, these algorithms generate a score that allows ranking
of all potential off-target sites in a genome for a specific nuclease target site. Search param-
eters, such as target sites, maximum mismatches per half-site and allowed spacer lengths
are entered as inputs using the online interface (Figure 3-2a) and ranked lists of potential
cleavage sites in the selected genome are given as PROGNOS outputs for further analy-
sis. Although two online tools—ZFN Site [20] and TALE-NT [28]—exist to help search
genomes for cleavage sites with homology to intended nuclease on-target sites, neither
automatically ranks the potential off-target sites, nor has led to a report of any new experi-
mentally verified off-target cleavage sites. In a direct comparison, we found that TALE-NT
was only able to predict two of the seven bona fide TALEN off-target sites in unrelated
gene families—three sites from previous work [116, 51] and four from this work—while
PROGNOS could predict six. Recently, a new tool for identifying TALEN off-target sites,
TALENoffer, was published [42]. Although it performs better than TALE-NT and does pro-
vide a rank-order for the potential off-target sites, it is outperformed by the refined TALEN
v2.0 algorithm (Table 3-5).
3.4.2 Validation of PROGNOS Algorithms with Previously Confirmed Off-target
Sites
To validate the initial PROGNOS ranking algorithms, we compared PROGNOS predictions
with the off-target sites of ZFN and TALEN pairs identified by others using experimental
characterization methods. If the same number of sites (1X) were interrogated as in the
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Figure 3-2: PROGNOS search interface and comparison to previous prediction meth-
ods. (a) The PROGNOS online interface allows users to enter the target site of their nucle-
ase pair and specify search parameters and primer design considerations. (b) A comparison
of PROGNOS predictions to previously reported methods identifying off-target sites for
different ZFNs [44, 88]. The Homology and Conserved Gs algorithms were used to deter-
mine what percentage of the sites with previously identified off-target activity fell within
the top fractions of PROGNOS rankings. The “1X” top fraction corresponds to searching
the same number of top PROGNOS sites as were investigated in the original paper and
“3X” corresponds to searching three times as many PROGNOS sites as were investigated
in the original paper. (c) A comparison of the PROGNOS search algorithms to previously
reported methods identifying off-target sites for TALENs [116, 51]. The top PROGNOS
rankings using the Homology-5TC and RVD-5TC algorithms were searched to determine
what percentage of off-target sites found to have activity fell within the top fractions of
PROGNOS rankings. (d) Venn diagram displaying the 13 known off-target sites iden-
tified for the heterodimeric CCR5 ZFNs during development and testing of the original
PROGNOS algorithms [88, 37]. The sites ranked at the top of the PROGNOS Homology
and Conserved G’s in silico algorithms (allowing 3X the number of sites searched by Pat-
tanayak et al. [88]) are compared to the 12 sites identified previously and 1 site uncovered
in this study.
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original studies, but the sites were chosen by taking the top-ranked PROGNOS predictions,
33 ± 21% (mean ± std) of the off-target sites previously found in studies of ZFNs targeting
CCR5 [88], VEGF [88], and kdrl [44] could be located. Since off-target searches using
the in silico PROGNOS predictions can be scaled up readily, we tripled (3X) the number
of sites interrogated from PROGNOS top-ranked lists, and found that PROGNOS could
identify 65 ± 24% of the off-target sites previously confirmed experimentally (Figure 3-
2b). Excluding sites in highly homologous gene pairs such as CCR5/CCR2, only three
bona fide TALEN off-target sites had previously been experimentally identified to date
[116, 51], making a rigorous analysis of the predictive power of PROGNOS for ranking
TALEN off-target sites more difficult. Nevertheless, we found that the “Homology-5TC”
and “RVD-5TC” algorithms in PROGNOS could predict several off-target sites confirmed
previously for TALEN pairs targeting the AAVS1 [51] and IgM [116] loci (Figure 3-2c).
Since no single off-target analysis method has yet been able to provide a comprehensive
list of all off-target sites of a nuclease (Figure 3-2d) [37, 88], the comparison of PROGNOS
predictions with previously published results may underestimate the power of PROGNOS.
Specifically, these comparisons are limited by the small number of off-target sites experi-
mentally validated previously, and do not reflect the ability of PROGNOS to predict new
off-target sites.
3.4.3 Validation of Novel CCR5 ZFN Off-target Site Predicted by PROGNOS
To date, the only nuclease pair to have its off-target sites experimentally interrogated using
two independent methods is a ZFN pair targeting CCR5 (analyzed using in vitro cleavage
[88] and IDLV [37]). These two studies located a total of 12 hetero-dimeric bona fide
off-target sites, verified by sequencing the resulting mutations. A comparison between
PROGNOS predictions using the “Homology” and “Conserved G’s” algorithms and those
12 sites identified experimentally shows that PROGNOS (analyzing the top 3X number of
sites interrogated by Pattanayak et al. [88]) was able to predict 10 out of the 12 off-target
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sites (Figure 3-2d.
3.4.4 PROGNOS Search Output
PROGNOS provides ranked lists of potential nuclease cleavage sites that can be used
to guide experimental evaluation of ZFN and TALEN off-target activities (Figure 3-3a).
Specifically, for each pair of ZFNs or TALENs, the user-friendly online interface of PROG-
NOS (http://bit.ly/PROGNOS or http://baolab.bme.gatech.edu/bao/Research/
BioinformaticTools/prognos.html) allows entry of the nuclease search parameters
and returns lists of the top-ranked off-target sites according to the PROGNOS algorithms, as
well as a full list of un-ranked potential off-target sites meeting the search parameters (Fig-
ure 3-3b). While the top-ranked sites provide a list of likely locations in a genome where
off-target cleavage may occur, neither the PROGNOS rankings nor any published method
can yet directly correlate the ranking with the precise level of observed off-target mutagen-
esis at a given site (Figure 3-4). Furthermore, to aid experimental analysis, PROGNOS also
provides PCR primer sequences that can be used to amplify the potential nuclease cleav-
age sites in a high-throughput manner, a unique feature not present in other online search
tools. Automated design of PCR primers significantly facilitates the analysis of off-target
sites, since an initial experimental study of off-target cleavage by a single pair of nucleases
typically requires at least 40 primers [54, 51], and an in-depth investigation of nuclease
off-target effects may require >250 primers [44, 88]. Although tools such as Primer3 [100]
can assist in primer design, they require a large amount of effort to generate primers opti-
mal for off-target analysis due to specific requirements of where the nuclease site must be
positioned within the amplicon. Although PCR amplification is an essential step in exam-
ining a potential off-target site, in previous investigations the success rates of amplifying
off-target loci varied from 31% [54] to 95% [51]. In contrast, the primers automatically
designed by PROGNOS had a robust 95% success rate across the 116 potential off-target
loci interrogated in this study (Figure 3-3c). PROGNOS also provides the sequences, the
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Figure 3-3: Using PROGNOS to identify nuclease off-target sites. (a) Outline of the
procedure to identify nuclease off-target activity. (b) Sample outputs of the PROGNOS
online software showing all sites found and what types of genomic regions they are located
in as well as rankings of the top potential off-target sites. The rankings include the closest
gene, the number of mismatches, the size of PCR product from the automatically designed
primers, and other helpful information. (c) Comparison of the success of the automatically
designed PROGNOS primers used in high-throughput full plate PCR of off-target sites to
primers designed in other off-target publications. (d) Sequencing reads of an off-target
location for the 3-finger ZFN pair that show evidence of NHEJ. In the wild-type (WT)
sequence, the ZFN binding sites are highlighted in yellow and mismatches to the intended
target sequence are lowercase red. In the sequencing reads, inserted bases are lowercase
and highlighted in blue. The size of the indel is displayed to the right of the sequence,
along with the number of times that mutation was observed.
sizes of expected cleavage products of the amplicons, and site of expected cleavage. This
information is used when testing for nuclease-induced mutations—typically short inser-
tions and deletions (indels) resulting from error-prone resolution of the DNA double strand
break through the non-homologous end-joining (NHEJ) repair pathway—using methods
such as the Surveyor Nuclease assay, high-throughput sequencing, or Sanger sequencing
of TOPO-cloned fragments (Figure 3-3d).
3.4.5 Determination of NHEJ-mediated Indels Using high-throughput SMRT se-
quencing
To experimentally measure nuclease activity at on-target and potential off-target sites iden-
tified by PROGNOS, we used Single Molecule Real-Time (SMRT) sequencing of the PCR
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Figure 3-4: Low correlation between predicted off-target ranking and observed ac-
tivity. The current goal of off-target prediction methods is to refine a global list of all
possible off-target sites in the genome into a list of the top ranked sites that are likely to
have off-target activity that can then be tested. An ideal prediction method would addi-
tionally be able to correlate local rankings (i.e. the 7th ranked site vs. the 12th ranked site)
with observed levels of off-target activity. The off-target prediction method described by
Gupta et al. [44] did not associate any rankings with the predicted off-target sites, however
Pattanayak et al. [88] did provide rankings, as well as detailed information about observed
off-target activity, and Gabriel et al. [37] provided the number of IDLV-CLIS events at each
predicted site which can be used as a ranking. Using the results from Pattanayak et al. and
the PROGNOS predictions for the same ZFNs, we constructed linear correlations measur-
ing the ability of the different off-target prediction methods to rank order sites for the CCR5
(a) and VEGF (b) ZFNs by their precise level of observed off-target activity. Similarly, we
constructed linear correlations for the Gabriel et al. prediction of the wild-type ZFNs (the
hetero-obligate ZFNs have only four points, making a linear correlation not statistically
meaningful) and the corresponding activity (c); several of the sites found by Gabriel et al.
are not found by PROGNOS so a meaningful comparison is not possible. The extremely
low correlation coefficients indicate that neither the current experimental-based prediction
methods, nor the PROGNOS algorithms can yet accurately model precise off-target activity
levels. This is likely due to variability in the cells and poorly understood factors such as
the genomic accessibility of a given off-target locus.
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amplicons. The consensus sequencing mode of the SMRT platform provides highly accu-
rate long length reads [117] that allowed determination of nuclease activity and specificity
with reasonable sensitivity, and at a lower cost per run than other deep sequencing plat-
forms. The good agreement between SMRT sequencing results and Sanger sequencing of
TOPO-cloned samples further confirmed the accuracy of the SMRT-based analysis of nu-
clease cleavage (Figure 3-5a). Further, the high quality of the SMRT consensus sequence
reads allowed us to achieve a much better signal to noise ratio for the mutation analysis
than other sequencing methods [54]. We found that only three sequencing reads from mock
treated control cells (∼0.003% of the total) contained indels flagged by the analysis and all
three were from the same genomic site, which in retrospect should have been excluded
from sequencing analysis due to several long adjacent homopolymer stretches known to be
error-prone during the sequencing process.
Although the spectrums of indels induced by ZFNs [44] or TALENs [54, 62] have
been investigated previously, the long SMRT read lengths provided a more comprehensive
analysis (Figure 3-5b). We found that ZFNs induced predominately 3, 4, and 5 bp insertions
or deletions, with just a small number of large deletions. In contrast, TALENs induced
indels over a much broader range, centered around 5 bp to 20 bp deletions, possibly due to
the flexibility of the +63 C-terminal TAL domain [18].
3.4.6 Prediction and Validation of Off-target Sites for Novel Nucleases
To demonstrate the application of PROGNOS in analyzing newly designed nucleases, we
investigated the off-target cleavage of four pairs of TALENs and two pairs of ZFNs (Ta-
ble 3-4). TALENs containing the Asn-Asn (NN) RVD have been shown to be less specific
than corresponding TALENs containing the Asn-Lys (NK) RVD [18]; however the differ-
ence in off-target activity of NN-TALENs and NK-TALENs has not been demonstrated in a
genome-wide context. For ZFNs, although both 3-finger (3F) and 4-finger (4F) ZFNs have
been shown to have off-target cleavage [44, 88, 37], there has been no direct comparison
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Figure 3-5: Using SMRT Sequencing to analyze nuclease activity. (a) SMRT sequenc-
ing produced very similar results to standard TOPO sequencing over a range of mutation
rates from ∼20% to ∼76%. Error bars are 90% confidence intervals. S2/S5 NK and S2/S5
NN are the TALENs targeting beta-globin compared in this study. S116/S120 and J7/J8
are NK-TALENs targeting beta-globin and CDH1, respectively from Lin et al. [69]. (b)
Comparison of the range and frequency of different sizes of indels observed in cells treated
with TALENs or ZFNs. The observed frequencies of the different sizes are normalized to
the frequency of the most common indel size for each nuclease type.
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of off-target cleavage induced by 3F- and 4F-ZFNs that target the same DNA sequence.
We expressed the TALENs and ZFNs in HEK-293T cells, and analyzed the PROGNOS
top-ranked off-target sites (Table 3-4a,b). We found that TALENs exclusively using the
NN RVD to target all of the guanosine nucleotides in the target sequence imparted higher
activity level than TALENs exclusively using the NK RVD at corresponding positions, in
agreement with previous reports [54, 18]. However, the NN-TALENs tested in this study
had higher off-target cleavage activity than the corresponding NK-TALENs. For the first
time, off-target cleavage by NK-TALENs was uncovered, as well as bona fide TALEN
off-target sites with substantial (>5%) sequence divergence from the intended target that
lacked a 5’ pyrimidine and a site with a spacer longer than 24 bp (Table 3-4a). For ZFNs,
we found that the 4F-ZFNs had higher on-target activity (consistent with previous reports
that additional fingers increased activity [9]) and much lower off-target activity compared
with the corresponding 3F-ZFNs targeting the same DNA site. Specifically, all six of the
off-target sites found for the 3F-ZFNs had equal or greater activity than the off-target site
of the 4F-ZFNs (a single site with 0.2% activity), with three sites having activity >1%
(Table 3-4b).
3.4.7 Refinement of PROGNOS Ranking Algorithms
Although the set of initial PROGNOS algorithms (2 for ZFNs and 4 for TALENs) per-
formed well in locating bona fide off-target sites for newly-designed nucleases based solely
on in silico prediction, a user would still need to choose a specific algorithm or use all
the available algorithms without knowing a priori which one would be most predictive for
their nuclease. Using the expanded set of bona fide off-target sites including those found in
this study (Table 3-4) as well as new insights into TALEN-DNA binding [112, 75], we re-
fined the PROGNOS algorithms so that they are more sensitive, efficient, and user friendly
compared with the initial algorithms. Although the “Homology”, “Conserved G’s” and
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Table 3-4: SMRT Sequencing confirms on-target and off-target activity at sites ranked
by PROGNOS We interrogated 138 highly ranked genomic loci for the novel TALENs (a)
and ZFNs (b) using SMRT, and observed off-target activity in 13 cases, 9 of which were
outside the globin gene family. The “match type” indicates the orientation of the left (L)
and right (R) nucleases at the site and the length of the spacer sequence. In sequences,
lower-case letters indicate mutations compared to the target site. Site sequences are listed
as 5’–(+) half-site–spacer–(-) half-site–3’. Therefore, the (-) half-site for TALENs and the
(+) half-site for ZFNs are listed in the reverse anti-sense orientation compared to the DNA
sequence that the nuclease binds. Rankings by the initial PROGNOS algorithms Homology
(column H), RVDs for NK (RK), RVDs for NN (RN), and Conserved G’s (C) are displayed
as well as the rankings by the refined “TALEN v2.0” algorithm for NK (TK) and for NN
(TN) and the “ZFN v2.0” algorithm (Z). 293T Modification Frequency is the percentage
of observed sequences showing evidence of non-homologous end-joining repair. (c) 15
off-target sites for the CCR5 ZFNs ranked by PROGNOS that had not been previously
investigated were interrogated using SMRT, validating a novel off-target site. Additionally,
6 known highly active off-target sites were sequenced as positive controls. The PROGNOS
rankings for the site near KDM2A are listed as “N/A” because the site was not found by
PRGONOS due to the high number of mismatches. * indicates P < 0.05 in cells expressing
active nuclease compared to cells expressing empty vector. ˆ indicates P < 0.05 for the













Type (+) (-) (+) half-site (-) half-site H RK RN TK TN NK NN
S2/S5 TALENs
HBB L-16-R 0 1 TCACCTTGCCCCACAGGGCAGT tCAGGAGTCAGGTGCA 1 1 1 1 1 23.0% * 48.7% *ˆ
FAM3D R-17-R 3 3 TGCcCCTGACTCCTta AaAtGAGgCAGGTGCA 4 15 25 5 6 0.1% * 0.05%
HBD L-16-R 2 2 TCACtTTGCCCCACAGGGCAtT tCAGGAGTCAGaTGCA 2 2 2 2 2 0% 5.0% *ˆ
GPR6 R-30-R 2 5 TcCACCTGgCTCCTGT gCAGGAGTtAaGgGtA 21 241 16 11 5 0% 0.09% *ˆ
Total Sites Interrogated: 21 20
S1/S7 TALENs
HBB L-15-R 0 0 TCACCTTGCCCCACAGGGCAGTAAC AGGAGTCAGGTGCACCA 1 1 1 1 1 0.3% * 42.8% *ˆ
LINC00299 R-23-R 3 5 TGGaGCACCTGACcCCa AGGAGaaAaGgGCACCt 17 8 50 5 10 0.2% * 0.1%
HBD L-15-R 3 1 TCACtTTGCCCCACAGGGCAtTgAC AGGAGTCAGaTGCACCA 2 2 3 2 2 0% 4.9% *ˆ
FAM3D R-21-R 3 5 ctGTGCcCCTGACTCCT AtGAGgCAGGTGCAttt 8 4 2 13 6 0% 0.1% *ˆ
Total Sites Interrogated: 24 25
b) Novel ZFNs
H C Z ZFN Activity
4F ZFNs
HBB L-5-R 0 0 TCACCTTGCCCC GCAGTAACGGCA 1 1 1 6.3% *
PLG R-5-R 3 1 TGCCaTTgaTGC GCAGTAACtGCA 24 41 28 0.2% *
Total Sites Interrogated: 23
3F ZFNs
HBB L-5-R 0 0 CCTTGCCCC GCAGTAACG 1 1 1 1.9% *
ATG7 L-6-L 1 0 CCTTGgCCC GGGGCAAGG 3 7 11 0.5% *
TMEM132C R-6-L 1 0 aGTTACTGC GGGGCAAGG 4 35 9 0.2% *
PARD3B L-5-L 0 1 CCTTGCCCC GGGGCAAGc 5 8 7 1.3% *
GLIS2 L-6-L 1 0 CCTgGCCCC GGGGCAAGG 9 6 4 0.6% *
AFF3 L-6-L 2 0 CCTaGgCCC GGGGCAAGG 16 37 20 2.9% *
RGS10 L-6-L 0 2 CCTTGCCCC GGGGCAgaG 22 39 15 5.2% *




CCR5 L-5-R 0 0 GTCATCCTCATC AAACTGCAAAAG 1 1 1 31% *
CSNK1G3 L-5-R 3 1 GcCtTCCcCATC AAAgTGCAAAAG 33 13 18 0.09% *
Total Sites Interrogated: 16
Known Off-
Target Sites
CCR2 L-5-R 1 1 GTCgTCCTCATC AAACTGCAAAAa 2 5 2 11% *
KDM2A R-5-L 2 5 CTaTTaCAGTTT GATGAGGtctca N/A N/A N/A 2.6% *
BTBD10 L-5-R 2 1 GTttTCCTCATC AAACTGCAAAAt 3 45 6 2.6% *
KCNB2 L-5-R 3 1 aTgtTCCTCATC AAACTGCAAAtG 29 33 8 1.3% *
WBSCR17 R-6-L 2 2 CTgTTcCAGTTT GcTGAGGATaAC 60 51 95 1.4% *
TACR3 L-5-R 1 3 GTCATCtTCATC AAACTGtAAAgt 17 197 26 8.6% *
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“RVDs” algorithms (including the “5TC” version for TALENs) all located bona fide off-
target sites, no algorithm was consistently superior across all ZFNs or all TALENs studied
(Figure 3-2b,c and Table 3-4). In developing the refined algorithms, we were able to unify
the different algorithms for each type of nuclease into a single algorithm (ZFN v2.0 for
ZFNs, TALEN v2.0 for TALENs). Compared with the original PROGNOS algorithms,
ZFN v2.0 and TALEN v2.0 achieved higher precision within the Top 16 rankings (repre-
senting the minimum recommended size of a small-scale off-target analysis), located higher
mean percentages of known off-target sites per nuclease across all nucleases tested (within
the top 3X rankings for previously investigated nucleases and within the same number of
sites as in the PROGNOS-based investigations, and had lower standard deviations of the
mean percentages, demonstrating that the refined algorithms performed more consistently
across all nucleases tested.
In developing the refined and unified ZFN algorithm, we added factors weighing a
model of the binding energy of each zinc finger subunit [88] and polarity effects reflecting
the distance of a mismatch from the FokI domain and allowed more flexible models of the
previous concepts of energy compensation between the two half-sites of a nuclease pair and
a stronger affinity for guanosine residues. This new “ZFN v2.0” algorithm outperforms the
initial “Homology” and “Conserved G’s” algorithms for ZFNs in terms of both identifying
a larger set of bona fide off-target sites for the nucleases tested and having superior precision
within the Top 16 rankings (Figure 3-6a). The Top 16 ranked sites were chosen as a cutoff
because by necessity nearly all of the novel off-target sites found were within the Top 24
rankings of one of the original algorithms since that was their initial criteria for being
selected for investigation. Therefore, a stricter cutoff was required in order to observe
differential performances between the algorithms for these new sites.
Recently, Sander et al. [101] used Bayesian machine learning to re-analyze the original
results of the in vitro cleavage experiments for CCR5 and VEGF ZFNs [88] and subse-
quently developed two separate classifiers that ranked all sequences in the human genome
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for their potential as off-target sites of either the CCR5 or VEGF ZFNs respectively. Their
work validated 25 new bona fide off-target sites for the CCR5 and 26 new sites for the
VEGF ZFNs, but did not locate—among any of the 15,882 possible off-target sites pre-
dicted for the CCR5 ZFNs by their classifier system—the novel off-target site for the CCR5
ZFNs predicted by the PROGNOS algorithms near CSNK1G3 that was validated in this
study (Table 3-4c).
Since the 51 new sites found by Sander et al. [101] were not part of the training set
for the “ZFN v2.0” algorithm, this provided an opportunity to test the new algorithm for
its ability to locate additional off-target sites. By extending the standard PROGNOS search
limit recommendations for the CCR5 ZFNs to allow for a larger number of possible off-
target sites (3X the number of possible off-target sites considered by Sander et al.), we
found that the refined ZFN algorithm successfully identified more than half (13 of 25 =
52%) of the new off-target sites for those ZFNs (Figure 3-6b). For the VEGF ZFNs, the
standard PROGNOS search provided enough potential off-target sites to make an appro-
priate 3X comparison to Sander et al. [101], and the refined algorithm again located more
than half (18 of 26 = 69%) of the new off-target sites for those ZFNs. Three additional
pairs of ZFNs (a 3-finger pair, a 4-finger pair, and a 5-finger CompoZr pair from Sigma-
Aldrich) which had previously been investigated using the Homology and Conserved G’s
PROGNOS algorithms [79, 1] were also re-analyzed using the refined algorithm and all
six of the previously located bona fide off-target sites were highly ranked by ZFN v2.0.
Taken together, these results provide significant evidence that the refined ZFN algorithm
was not overtrained to existing sites during its development and is able to robustly predict
additional bona fide off-target sites. An analysis of each of the components of the ZFN v2.0
algorithm showed that while all play a part in the improved performance, some parameters
are more critical to the algorithm than others (Figure 3-7).
In developing the refined and unified TALEN algorithm, we added new parameters
based on compensatory effects of strong RVDs (NN and HD) [112] on adjacent mismatches
63
Figure 3-6: Improved performance of the refined PROGNOS algorithms. (a) The
performance of the two initial ZFN algorithms and the refined “ZFN v2.0” algorithm are
compared for their ability to predict off-target sites for the all ZFNs in the training and
validation sets. Percentages of off-target sites located were calculated according to 3X
limits for previous studies and within the number of sites interrogated for PROGNOS-
based studies (typically the top 24 ranked sites). Error bars represent standard deviation.
(b) The expanded landscape of 38 total heterodimeric off-target sites for the CCR5 ZFNs
found by four different experimental-based prediction methods and the refined “ZFN v2.0”
PROGNOS algorithm. The PROGNOS sites are drawn from the top rankings spanning
3X the number of predictions by the Bayesian abstraction of the in vitro cleavage profile.
(**) Note that only six of the sites found using ChIP-Seq were provided by Sander et al.
[101], so the full degree of overlap of all ChIP-Seq sites with sites found by other methods
is unclear. (c) The performance of the four original TALEN algorithms and the refined
“TALEN v2.0” algorithm are compared for their ability to predict off-target sites for all
TALENs in the training and validation sets.
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Figure 3-7: Performance of ZFN v2.0 Algorithm Variants. To determine the impact
of each of the individual parameters of the ZFN v2.0 algorithm, each parameter was sys-
tematically removed from the analysis of both the training set (a) and the full list of ZFN
off-target sites comprising the training set and the validation set (b). The specific alterations
to the parameters in the algorithm formula are supplied in the graph. To measure aggregate
performance of the algorithms across a wide range of ZFNs, we measured the percentage
of known off-target sites for each ZFN pair that the algorithms were able to identify (within
3X limits for previously studied ZFNs, and within the limit of the original Homology and
Conserved G’s PROGNOS experimental searches for newly studied ZFNs), and then took
the mean of these percentages across all ZFNs. In some cases, algorithms tied in perfor-
mance by this metric, so we further measured the ability of the algorithms for the total
number of off-target sites that they identified within the defined limits. The ordering of the
algorithm variants was chosen based on the results for the training set data (a) and main-
tained in the same ordering for the full off-target set (b). From this analysis, we observed
that while removing any one of the individual parameters does not cause a severe decrease
in effectiveness of the algorithm (with the exception of setting either First Penalty or Ad-
ditional Penalty to 0), it is only when all of the parameters are incorporated that optimal
results—both in the training set and the full set—are achieved.
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and polarity effects indicating that mismatches further from the N-terminus are less dis-
ruptive [75]. These new considerations were combined with a model of dimeric nucle-
ase interactions, as well as RVD-nucleotide association frequencies. To improve upon the
RVD-nucleotide association frequencies derived from natural TAL effectors [28], as were
used in the initial “RVDs” algorithm and the TALE-NT online tool [28], we calculated as-
sociation frequencies based on SELEX data from engineered TAL domains [77, 116, 51]
(Figure 3-8 and Table 3-1). Importantly, this generated an association frequency for the 5’
“Position 0” in the TALEN binding site that allowed us to use this parameter to unify the
“5TC” and standard versions of the “RVDs” algorithm. Further, we found that while the nu-
cleotide frequencies for the RVDs NI, HD, NK, and NG did not appreciably vary between
engineered TALEs and natural TALEs, the results for NN were substantially different. Al-
though the NN RVD is still the least specific of all the standard RVDs, in engineered TALEs
it showed a stronger preference for its intended base (guanosine) and a reduced preference
for adenosines and cytidines compared with that of naturally occurring TALEs (Table 3-
1). We found that the new unified “TALEN v2.0” algorithm outperforms the four initial
algorithms for TALENs in terms of both having higher precision within the Top 16 rank-
ings and locating a higher mean percentage of known off-target sites per nuclease across
all nucleases tested (Figure 3-6c). The refined TALEN algorithm was additionally able to
predict several bona fide TALEN off-target sites not in its training set that were found using
the initial PROGNOS algorithms [79], demonstrating that the refined algorithm was not
overtrained during development and retains robust predictive capabilities. An analysis of
each of the components of the TALEN v2.0 algorithm showed that while all play a part in
the improved performance, some parameters are more critical to the algorithm than others
(Figure 3-9).
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Figure 3-8: Average RVD-nucleotide frequencies of engineered TAL domains. Pub-
lished SELEX data from nine engineered TAL domains [77, 116, 51] were compiled to
derive the average nucleotide association frequencies for the 5’ base and the 5 common
RVDs (Table 3-1). These frequencies are employed in the “TALEN v2.0” prediction algo-
rithm.
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Figure 3-9: Performance of TALEN v2.0 Algorithm Variants. To determine the impact
of each of the individual parameters of the TALEN v2.0 algorithm, each parameter was sys-
tematically removed from the analysis of both the training set (a) and the full list of known
TALEN off-target sites comprising the training set and the validation set (b). The specific
alterations to the parameters in the algorithm formula are supplied in the graph. Because
investigations of TALEN off-target activity have been much more limited than ZFNstyp-
ically investigating ∼20 locations and finding 1-2 bona fide off-target sites as opposed to
investigating 30-100 potential sites out of up to thousands of predicted locationswe were
able to use more precise measurements of the algorithms’ performances. Our initial chief
metric for this analysis was number of bona fide sites found in the Top 16 rankings, but
as the total number of bona fide sites within those rankings was so low (6 sites was the
highest result in the training set) we found that there were not any differences in this metric
for many of the variants. We therefore further included secondary and tertiary measure-
ments of the total number of bona fide off-target sites found within the search limits (3X
for previous investigations and 24 sites for novel nucleases tested) and the mean rank of all
off-target sites located (taking the reciprocal in this case so that larger values implied a su-
perior performance). The ordering of the algorithm variants was chosen based on the results
for the training set data (a) and maintained in the same ordering for the full off-target set
(b). While removing some of the individual parameters does not cause a marked decrease
in effectiveness of the algorithm, it is only when all of the parameters are incorporated that
optimal results—both in the training set and the full set—are achieved.
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3.4.8 Sensitivity and Specificity of PROGNOS Search Algorithms
When applying the initial PROGNOS algorithms to identify off-target sites for newly con-
structed NN-TALENs and 3- and 4-finger ZFNs, we obtained a very manageable average
false positive ratiodefined as the number of interrogated sites with no detectable activity
compared to the number with detectable activityof only ∼11:1, which is less than 2-fold
higher than current experimental prediction methods (Figure 3-10a). When interrogating
three additional pairs of NN-TALENs with the initial algorithms, we observed a similarly
low false positive ratio of 11:1 [79]. For NK-TALENs, the false positive ratio was higher
(∼21:1); however, since no previously published method has identified any off-target sites
for NK-TALENs, we were not able to make a meaningful comparison of the false positive
ratio with experimental-based prediction methods. As the new “ZFN v2.0” and “TALEN
v2.0” algorithms have higher precision among the Top 16 rankings, we would expect that
their false positive ratios would be even lower than the initial algorithms when used as the
basis for investigations of novel nucleases.
As mentioned above, to date only a single nuclease pair (the heterodimeric sites of
the CCR5 ZFNs) has had its off-target cleavage investigated by independent experimental
prediction methods [88, 101, 37], and it is therefore the only pair for which a false negative
rate analysis can be conducted. Defining the false negative rate as the percentage of all
known off-target sites that are not predicted by the particular method within a top portion
of the rankings, the PROGNOS algorithms had false negative rates equal or superior to the
IDLV and in vitro cleavage experimental prediction methods (Figure 3-10b). A Precision-
Recall analysis of the different predictive methods for the CCR5 ZFNs using the false
discovery and true positive rates also demonstrates that the PROGNOS algorithms perform
comparably to experimental based prediction methods.
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Figure 3-10: Sensitivity and specificity analysis of PROGNOS algorithms. (a) Average
false positive ratios are shown for the PROGNOS investigation of novel nucleases using
the initial algorithms, and for previous experimental prediction methods. Ratios are also
shown for individual nucleases in the three different categories of nuclease that have been
investigated previously by experimental prediction methods. (b) The false negative rates
of the different PROGNOS algorithms and previous experimental prediction methods are
shown. These were determined by each methods ability to identify the 38 known hetero-
dimeric off-target sites of the CCR5 ZFNs in their top ranking predictions.
Table 3-5: Comparison of TALENOffer to PROGNOS TALEN v2.0 Algorithm For
the full set of TALEN off-target sites, as well as different relevant subsets, the PROGNOS
TALEN v2.0 algorithm consistently outperforms the TALENoffer search program in terms
of both having lower (better) mean rankings for all off-target sites and a higher (better)
number of sites in the Top 16 rankings of the different TALENs. For all TALENs and
for both algorithms, the off-target sites in highly homologous, closely related genes were
ranked #2.
All Known TALEN Off-Target Sites:
Training TALEN v2.0 Ranking TALENoffer Ranking
Mean Rank of Off-Target Sites 7.8 45.8
# of sites in Top 16 Rankings 12 out of 14 9 out of 14
Excluding Highly Homologous Sites In Closely Related Genes:
Mean Rank of Off-Target Sites 10.1 65.1
# of sites in Top 16 Rankings 8 out of 10 5 out of 10
Excluding Nucleases in TALEN v2.0 Training Set and Sites in Highly Homologous Genes:
Mean Rank of Off-Target Sites 12.8 110.4
# of sites in Top 16 Rankings 4 out of 5 2 out of 5
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3.5 Discussion
Engineered nucleases can readily be designed and optimized to target specific endogenous
sequences in a genome. However, to reach their potential for generating research model
systems and treating human diseases, the specificity of engineered nucleases must be bet-
ter understood. However, the analysis of the location and frequency of TALEN and ZFN
off-target effects has been beyond the reach of most laboratories due to the limitations
of the existing methods. We created PROGNOS, an online search tool solely based on
bioinformatics and the current understanding of nuclease-DNA interactions, which allows
users to predict potential nuclease off-target sites by following a simple set of instructions,
and to evaluate the sites using standard molecular biology techniques if so desired (Fig-
ure 3-11). The novel bioinformatics ranking algorithms in PROGNOS predict many of
the off-target sites of the CCR5 ZFNs that were identified previously using experimental
methods and also identified a novel off-target site that was missed in those studies. How-
ever, there are several highly active (>5% mutation rate) off-target sites for these ZFNs that
PROGNOS did not rank highly, suggesting that there are still unknown factors influencing
ZFN off-target activity that are not accounted for in our current models. Future unbiased
genome-wide analysis of off-target activity (such as the IDLV method [37]) will be critical
to build a larger data base of sites with low sequence homology from which further insight
into the factors affecting off-target activity can be gained. Nevertheless, PROGNOS is able
to successfully predict many off-target sites and overcomes the drawbacks of the current
experimental-based prediction methods that limit the number of nucleases tested, as evi-
denced by the fact that no bona fide off-target sites for new ZFNs or TALENs have been
reported over the last two years (Sept 2011 through Dec 2013) [116, 51]. The improved
performance of the refined “ZFN v2.0” and “TALEN v2.0 algorithms over the initial algo-
rithms highlights a key advantage of bioinformatics-based predictions: as more bona fide
off-target sites are discovered, increasingly better predictive models can be incorporated.
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Figure 3-11: Flowchart of PROGNOS-aided search of off-target sites. The entire pro-
cess of designing a nuclease, confirming on-target activity, and testing off-target activity
can be completed with minimal “hands-on” time when aided by PROGNOS. After trans-
fection and genomic DNA harvesting, the off-target search process takes several days of
preparation before sequencing, and several days after to process the results.
PROGNOS allowed interrogation and comparison of the off-target activities of sev-
eral novel nucleases targeting the beta-globin gene. We directly compared 3-finger vs.
4-finger ZFNs that targeted the same site, and compared NK-TALENs vs. NN-TALENs
that shared target sites. We found that these NN-TALENs and 3-finger ZFNs had more
off-target activity than the corresponding NK-TALENs and 4-finger ZFNs, respectively.
While NN-TALENs generally have high on-target cleavage, this may be accompanied by
decreased specificity leading to high off-target activity. To confirm the conclusion that the
4F-ZFNs targeting this site are more specific than the 3F versions, we interrogated several
of the validated 3F-ZFN off-target sites in cells expressing 4F-ZFNs and found no statisti-
cally significant off-target activity. Our comparison of the specificity of NN-TALENs vs.
NK-TALENs is somewhat limited by the fact that the NN-TALENs had higher on-target
activity than the corresponding NK-TALENs, but the dramatic difference in off-target ac-
tivity at HBD for the S2/S5 NN- and NK-TALENs (Table 3-4) strongly supports the notion
that NK-TALENs have improved specificity over NN-TALENs.
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Although TALENs seem to be much easier to design and appear less cytotoxic than
ZFNs, there still remain concerns about off-target effects. The three previously reported
cases of TALEN off-target sites shared only 78% [116], 74% [51], and 72% [51] sequence
homology to the intended target site. We observed off-target activity at four additional sites
sharing only 81%, 78%, and two cases of 76% homology to the intended target. Given
the abundance of sites in a genome that share that level of homology with a TALEN target
site, these findings strongly reinforce the need to interrogate these types of genomic loci
for possible off-target cleavage.
The lack of discrimination of NN RVDs between guanosine and adenosine is a major
concern. We report here, at the GPR6 off-target site for the S2/S5 TALENs, a case where
there are two substitutions of G→A in one half-site and the NN TALENs show off-target
activity while the NK TALENs do not. In the HBD site for both TALEN pairs, even though
there are no G→A substitutions, the NN TALENs show high off-target activity while the
NK TALENs show none at all. It is likely then, that NN may increase off-target activity
of the TALENs through alternative means; perhaps the strong affinity of the NN RVD can
compensate for mismatched bases in other positions in the TALEN binding site. Although
NN imparts higher activity than NK, we caution its use due to increased off-target effects.
Previously, TALENs had been shown to have strong preference for a pyrimidine in the
5’ position of the binding site. We report here, the first cases of off-target activity at sites
lacking a 5’ pyrimidine. Both of these were homodimeric sites of the S1 TALEN where
an adenosine was in the 5’ position of one of the half-sites. It remains to be determined
whether this is a general feature of all TALENs, or if somehow specific to a characteristic
of the S1 TALEN.
We employed wild-type FokI domains that allow homodimerization of nucleases in
order to see a broader picture of nuclease off-target activity. We found that in several
cases, homodimers of one nuclease showed nearly equal, or greater activity at an off-target
site compared to the activity of the heterodimer at the target site. While research into the
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fundamental basis of nuclease off-target effects should continue to look at homodimeric
interactions, we would strongly recommend use of hetero-obligate FokI architectures [30]
for use in nucleases for targeted genome editing in order to reduce the off-target effects.
TALENs using the +63 C-terminal truncation (as were used here) have been shown
to cleave over a wide range of spacers [18]. This makes design of TALENs easier and
increases the number of potential sequences that can be targeted, but it also increases the
number of potential regions of the genome that could be cleaved through off-target activ-
ity. At the GPR6 off-target site for the S2 homodimer, we observed off-target activity with
a 30 bp spacer—the longest reported for an off-target site. Reducing the range of spac-
ers that TALENs can cleave at—potentially through use of shorter C-terminal truncations
[18]—has the potential to greatly reduce TALEN off-target effects.
3.6 Conclusion
In summary, PROGNOS provides a user-friendly, web-based tool for rapid identifica-
tion of potential nuclease off-target cleavage sites that can be evaluated using standard
molecular biology techniques. The bioinformatics-based ranking algorithms in PROGNOS
identify most nuclease off-target cleavage sites found by existing experimental methods.
PROGNOS has relatively low false positive ratios and comparable false negative rates to
experimental-based predictions, making it a robust method that can be readily implemented
by most laboratories. Screening potential target sites using PROGNOS can facilitate the se-
lection of better nuclease target sites that minimize the number of likely genomic off-target
sites. PROGNOS allows nuclease off-target analysis to become a routine component of
nuclease design and testing, facilitating the discovery of new off-target sites for ZFNs and
TALENs, which expand the off-target database and may improve the PROGNOS algo-
rithms. These capabilities give PROGNOS the potential to help expand and expedite the
application of engineered nucleases for a wide range of biological and medical applications.
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CHAPTER IV
USING PROGNOS TO EXPAND THE DATASET OF NUCLEASES
WITH KNOWN OFF-TARGET SITES
4.1 Introduction
A major advantage of in silico predictive models is that they can be iteratively refined and
improved as more data become available. Although the algorithms developed in Chapter 3
successfully located several bona fide off-target sites, the data available at the time were
fairly limited; off-target sites were known for only three different ZFNs and two different
TALENs (for a total of only 3 TALEN off-target sites) in 2011 when the study was initiated.
By applying the PROGNOS algorithms to many different ZFNs and TALENs, the training
set of known off-target sites was greatly expanded to allow for more sophisticated machine
learning techniques that reveal underlying patterns and trends that can better differentiate
between bona fide off-target sites and other sites with homology to the intended target of
the nuclease. This work moves the field closer to the ultimate goal of off-target prediction
algorithms that allow for screening of potential nuclease target sites in order to design, with
reasonable confidence, a nuclease with no likely off-target sites in the genome of interest.
In addition to locating new off-target sites, the following studies also revealed information
about off-target activity related to different delivery methods, nuclease types, cell types,
and doses.
4.2 Methods
Genomic DNA samples were provided to me by various collaborators. The genome of
interest was scanned using the PROGNOS algorithm [34] and potential off-target sites were
rank-ordered. Using primers designed by the PROGNOS algorithm, PCR reactions were
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performed and amplicons were sequenced and analyzed exactly as previously described
(Section 3.3.7.2, Section 3.3.8.1, and Section 3.3.8.2).
4.3 Results
4.3.1 Lentiviral delivery of ZFNs into mouse SC-1 cells1
Delivery of nucleases into primary cells is a challenge in the field. Packaging nucleases into
lentiviral vectors allows for efficient delivery. We tested the on-target and off-target activ-
ity of ZFNs delivered into murine SC-1 embryonic fibroblasts targeting the “safe-harbor”
Rosa26 locus. After analyzing the top 24 sites predicted by the PROGNOS ZFNv2.0 algo-
rithm [34], robust activity was observed at the target site and modest off-target activity at
the locus near Lgals3 (Table 4-1).
In addition, collaborators also had lentivirus encoding the CCR5-ZFNs [89] available.
Although the mouse homolog to CCR5 contains several mismatches within the binding site
of the ZFNs designed for the human gene, these ZFNs were also interrogated for off-target
activity after lentiviral transduction (Table 4-1).
4.3.2 Lentiviral delivery of ZFNs into rat cells2
4.3.2.1 Abstract
ZFNs are promising tools for genome editing for biotechnological as well as therapeutic
purposes, however delivery remains a major issue impeding targeted genome modification.
Lentiviral vectors are highly efficient for delivering transgenes into cell lines, primary cells
and into organs, such as the liver. However, the reverse transcription of lentiviral vec-
tors leads to recombination of homologous sequences, as found between and within ZFN
monomers. We used a codon swapping strategy to both drastically disrupt sequence identity
between ZFN monomers and to reduce sequence repeats within a monomer sequence. We
1Collaboration with Kerstin Schmidt and Dr. Dorothee von Laer, Division of Biology, Innsbruck Medical
University, Austria
2Modified from: Abarrategui-Pontes C, Creneguy A, Thinard R, Fine EJ et al. (2014). Codon Swapping
of Zinc Finger Nucleases Confers Expression in Primary Cells and In Vivo from a Single Lentiviral Vector.
Human Gene Therapy [1]
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Table 4-1: Rosa26 and CCR5 ZFN off-target activity at sites ranked by PROGNOS.
23 sites from throughout the top-ranked cleavage sites of the Rosa26 and CCR5 ZFNs,
as determined by the PROGNOS ‘ZFN v2.0’ algorithm, were evaluated using SMRT se-
quencing in transduced SC-1 cells. The site in the Eif4g3 locus was chosen based on a
‘rational design’ analysis of the zinc finger binding helices. The ‘match type’ indicates the
orientation of the left (L) and right (R) nucleases at the site and the length of the spacer
sequence. Site sequences are listed as 5’–(+) half-site–spacer–(-) half-site–3’. Therefore,
the (+) positive half-site is listed in the reverse anti-sense orientation as compared to the
DNA sequence that the ZFN binds. In sequences, lower-case letters indicate mismatches
as compared to the target site. “SC-1 cells modification frequency” is the percentage of
observed sequences showing evidence of NHEJ events. For all sites shown, significantly







RankingsZFN Closest Gene Match Type (+) (-) (+) half-site (-) half-site
Rosa26
Gt(ROSA)26Sor L-6-R 0 0 GACTCCCGCCCA AGAAAGACTGGAGTTGCA 1 29.05%
Lgals3 L-6-R 5 4 ctCcCCCcaCCA ccAAAGACTGttGTTGCA 20 0.07%
Total Sites Interrogated: 23
CCR5
Gm2176 L-6-R 1 2 GTCAgCCTCATC AAACTGaAAAtG 2 0.46%
Syt17 L-5-R 3 1 GagATCCaCATC AAACTGCAAgAG 7 3.87%
Ccr5 L-5-R 1 2 GTCtTCCTCATC AAgCTGCAAAAa 10 0.06%
Ppfia2 L-5-R 2 2 tTCAgCCTCATC AAAacGCAAAAG 23 0.45%
C530044C16Rik L-5-R 3 1 GTCAggCTCAgC AAACTGCAAAgG 26 0.72%
BC031181 L-5-R 3 2 aagATCCTCATC AAACaGgAAAAG 46 13.29%
Mamdc2 L-5-R 3 1 tTCAgtCTCATC tAACTGCAAAAG 54 0.95%
Eif4g3 L-5-R 5 1 caCtTaCTCcTC AAACTGgAAAAG 3152 18.47%
Total Sites Interrogated: 23
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constructed lentiviral vectors encoding codon-swapped ZFNs or unmodified ZFNs from a
single mRNA transcript. We reduced total identity between ZFN monomers from 90.9% to
61.4% and showed that a single lentivirus allowed efficient expression of functional ZFNs
targeting the rat UGT1A1 gene after codon-swapping, leading to much higher ZFN activity
in cell lines (up to 7-fold increase compared to unmodified ZFNs and 60% activity in C6
cells), as compared to plasmid transfection or a single lentivirus encoding unmodified ZFN
monomers. Off-target analysis located several active sites for the 5-finger UGT1A1-ZFNs.
4.3.2.2 Methods
C6 cells (5 ∗ 104) were seeded in each well of a 6-well plate one day before transduction.
On the day of transduction, the medium was changed before addition of the viral particles.
Cells were kept at 37°C for four days before genomic DNA was harvested and subjected to
off-target analysis.
4.3.2.3 Results
The high levels of targeted DSBs in the UGT1A1 gene observed after C6 cell transduction
with codon-swapped lentivirus gave the opportunity to look for potential off-target effects,
which may not be easily detectable with a low ZFN activity, as observed after transfection.
Off-target sites were chosen for investigation based on a mixture of the top-ranked sites
by the PROGNOS method [34]. Using SMRT sequencing, we interrogated 22 genomic
loci that were highly ranked for cleavage in the rat genome by the Ugt1A1 ZFNs (the
intended target site and 21 potential “off-target” sites) in transduced C6 cells. High levels of
modification (∼64.4%) at the UGT1A1 intended target was confirmed and we also detected
off-target activity at 6 additional loci (Table 4-2). Off-target sites were found in an intronic
region of the Tarsl2 gene at a frequency of ∼10% and in five other sites at low frequency.
Of note, Tarsl2 and Gbas off-target sites share only 80% sequence identity with the target
site.
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Table 4-2: UGT1A1 ZFN off-target activity at sites ranked by PROGNOS. The 22 top-
ranked cleavage sites of the UGT1A1 ZFNs, as determined by the PROGNOS ‘homology’
and ‘Conserved G’s’ algorithms, were evaluated using SMRT sequencing in transduced
C6 cells. The ‘match type’ indicates the orientation of the left (L) and right (R) nucle-
ases at the site and the length of the spacer sequence. Site sequences are listed as 5’–(+)
half-site–spacer–(-) half-site–3’. Therefore, the (+) positive half-site is listed in the reverse
anti-sense orientation as compared to the DNA sequence that the ZFN binds. In sequences,
lower-case letters indicate mismatches as compared to the target site. “C6 cell line mod-
ification frequency” is the percentage of observed sequences showing evidence of NHEJ
events. For all sites shown, significantly higher (p < 0.05) frequencies of indels were ob-
served in transduced cells as compared to mock treated cells. Our analysis revealed that
the locus near the Ftcd gene contains a homozygous C→T SNP at the second position of







Closest Gene Match Type (+) (-) (+) half-site (-) half-site Homology Conserved G’s
Ugt1a1 L-5-R 0 0 CTCCGGTTCCCATGG ATGAAGGAATATGCA 1 1 64.469%
Tarsl2 L-5-R 3 3 CTCCtaTcCCCATGG ATGAAGGAAgcTGCt 9 2 10.464%
Gbas L-6-R 2 4 CTCaGGTTCCCgTGG ATGgAGGAATATctt 4 22 1.282%
Il1rapl1 L-5-R 5 2 aTCCGGTgCCCtTtt cTGcAGGAATATGCA 29 9 0.229%
Myo16 R-6-L 5 3 TtCAatgcCCTTCAT CCtTGGGtACtGGAG 205 12 0.157%
Ssr1 R-6-L 2 4 TGCATATTCCTTgcT gCATGGGAcCaGaAG 3 20 0.117%
Ftcd R-6-L 5 4 gtCAcAaTCCaTCAT atgTGGGAACaGGAG 240 13 0.051%
Total Sites Interrogated: 22
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4.3.2.4 Discussion
When nucleases cut at other locations in the genome other than their intended target, they
can potentially induce unwanted gene disruption, destabilization of the cell’s genome, or
transformation of the cell into a cancerous pheno- type. Therefore, it is important to reveal
potential off-target sites of a given pair of ZFNs. A pre-requisite for detecting off-target
sites is to induce sufficient on-target activity. Because of high ZFN activity in C6 cells, we
could investigate off-target effects using the PROGNOS algorithm in these cells [34]. Given
that only 21 potential off-target sites were interrogated, finding six bona fide locations of
off-target activity, validated as having a statistically significant mutation frequency greater
than untreated cells, was higher than expected. Based on off-target studies of other 3- and
4-finger ZFNs, an analysis of this size would be expected to yield perhaps four bona fide
off-target sites [34, 37, 44, 88, 101]. Moreover, this study is the first report of bona fide
off-target activity discovered for 5-finger ZFNs with heterodimeric FokI domains. In our
study, the levels of on-target activity after lentiviral transduction were much higher than
in previous studies [34]. Thus, it is probable that conducting these studies by delivering
ZFNs using a single lentiviral vector and our codon swapping approach revealed off-target
sites that wouldn’t have been detected otherwise with an approach that yielded lower on-
target activity. Our data highlight the impact of the nuclease design and of the efficacy of
delivery methods on off-target effects and thus on the biosafety of artificial nucleases for
gene therapy purposes.
4.3.3 Dosing experiments with GFP ZFNs3
The pair of ZFNs targeting a sequence in the green fluorescent protein (GFP) have been
used in many previous studies [90], but their off-target activity had never been charac-
terized. The GFP-ZFNs were transfected into a special line of HEK-293T cells with an
integrated copy of the GFP gene. Several different doses were transfected to examine the
3Collaboration with Dr. Zhong Chen and Dr. Steffen Meiler, Medical College of Georgia
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Figure 4-1: GFP-ZFN Dose Response
dose-response and to determine if a “sweet-spot” of the on-target:off-target activity ratio
could be found. We interrogated the top 23 sites ranked by the PROGNOS ‘Homology’ and
‘Conserved G’s’ algorithms [34] and found one bona fide off-target site near the TM2D1
locus resulting from homodimeric binding of the left zinc finger to a sequence with a sin-
gle A→G mismatch in the 2nd position of the right half-site. Although a dose-dependent
response for both the on-target and off-target sites was observed, the on-target:off-target
specificity ratio did not appreciably vary (Figure 4-1).
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4.3.4 TALENs facilitate targeted genome editing in human cells with high specificity
and low cytotoxicity4
4.3.4.1 Abstract
Designer nucleases have been successfully employed to modify the genomes of various
model organisms and human cell types. While the specificity of ZFNs and RGENs has
been assessed to some extent, little data are available for TALENs. Here, we have engi-
neered TALEN pairs targeting two human loci (CCR5 and AAVS1) and performed a detailed
analysis of their activity, toxicity and specificity. The TALENs showed comparable activ-
ity to benchmark ZFNs, with allelic gene disruption frequencies of 15-30% in human cells.
Notably, TALEN expression was overall marked by a low cytotoxicity and the absence
of cell cycle aberrations. Bioinformatics-based analysis of designer nuclease specificity
confirmed fairly substantial off-target activity of ZFNs targeting CCR5 and AAVS1 at six
known and five novel sites, respectively. In contrast, only marginal off-target cleavage ac-
tivity was detected at four out of 49 predicted off-target sites for CCR5- and AAVS1-specific
TALENs. The rational design of a CCR5-specific TALEN pair decreased off-target activity
at the closely related CCR2 locus considerably, consistent with fewer genomic rearrange-
ments between the two loci. In conclusion, our results link nuclease-associated toxicity to
off-target cleavage activity and corroborate TALENs as a highly specific platform for future
clinical translation.
4.3.4.2 Methods
Target sites at the two chosen human loci where identified in proximity of benchmark ZFN
targets without using previously published algorithms. TALE-based DNA binding domains
were assembled using a previously described Golden Gate assembly kit [14] that was modi-
fied with four different Level 3 destination vectors to express functional nuclease monomers
4Modified from: Mussolino C, Alzubi J, Fine EJ et al. (2014). TALENs facilitate targeted genome editing
in human cells with high specificity and low cytotoxicity. Nucleic Acids Research [79]
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based on our previously optimized TALEN scaffold [80] (∆135/+17). These vectors in-
cluded the 17.5th repeat and the wild-type FokI cleavage domain (pVAX CMV TALshuttle(xx);
‘xx’ stands for the four different 17.5th RVDs used, NI, NG, HD and NN). The ZFN ex-
pression plasmids were generated by subcloning previously published zinc-finger arrays
(codon-optimized and synthesized by GeneArt/Life Technologies, Regensburg) into the
pRK5.N backbone [3], which includes an N-terminal HA tag and the SV40 nuclear local-
ization domain and either of the obligate heterodimeric FokI variant KV or EA [114] at the
C-terminus.
HEK-293T cells were cultured in Dulbeccos modified Eagles medium (DMEM, PAA)
supplemented with 10% Fetal Bovine Serum (FBS, PAA), 100 U/ml penicillin (PAA) and
100 µg/ml streptomycin (PAA). Cells were transfected with polyethylenimin (PEI) as pre-
viously described [80]. Genomic DNA was extracted from HEK-293T cells 3 days post-
transfection with ZFNC, ZFNA, TC06, TC-NC, TA04 or empty vector. Potential off-target
sites for the TALENs were chosen from the PROGNOS RVD-5TC and Homology-5TC
rankings to contain a mixture of the top-ranked sites from both algorithms [34]. In addi-
tion, CCR2 was also interrogated for the TC-NC TALENs to facilitate comparison at that
off-target site, even though this site did not appear in the 5TC PROGNOS rankings because
of the lack of the 5’ pyrimidine in one of the half-sites. The ‘specificity factor’ in Tables 4-3
and 4-4 is calculated as the ratio of on-target to off-target mutagenesis frequency based on
the detected indels events.
4.3.4.3 Results
We investigated the specificity of our CCR5- and AAVS1-specific designer nucleases by
high-throughput sequencing at potential off-target sites predicted in silico using the recently
developed PROGNOS software [34]. When applying the bioinformatics tool, four of seven
previously validated off-target sites (Table 4-3; [37, 88]) were listed in the top 32 off-
target sites for the CCR5-specific ZFN For the AAVS1-specific ZFN, few specificity data are
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available in the literature. PROGNOS confirmed the prediction of two out of five previously
identified but not validated [50] off-target sites in the top 23 list of predicted off-target
sites. We also used PROGNOS to predict the top 15 off-target sites for TC06 and TC-NC
CCR5-specific TALENs, respectively, and the top 22 off-target sites for the AAVS1-specific
TALEN TA04.
For the CCR5-specific ZFN, we confined high-throughput sequencing analysis to those
sites that were previously identified and we confirmed off-target cleavage activity at six
out of seven sites analyzed, sometimes with disruption activities over 12%, i.e. almost as
high as at the CCR5 locus. Moreover, PROGNOS was able to predict a novel off-target
site on chromosome 5 [34]. Analysis of off-target cleavage of the AAVS1-specific ZFN
pair revealed activity of up to 4.4% at 5 out of the 23 predicted off-target sites (Table 4-4).
Hence, we validated three previously predicted off-target sites and identified and validated
two additional off-target sites for the AAVS1-specific ZFN. In addition to CCR2, the two
CCR5-specific TALEN pairs exhibited minor off-target cleavage activity (0.12%) at a total
of three off-target sites. The AAVS1-specific TALEN pair revealed statistically significant
activity (0.13%) at 1 out of the 22 predicted off-target sites (Table 4-4).
The majority of mutations retrieved at the analyzed loci consisted of short deletions in
the respective spacer sequences, as previously reported [62], and DNA repair seemed to be
driven mostly by microhomology-mediated repair.
In summary, the high-throughput sequencing results exposed important information re-
garding the specificity of the assessed nucleases. In particular, compared to the benchmark
ZFN, our CCR5-specific TALENs are better tolerated when expressed in human cells and
can be designed to discriminate between highly identical sequences, such as CCR5 and
CCR2. The CCR5:CCR2 targeting ratio was determined to be in the range of 3:1 for the
ZFN, and 130:1 or 7:1 for the TALEN pairs TC-NC and TC06, respectively. The calcu-
lated ‘specificity factor’, indicating the ratio of the frequency of on-target mutagenesis to
the overall frequency of off-target mutagenesis, was 1:2 for the CCR5-specific ZFN, 60:1
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Table 4-3: Off-target sites of CCR5-specific designer nucleases. In addition to CCR5 and
CCR2, the top 14 PROGNOS off-target loci for each of the TALEN pairs and several pre-
viously identified loci for the CCR5 ZFNs were interrogated with SMRT sequencing. The
‘match type’ indicates the orientation of the left (L) and right (R) nucleases at the site and
the length of the spacer sequence. Site sequences are listed as 5’–(+) half-site–spacer–(-)
half-site–3’. Therefore, the (-) half-site for TALENs and the (+) half-site for ZFNs are
listed in the reverse anti-sense orientation compared to the DNA sequence that the nucle-
ase binds. Lowercase red letters indicate mismatches as compared to the target site. PCR
amplification failed for sites listed as “N/A”. For some nucleases, two biological replicates
(‘Rep #1’ and ‘Rep #2’) were analyzed. The ‘specificity factor’ is calculated as the ratio
of on-target to total observed off-target mutation frequencies. * indicates that significantly
higher (p < 0.05) frequencies of indels were observed in nuclease-treated cells as compared




half-site Modification Frequency Specificity
FactorClosest Gene Match Type (+) (-) (+) half-site (-) half-site Rep #1 Rep #2
ZFNC
CCR5 L-5-R 0 0 GTCATCCTCATC AAACTGCAAAAG 27.89% * 14.40% * 0.48
CCR2 L-5-R 1 1 GTCgTCCTCATC AAACTGCAAAAa 9.88% * 7.95% *
KRR1 L-5-R 2 2 GgCcTCCTCATC AAACTGgAAAtG N/A
KCNB2 L-5-R 3 1 aTgtTCCTCATC AAACTGCAAAtG 1.10% *
BTBD10 L-5-R 2 1 GTttTCCTCATC AAACTGCAAAAt 6.33% *
TACR3 L-5-R 1 3 GTCATCtTCATC AAACTGtAAAgt 12.64% *
KDM2A R-5-L 5 2 tgagaCCTCATC AAACTGtAAtAG 8.58% *
WBSCR17 R-6-L 2 2 GTtATCCTCAgC AAACTGgAAcAG 2.70% *
Total Sites Interrogated: 2 8
TC-NC
CCR5 L-15-R 0 0 TGTGGGCAACATGCTGGTC AACTGCAAAAGGCTGAAGA 11.43% * 7.85% * 59.6
CCR2 L-15-R 0 2 TGTGGGCAACATGCTGGTC AACTGCAAAAaGCTGAAGt 0.07% * 0.07% *
NRXN1 R-15-R 4 5 TaTTCAGCaaaTTGCAGTT cACTGtActAGGtTGAAGA 0.05% 0.12% *
Total Sites Interrogated: 16 16
TC06
CCR5 L-14-R 0 0 TTTGTGGGCAACATGCTGG ATAAACTGCAAAAGGCTGA 21.53% * 6.51
CCR2 L-14-R 0 1 TTTGTGGGCAACATGCTGG ATAAACTGCAAAAaGCTGA 3.08% *
TBL1X L-18-L 5 5 TaaGTaGGCAACATcCTGt CtAtCtTcTTGCCCAaAAA 0.12% *
TRMT44 L-22-L 5 3 TTTGaGGGggAaATGCTtG CCAGCgTGgTGCCCACAcA 0.12% *
Total Sites Interrogated: 16
for TALEN TC-NC and 7:1 for TALEN TC06 (Table 1). A similar trend was observed
for the AAVS1- specific nucleases. While we identified and validated five novel off-target
sites for the AAVS1-specific benchmark ZFN, with a specificity factor of 1:2, we detected
off-target cleavage activity at a single predicted site for TALEN TA04, with a calculated
specificity factor of 27:1 (Table 4-4).
4.3.4.4 Discussion
Nuclease specificity is a key factor for advancing targeted genome engineering into the
clinic. Here we show that expression of TALENs is generally well tolerated by human
cells. In contrast, expression of our ZFN pairs reduced cell survival, was associated with
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Table 4-4: Off-target sites of AAVS1-specific designer nucleases. In addition to sev-
eral previously predicted (but unconfirmed) off-target sites for the AAVS1 ZFNs [50], the
top PROGNOS off-target loci for the AAVS1 TALENs and ZFNs were interrogated with
SMRT sequencing. The ‘match type’ indicates the orientation of the left (L) and right (R)
nucleases at the site and the length of the spacer sequence. Site sequences are listed as
5’–(+) half-site–spacer–(-) half-site–3’. Therefore, the (-) half-site for TALENs and the
(+) half-site for ZFNs are listed in the reverse anti-sense orientation compared to the DNA
sequence that the nuclease binds. Lowercase red letters indicate mismatches as compared
to the target site. The ‘specificity factor’ is calculated as the ratio of on-target to total ob-
served off-target mutation frequencies. All sites shown had significantly higher (p < 0.05)








FactorClosest Gene Match Type (+) (-) (+) half-site (-) half-site
ZFNA
AAVS1 L-6-R 0 0 ACCCCACAGTGG TAGGGACAGGAT 9.09% 0.55
CHRAC1 R-6-L 2 3 caCCCACAGTGG ctGGGACAGGAg 2.95%
ATRNL1 L-5-R 5 0 caCCCACAGatt TAGGGACAGGAT 3.71%
BEGAIN R-6-L 2 2 cCCCCACtGTGG cAGGGACAGGAc 4.40%
LINC00548 L-6-R 1 1 ACCCCACAGTaG TAGGGACAGGAa 4.15%
H19 L-5-R 1 3 tCCCCACAGTGG gAGGGcCAGGAg 1.28%
Total Sites Interrogated: 24
TA04
AAVS1 R-15-L 0 0 TCTGTCCCCTCCACCCCAC GACAGGATTGGTGACAGAA 12.57% 26.9
CPN1 L-11-R 5 5 cCacTCCCtcCCACCCCAC aAtAGGATTGGgGgCAGgA 0.13%
Total Sites Interrogated: 23
cell cycle arrest and increased cell death, all of which suggest surplus DNA cleavage at off-
target sites. Using the newly developed PROGNOS bioinformatics tool [34], we predicted
potential ZFN and TALEN off-target sites in the human genome and screened them by
high-throughput sequencing. Importantly, the top 32 ranked potential off-target sites of
the CCR5-specific ZFN included four off-target sites in the top seven that were previously
verified experimentally [37, 88] and one novel site [34]. The top 23 predicted off-target
sites for the AAVS1-specific ZFN included two previously predicted sites and allowed us
to verify a total of five novel off-target sites. PROGNOS was also successfully employed
to predict four novel off-target sites for TALENs targeting beta-globin [34]. These results
clearly validate and underline the high predictive value of PROGNOS that can be reliably
applied to predict both ZFN and TALEN off-target sites.
In our study we have profiled TALEN off-target activity in a non-clonal cell population
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with high-throughput sequencing. Many previous reports have either focused on identify-
ing the integration site of non-integrating viral vectors trapped in TALEN-induced DSBs
[84] or using Surveyor/T7E1 assays to monitor off-target activity at genomic loci predicted
by bioinformatics [113]. However, the small number of off-target sites identified and ana-
lyzed or the use of genomic DNA extracted from clonally derived cell populations or live
animals [113, 85] may likely not provide enough depth to identify rare mutagenic events
at off-target sites as those identified here. The five novel off-target sites of the widely used
AAVS1-specific ZFN are certainly of importance to those researchers currently using or
planning to use this nuclease pair for targeted integration at the AAVS1 ‘safe harbor’ lo-
cus. Given the superior toxicity profile and the absence of significant off-target activity, our
AAVS1-specific TALEN pair TA04 might be a valid alternative for targeted gene addition
into the AAVS1 ‘safe harbor’ site, in particular in primary cells.
Due to the high sequence similarity with CCR5, assessment of nuclease specificity
confirmed that the major off-target sites of our CCR5-specific ZFN and TALEN pairs were
found in the CCR2 locus. As reported before, concomitant cleavage at CCR2 and CCR5
results in deletion of the intervening sequence [21, 65]. We show that nucleases, which
are not specific enough to discriminate between these two highly similar loci (i.e. ZFNC
and TC06), induce deleterious genomic rearrangements, including deletions and inversions.
Even though not investigated further, we envision that simultaneous off-target activity on
two different chromosomes can induce translocations between two major off-target sites,
as previously shown [12]. Importantly, we show that such deleterious genotoxic events can
be restrained by using rationally designed nucleases, such as TALEN TC-NC, which shows
an unprecedented CCR5:CCR2 targeting ratio of ∼130:1. We speculate that the ability of
TALEN TC-NC in discriminating between CCR5 and CCR2 is based on the fact that one of
the two TC-NC subunits targets a T in position 0, which is not present in CCR2. Thus, the
5’-T can be used as a major discriminant between highly similar off-target sites to overcome
cytotoxic side effects.
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Examination of the few off-target sites shows that TALENs tolerate up to five mis-
matches in their 19-bp target half-sites. Whether the position of these mismatches has
an impact on the overall binding affinity of TALEN monomers has not been addressed
here. In any case, a systematic analysis of TALEN off-target activity may provide novel
design guidelines that can be taken into consideration in the future to avoid potential off-
target activity at sites with more than 74% nucleotide identity to the intended target site.
Our sequencing data revealed some off-target mutagenic events at predicted homodimeric
TALEN off-target sites for our CCR5-specific TALENs. Thus, TALEN specificity can be
further increased by coupling the TALE DNA binding domains to obligate heterodimeric
FokI endonuclease variants [30, 108] that have been shown to abolish cleavage of ZFNs at
homodimeric off-target sites [37]. Even though most of our findings are based on TALENs
with the ∆135/+17 scaffold developed in the Cathomen lab [80], we believe that they can
be extended to alternative TALEN designs with longer linkers [77]. Importantly, as shown
for ZFNs [47], our short 17-residue linker may improve specificity by limiting spacer tol-
erability. Additionally, intranuclear concentration of the designer nucleases and duration
of the expression are important parameters affecting cleavage specificity. For instance, de-
livery of a CCR5-specific ZFN pair in the form of proteins resulted in short persistence in
the transduced cells and was associated with reduced off-target activity at CCR2 [39].
We systematically measured higher off-target activity of the CCR5-specific ZFNs than
previously published [37, 88]. We reason that this is most likely due to the cell line (HEK-
293T versus K562 cells) and the transfection method (PEI versus nucleofection) that we
used, which may result in higher intranuclear nuclease expression levels. Also, our ZFNs
contain a slightly different obligate heterodimeric FokI domain [114] compared to the most
commonly used one [76] and a different epitope tag (HA versus FLAG). Given that we were
able to identify previously reported off-target sites at much higher frequencies demonstrates
that PEI-mediated transfection of HEK-293T cells represents an ideal ‘mutation-prone sys-
tem’ to evaluate nuclease specificity and further emphasizes the high specificity of the
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TALENs tested here.
Taken together, our results establish TALENs as a safe and specific platform to edit
the human genome, paving the way for their use for clinical translation. As mentioned
previously, RGENs have been established as a versatile tool to modify the human genome
[73, 19]. Although there has been some concern regarding their specificity [35, 87, 53, 21],
it will be interesting to see whether this novel class of designer nucleases can match the
high specificity set by TALENs, e.g. as recently shown by truncating the gRNA molecule
[36].
4.3.5 Functional Gene Correction of IL2RG by TALEN-mediated Genome Editing5
4.3.5.1 Abstract
Gene editing with engineered nucleases allows for precise and complex changes to be made
to the human genome, but translation of this technology for the treatment of human disease
is complicated by the diversity of disease-causing mutations in patient populations. Here
we show that nuclease-mediated targeting of IL2RG cDNA to IL2RG Exon 1 provides
endogenous control over transgene expression, functionally correcting the IL2RG gene.
Using TALENs, we achieved high frequencies of IL2RG gene replacement in cell lines (up
to 20%) and CD34+ hematopoietic stem/progenitor cells (up to 2.9%). Targeted addition
of wild-type IL2RG cDNA to the endogenous IL2RG promoter showed decreased levels of
IL2Rγ activity, but modification of the cDNA with codon-optimization and the introduction
of an artificial intron increased IL2Rγ activity to wild-type levels. Off-target activity was
analyzed in 293T, K562, and CD34 cells. This strategy has potential clinical application
for multiple genetic diseases by providing a functional gene in patients with essentially any
disease-causing mutation while maintaining endogenous gene expression patterns.
5Modified from: Kildebeck EJ, Clark JT, Hendel A, Fine EJ, Bao G, Porteus MH (manuscript in prepa-
ration). Functional Gene Correction of IL2RG by TALEN-mediated Genome Editing
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Table 4-5: Off-target site identification in 293T cells. The top PROGNOS off-target loci
for the IL2RG TALENs were interrogated with SMRT sequencing. The ‘match type’ in-
dicates the orientation of the left (L) and right (R) nucleases at the site and the length of
the spacer sequence. Site sequences are listed as 5’–(+) half-site–spacer–(-) half-site–3’.
Therefore, the (-) half-site for TALENs is listed in the reverse anti-sense orientation com-
pared to the DNA sequence that the nuclease binds. Lowercase red letters indicate mis-
matches as compared to the target site. All sites shown had significantly higher (p < 0.05)






RankingClosest Gene Match Type (+) (-) (+) half-site (-) half-site
IL2RG R-14-L 0 0 TAATGATGGCTTCAACAT ATTCCCTGGGTGTA 18.18% 1
TNN L-15-L 2 3 TACACCCAtGaAAT ATgCCtTGGtTGTA 9.08% 2
HDDC2 L-25-L 1 4 TACACtCAGGGAAT ATTCtCTGGagGcA 0.62% 4
TMEM182 L-14-L 1 4 TACACCCAGGtAAT AcTCCCTGaaTtTA 0.71% 9
DEK L-11-L 4 1 TACAgCtgGGGAAa ATTgCCTGGGTGTA 0.90% 12
GPD2 L-13-L 3 4 TACACCaAaGaAAT ATTttCTGGtTGTt 2.52% 23
SLC19A1 L-13-L 1 4 aACACCCAGGGAAT ATTCCtTGGGTcgc 0.70% 24
CCDC171 L-30-L 3 3 acCACCCAGaGAAT ATgCCtTGGtTGTA 0.58% 25
CSNK1G3 L-17-R 3 2 TAggCCCAGGGAgT gaGTTGAAGCCATCATTA 3.73% 26
Total Sites Interrogated: 24
4.3.5.2 Results
Because HEK-293T cells have previously been shown to be a mutation-prone cell line
that can be used as a model system to screen for off-target activity [79], we first analyzed
genomic DNA from HEK-293T cells transfected with TALEN plasmids. The top 24 sites
predicted by the PROGNOS TALEN v2.0 algorithm [34] were analyzed and bona fide off-
target activity was observed at 8 sites (Table 4-5). Having determined that the TALENs did
induce off-target activity in the 293T model system, we began to investigate methods to
reduce off-target activity and the relative off-target mutagenesis tendencies of different cell
lines.
Since gene repair through homologous recombination was the ultimate goal of our ap-
proach, we next examined off-target activity in the K562 cell line—a model system for
homologous recombination. Furthermore, because delivery of nuclease protein has been
previously linked to lower off-target activity compared to expression from plasmids [39],
we sought to also examine the effects of delivery as mRNA transcripts compared to DNA
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Table 4-6: Off-target activity in K562 cells. The top PROGNOS off-target loci for the
IL2RG TALENs were interrogated with SMRT sequencing. Consistent activity across all
replicates was observed at the locus near TNN. On-target activity was quantified as the
percentage of sequences modified through either NHEJ or HDR. ‘NHEJ’ sequencing reads









Plasmid 1 57:1 0.36% 13 3614
Plasmid 2 52:1 0.32% 7 2161
Plasmid 3 38:1 0.41% 10 2443
mRNA 1 36:1 1.33% 18 1350
mRNA 2 22:1 1.46% 18 1230
mRNA 3 47:1 1.08% 60 5540
plasmids. We therefore nucleofected K562 cells with donor DNA to act as a template for
homologous recombination, and either mRNA or plasmids encoding the TALENs. In all
samples tested, the off-target site near the TNN locus, which was found to have the highest
level of off-target activity in HEK-293T cells (Table 4-5), also had the highest off-target
activity in K562 cells. However, while the ratio of on-target activity to off-target activ-
ity near TNN was ∼2:1 in HEK-293T cells, the ratios were much higher (i.e. less off-target
activity) in K562 cells (Table 4-6), affirming the notion that HEK-293T cells are highly sus-
ceptible to off-target nuclease activity. While we observed consistent activity at the TNN
locus across all replicates, providing evidence that nuclease off-target activity is a highly
repeatable phenomenon, we did not observe any statistically significant differences in the
on-target:off-target ratios between plasmid and mRNA delivery of the TALENs (although
the ratio was 1.4-fold greater for plasmid delivery).
91
4.3.6 TALEN pairs with one inactive FokI domain have increased specificity6
4.3.6.1 Abstract
Transcription Activator-Like Effector Nucleases (TALENs) have the potential to become
a powerful tool for genome editing in a wide range of biomedical applications. However,
TALEN pairs that target an intended gene locus (on-target) may also cleave similar se-
quences in the genome (off-target), inducing genomic mutagenesis and instability. Here
we show that TALEN pairs targeting the human beta-globin gene with one inactive FokI
domain had similar levels of on-target gene modification, but lower levels of off-target
cleavage compared with the TALEN pair having two active FokI domains (normal TALEN
pair), in contrast to ZFN nickase pairs. TALEN pairs with one inactive FokI domain may
thus prove a general method for improving the specificity of TALENs for genome editing
applications.
4.3.6.2 Results
As a potentially effective way to reduce TALEN off-target mutagenesis, we constructed and
evaluated TALEN pairs that consist of one inactive and one active FokI domain, similar to
the “nickase” Zinc Finger Nucleases (ZFNs) [94, 128]. Specifically, four TALEN pairs
were constructed and characterized based a previously validated TALEN pair targeting the
β-globin mutation responsible for sickle cell anemia, with ‘L4’ and ‘R4’ representing the
‘left’ and ‘right’ TALENs respectively [125]:
i) a pair with both FokI domains active (L4+/R4+, referred to as normal pair of TALENs)
ii) a pair with the right FokI domain inactivated (L4+/R4-)
iii) a pair with the left FokI domain inactivated (L4-/R4+)
iv) a pair with both FokI domains inactive (L4-/R4-).
6Modified from: Cradick TJ, Lindsay C, Kumaran RI, Fine EJ, et al. (manuscript in revision). TALEN
pairs with one inactive FokI domain have increased specificity
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Table 4-7: L4+R4+ TALEN off-target activity at sites ranked by PROGNOS. 49 sites
were chosen for interrogation based on the top-ranked sites of the L4R4 TALENs, as de-
termined by a mixture of the ‘Homology’ and ‘RVDs’ PROGNOS algorithms (preference
given to potential heterodimeric sites), were evaluated using SMRT sequencing in trans-
fected HEK-293T cells. The ‘match type’ indicates the orientation of the left (L) and right
(R) nucleases at the site and the length of the spacer sequence. Site sequences are listed
as 5’–(+) half-site–spacer–(-) half-site–3’. Therefore, the (-) negative half-site is listed in
the reverse anti-sense orientation as compared to the DNA sequence that the TALEN binds.
In sequences, lower-case letters indicate mismatches as compared to the target site. “293T
cells modification frequency” is the percentage of observed sequences showing evidence of
NHEJ events. The target site in the HBB gene contains a mismatch in the left binding site
because the TALEN is designed to target the sickle allele, not the wild-type allele found in
293T cells. For all sites shown, significantly higher (p < 0.05) frequencies of indels were






Closest Gene Match Type (+) (-) (+) half-site (-) half-site
HBB L-15-R 1 0 TGCACCTGACTCCTGa TACTGCCCTGTGGGGCAA 39.57%
HBD L-15-R 2 2 TGCAtCTGACTCCTGa cAaTGCCCTGTGGGGCAA 12.66%
GREB1L L-17-R 5 5 TaCAgCTaACaCaTGT TACTtgCtTGTGGGGtAg 0.39%
TMED10 L-14-R 5 5 TGtACCccACTCCTcc TACTGtttTGTtGGGtAA 0.09%
Total Sites Interrogated: 49
Here, ‘+’ or ‘-’ represent respectively TALEN monomers with an active or inactive FokI
domain. The on- and off-target cleavage activities were systematically quantified for all
four pairs of TALENs. We found that TALEN pairs with one inactivated FokI domain had
the same on-target activity as the normal TALEN pair in HEK-293T cells, but with lower
off-target activity.
Initially, an off-target screen was conducted using the L4+R4+ ‘normal’ TALEN pair
at potential off-target sites predicted by the PROGNOS algorithm [34]. From this search,
three heterodimeric off-target sites were discovered (Table 4-7)—heterodimeric sites were
of particular interest for this study because they would allow analysis of how the inactiva-
tion of one of the two FokI domains affected activity.
Following the initial off-target screen, we determined that the sites at the HBD and
GREB1L loci had off-target activity sufficiently above the detection limit of the assay to
warrant investigation using the inactive FokI domains. Using SMRT sequencing, the HBB,
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Figure 4-2: TALEN pairs with one inactivate cleavage domain have lower off-target
NHEJ. Using SMRT sequencing, the on- (HBB) and off-target (HBD, GREB1L) indel per-
centages were calculated and compared for the variants to the level of the L4+/R4+ TALEN
pair.
HBD, and GREB1L loci were analyzed from HEK-293T cells transfected with each of
the four different TALEN pairs (Figure 4-2). As expected, the L4-R4- control TALENs
had no NHEJ activity at any loci. Surprisingly, the L4+R4- TALENs had higher on-
target activity and substantially lower off-target activity at both HBD and GREB1L than
the L4+R4+ TALENs. The L4-R4+ TALENs had reduced activity only at the off-target
site near GREB1L. At this time, the reason for the differences in performance observed by
inactivating the left vs. the right FokI domain are unknown.
4.3.7 Total increase in off-target dataset expansion
Due to the difficulty of previous off-target prediction methods, as of 2011, only 7 TAL-
ENs and ZFNs had identified off-target sites. By utilizing the solely bioinformatics-based
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Table 4-8: All nucleases investigated using PROGNOS. 9 total TALENs and 7 total
ZFNs were investigated using PROGNOS in various cell types and species. *a modified




SitesNuclease Name ZFN/TALEN Species Target Gene Cell Type Delivery Method Year Publication? Thesis Section
S2/S5 NK TALEN Human HBB HEK-293T 1 21 FuGene Transfection 2012
Fine EJ, et al. [34] Table 3-4
S2/S5 NN TALEN Human HBB HEK-293T 3 20 FuGene Transfection 2012
S1/S7 NK TALEN Human HBB HEK-293T 1 24 FuGene Transfection 2012
S1/S7 NN TALEN Human HBB HEK-293T 3 25 FuGene Transfection 2012
ZFN 3F ZFN Human HBB HEK-293T 6 23 FuGene Transfection 2012
ZFN 4F ZFN Human HBB HEK-293T 1 23 FuGene Transfection 2012
L4/R4 TALEN Human HBB HEK-293T 3 49 FuGene Transfection 2013 Cradick et al. (in revision) Table 4-7
TC-NC TALEN Human CCR5 HEK-293T 2 16 PEI Transfection 2013
Mussolino et al. [79]
Table 4-3
TC06 TALEN Human CCR5 HEK-293T 3 16 PEI Transfection 2013
TA04 TALEN Human AAVS1 HEK-293T 1 23 PEI Transfection 2013
Table 4-4
ZFNA ZFN Human AAVS1 HEK-293T 3 24 PEI Transfection 2013
GFP-ZFNs ZFN Human GFP HEK-293T* 1 23 Lipofectamine Transfection 2013 Figure 4-1
Ugt1a1-ZFNs ZFN Rat UGT1A1 C6 6 22 Lentiviral Vector 2013 Abarrategui-Pontes et al. [1] Table 4-2
L3/R3 TALEN Human IL2RG HEK-293T/K562 8/1 24 FuGene / Nucleofection 2014 Kildebeck et al. (in preparation) Table 4-5
Rosa26-ZFNs ZFN Mouse Rosa26 SC-1 1 23 Lentiviral Vector 2014
Table 4-1
CCR5-ZFNs ZFN Mouse CCR5 SC-1 7 23 Lentiviral Vector 2014
Figure 4-3: Nuclease Off-Target Studies Over Time.
PROGNOS algorithms to predict off-target sites, we were able to study 16 different nucle-
ases and identify bona fide off-target sites for all of them (Table 4-8). This represents an
increase of ∼230% over the 2011 level. Further underscoring the contributions of PROG-
NOS to the field is the fact that only one study was published between 2011 and 2014
identifying off-target sites for a new nuclease (Figure 4-3). In total, the nucleases studied
by PROGNOS represent over half (64%) of all published ZFNs and TALENs with known
off-target sites.
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4.3.8 Engineered nucleases and lentiviral vectors have different off-target profiles7
4.3.8.1 Introduction
Gene therapy approaches continue to gain momentum as methods employing integrating
viral vectors [2] or engineered nucleases [41] demonstrate great success in improving effi-
cacy. However, “off-target” effects remain a major safety concern as the negative outcomes
of the X-SCID clinical trials [46] continue to haunt the field. Potentially harmful modi-
fications to the genome can be made by viral vectors randomly integrating their cargo or
by nucleases—including zinc-finger nucleases (ZFNs), transcription activator-like effec-
tor nucleases (TALENs), and RNA-guided endonucleases (RGENs) such as CRISPR/Cas9
systems—creating DNA breaks at locations other than their intended target site, which are
then repaired in an error-prone manner by non-homologous end-joining (NHEJ). While
many factors influence whether the off-target effects will result in an adverse clinical out-
come, one metric that can be used to compare gene therapy methods is the genomic context
of the off-target event. For example, disruptions within genes are more likely to be detri-
mental to a patient than those in regions with no currently known function.
We used the QuickMap tool [4] to compare the genomic contexts of the off-target events
between two prominent gene therapy platforms: lentiviral vectors (LVs) and engineered
nucleases. Our LV dataset consisted of 806 integration sites gathered from three indepen-
dent publications. By combining nearly all bona fide off-target sites identified for ZFNs,
TALENs and RGENs in the human genome to date (totaling 282 sites from 35 different
nucleases), we created an engineered nuclease dataset of sufficient size to permit statistical
comparisons. As a control, QuickMap provides a dataset of 106 random locations in the
human genome.
7Modified from: Fine EJ & Bao G (manuscript submitted). Engineered nucleases and lentiviral vectors
have different off-target profiles
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4.3.8.2 Datasets
All sites were converted to coordinates in the hg19 build of the human genome prior to
QuickMap analysis.
Our engineered nuclease dataset is drawn from a diverse set of observations in order to
ensure that the results are truly representative. The results were obtained from the experi-
ments described in this thesis and 12 additional manuscripts [53, 35, 119, 88, 87, 21, 22, 68,
37, 101, 57, 43, 51], from 7 independent laboratories which employed 9 different methods
to locate off-target activity. The set of 282 off-target sites is diverse, consisting of 35 differ-
ent nucleases with a mean of 8 sites per nuclease and only a modest non-parametric skew
of 0.43 due to the presence of some nucleases with larger numbers of identified off-target
sites.
Our lentiviral vector (LV) integration site dataset is drawn from 6 separate transductions
of 4 different cell types by 3 independent laboratories [121, 5, 7]. Although there are many
additional publications analyzing LV integrations, only a small fraction are in human cells
(many are performed in mice) and listed the genomic coordinates of the integration events;
indeed, two of these datasets were only obtained through personal correspondence with the
authors (many thanks to Dr. Duran Üstek and Dr. Nirav Malani).
4.3.8.3 Results
In comparing the two platforms, we observed marked differences in the preference of where
off-target activities occurred. Compared to the random dataset, LVs showed a strong pref-
erence (3.2-fold) for integration within cancer-associated genes, which was not observed
in the off-target activity of nucleases (Figure 4-4a). For off-target events within genes, LVs
also showed a clear preference compared to the random control (1.7-fold), whereas nucle-
ases only had a modest preference (1.3-fold) (Figure 4-4b). In contrast, nucleases modify
exons much more frequently than LVs (Figure 4-4c). Finally, we compared the three dif-
ferent major classes of engineered nucleases (ZFNs, TALENs, and RGENs) and found no
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Figure 4-4: Comparison of engineered nuclease and lentiviral vector off-target pro-
files. Error bars are 95% confidence intervals. P-values calculated using two-tailed Fisher’s
exact test. (a) Percentage of sites located within cancer-associated genes. (b) Percentage of
sites located within all genes. (c) Percentage of sites located within exons. (d) Comparison
of the percentage of sites located within genes for different types of engineered nucleases.
statistically significant difference between the percentage of off-target sites located within
genes (Figure 4-4d), suggesting a similar underlying mechanism in how off-target sites are
accessed. The limited sample size did not permit statistically meaningful comparisons for
other metrics such as cancer-associated genes or exons for the three classes of engineered
nucleases.
4.3.8.4 Discussion
There are some limitations to our study. One limitation is that most engineered off-target
studies take place in immortalized cell lines. Indeed, in our dataset, all sites were discov-
ered in K562, HEK-293, or U2OS cells except for two sites found in hESCs. In contrast,
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many LV integration site analyses take place in primary cells. To compensate for this, we
obtained LV data from HEK-293 and K562 cells to make our datasets more comparable.
However, as we lack substantial data on engineered nuclease off-target activity in primary
cells, it remains possible that the location pattern reported here are different than what
might be observed in primary cells.
In conclusion, our study shows that engineered nucleases and LVs can produce different
profiles of off-target modifications. Whether disruptions within exons or within cancer-
associated genes are more prone to trigger adverse clinical outcomes will require future
investigations.
4.4 Conclusion
The large number of additional nucleases that were able to be successfully analyzed by the
PROGNOS algorithms [34] to locate new bona fide off-target sites demonstrates that the
two major goals of the original approach were achieved:
• A method so easy to apply that it could be readily used on large numbers of nucleases
• Reasonably accurate predictive algorithms that successfully locate sites of bona fide
off-target activity
The substantial (∼230%) increase in the total number of ZFNs and TALENs with known
bona fide off-target sites created a dataset large enough to attempt to use for machine learn-
ing and also allowed insight into the nature of the genomic context of where nuclease
off-target activity occurs. Throughout the course of identifying off-target sites for the vari-
ous ZFNs and TALENs, several insights into the general nature of nucleases and off-target
activity were gained:
• Lentiviruses can delivery ZFNs into a variety of cell types that are refractory to tra-
ditional transfection techniques and achieve robust nuclease activity.
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• ZFNs with additional numbers of zinc finger units do not necessarily confer higher
specificity.
• While varying the delivered dose of nuclease does affect the activity level accord-
ingly, there is not necessarily an optimal zone which can achieve a high on-target:off-
target ratio.
• TALENs are generally more specific than ZFNs.
• TALENs can be rationally designed to discriminate between highly similar sequences.
• The locations of off-target activity are consistent across different cell types and the
level of off-target activity is consistent across experimental replicates.
• mRNA delivery of nucleases does not necessarily confer an improved on-target:off-
target ratio compared to plasmid delivery.
• Nucleases have a distinct tendency (compared to a random control) for off-target
activity to occur in exons.
• While nucleases do not have a tendency for off-target activity to occur in cancer-
associated genes, this tendency is observed in lentiviral vectors.
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CHAPTER V




Machine learning is a powerful approach for building predictive models which can greatly
facilitate the analysis of large datasets. While the field of genome engineering has histor-
ically been a relatively low-throughput environment that did not generate sufficient data
on which to train machine learning algorithms, the development of transcription activator-
like repeat nucleases (TALENs) and RNA-guided endonucleases (RGENs) based on the
CRISPR/Cas9 system have led to a rapid increase in the amount of raw data available. This
has enabled several recent efforts to incorporate machine learning techniques into genome
engineering research. Doench et al. [27] trained a logistic regression classifier on a dataset
of >1800 RGENs to better predict highly active target sites within genes. In the realm of
off-target analysis, Sander et al. [101] applied a Naı̈ve Bayesian algorithm to the full set of
sequences cleaved by ZFNs in vitro in order to build a model that could rank any sequence
in the genome for its likelihood as an off-target site for that pair of zinc finger nucleases
(ZFNs); this approach was later extended as a method to analyze pairs of TALENs as well
[43]. While that approach is highly effective at predicting off-target activity for a particu-
lar nuclease, the reliance on extensive experimental work to obtain the necessary in vitro
cleavage data for that nuclease limits its broader applicability.
The extreme ease with which the newer generation TALENs and CRISPRs can be de-
signed and constructed—compared to earlier technologies such as ZFNs or meganucle-
ases—has triggered a paradigm shift in the genome engineering field. It is now possible
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to rapidly create dozens of nucleases in a matter of a few weeks that are highly efficient
at modifying their intended target site. As a result, off-target prediction methods that rely
on experimental characterization of the nuclease create a bottleneck in the development
process. There is therefore a great need for methods that can predict off-target activity for
a nuclease purely in silico based solely on the sequence of the intended target site.
To address this need, we trained classifiers on a set of all known off-target sites in order
to develop two generalized models, one for ZFNs and one for TALENs, which reliably
predict off-target sites in a genome for any given nuclease target sequence. This approach
will allow for judicious target site selection in the initial design of a nuclease in order to
choose an approach that has the minimal potential for off-target activity.
5.3 Methods
The scikit-learn package for Python was used to implement all machine learning ap-
proaches.
5.3.1 Feature Extraction
All features were scaled to values between 0 and 1 for input into learning algorithms since
many algorithms are not scale invariant. Because ZFNs and TALENs can target different
lengths of sequence as well as different bases at each position, special care was taken to
ensure that all features could be generalized to any ZFN or any TALEN.
Because ZFNs and TALENs operate as dimers, most of the features were extracted
separately for each monomeric half-site. During training, the ordering of the ‘left half-site’
vs. ‘right half-site’ designation was randomized in order to eliminate any biases.
5.3.1.1 ZFNs
Because ZFNs consist of individual zinc fingers that bind to a triplet of bases, many features
were created relating to the division of the intended binding site into base triplets. There is
well-documented evidence that many zinc finger subunits exhibit context-dependent effects
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due to the bases surrounding the triplet, but a generalized set of rules regarding these effects
has not been established [72].
The following were extracted as one-hot encoded features (either 1 if the statement was
true, or 0 if it was false) separately for each half-site:
• The closest base to the FokI domain is matched to its target sequence
• The 2nd closest base to the FokI domain is matched to its target sequence
• The 3rd closest base to the FokI domain is matched to its target sequence
• The closest triplet of bases to the FokI domain has 0 mismatches
• The closest triplet of bases to the FokI domain has 1 mismatch
• The closest triplet of bases to the FokI domain has 2 mismatches
• The closest triplet of bases to the FokI domain has 3 mismatches
• The furthest triplet of bases from the FokI domain has 0 mismatches
• The furthest triplet of bases from the FokI domain has 1 mismatch
• The furthest triplet of bases from the FokI domain has 2 mismatches
• The furthest triplet of bases from the FokI domain has 3 mismatches
• The 3rd further base from the FokI domain is matched to its target sequence
• The 2nd further base from the FokI domain is matched to its target sequence
• The furthest base from the FokI domain is matched to its target sequence
The following were extracted as decimal percentages (i.e. ranging from 0–1) regarding
the triplets lying between the most proximal triplet to the FokI domain and the most distal
triplet from the FokI domain:
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• The % of triplets that contain 0 mismatches
• The % of triplets that contain 1 mismatch
• The % of triplets that contain 2 mismatches
• The % of triplets that contain 3 mismatches
• The % of triplets that contain a matched base at the position proximal to the FokI
domain
The following were extracted as decimal percentages (i.e. ranging from 0–1) regarding
the full sequence of each half-site:
• The % of all positions where the base matches the intended target (Homology)
• The % of intended guanosine targets that remain matched (Conserved G’s)
The following were extracted as decimal percentages (i.e. ranging from 0–1) regarding
the relationship between the two half-sites:
• The ratio of %Homologies of [less well-matched half-site]:[more well-matched half-
site] (so that the resulting value is ≤ 1)
• The ratio of %Conserved G’s of [less well-matched half-site]:[more well-matched
half-site] (so that the resulting value is ≤ 1)
5.3.1.2 TALENs
Many of the extracted features were based on the approach of the TALEN v2.0 algorithm
previously developed (Section 3.3.3.2). Interactions between individual RVDs and the cor-
responding DNA bases in a target site were scored using binding frequencies derived from
SELEX experiments as previously described (Table 3-1). As in the TALEN v2.0 algorithm,
the concepts of TALEN polarity [75] and the effects of strong RVDs [112] were also taken
into account.
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The following features were extracted as decimal percentages (i.e. ranging from 0–1)
by normalizing the RVD-DNA interaction scores of the potential binding site to the RVD-
DNA interaction scores of the intended binding site:
• The normalized score of position 0 (5’ to where the RVDs begin)
• The average normalized score of positions 1 to 5 (starting at the 5’ end of the binding
site)
• The average normalized score of positions 6 to N-5 (where ‘N’ is the 3’ distal RVD)
• The average normalized score of positions N-4 to N-1
• The normalized score of position N
• The average normalized score of all positions (0 to N)
The following were extracted as decimal percentages (i.e. ranging from 0–1):
• The percentage of strong RVDs (NN or HD) which matched their intended base
(calculated separately for each half-site)
• The ratio of the average normalized score of all positions of of [less well-matched
half-site]:[more well-matched half-site] (so that the resulting value is ≤ 1)
5.3.2 Cross-Validation
In order to mitigate the possibility of over-fitting the model to the training data, we utilized
a nested (5 iterations) 4-fold cross-validation strategy. Because the ratios of the two classes
in our datasets are highly unbalanced, we used the StratifiedKFold method which en-
sures that each fold contains the same percentage of each class (i.e. bona fide active vs.
inactive/untested) as the overall dataset.
The average precision (the area under the Precision-Recall curve) was used as a metric
to score the performance of the classifiers. To construct the Precision-Recall curve, the
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decision function of the classifier (which provides a confidence estimate of the classifica-
tion assignment, based on the signed distance to the hyperplane) was used to rank-order all
samples. The mean of the best score from each of the 5 nested cross-validation iterations
was used to evaluate the performance of a classifier.
5.3.3 Datasets
By aggregating nearly all published bona fide off-target sites for ZFNs and TALENs,
we were able to create datasets of sufficient size to permit training machine learning al-
gorithms. Because of the wide variety of experimental methods utilized in the various
manuscripts documenting off-target activity from which we drew our dataset, it is difficult
to make quantitative comparisons as to the exact level of off-target activity at each different
off-target site. Therefore rather than train an estimator to predict exact rates of off-target
activity, we strove to create a model which would classify a potential site as either ‘active’
or ‘inactive’. For our datasets, the ‘active’ class consisted of all bona fide off-target sites
as well as on-target sites. To generate the ‘inactive’ class, we used the PROGNOS algo-
rithm [34] to search the genome for all sites with >66% homology to the intended target
sequence. Since the resulting ‘inactive’ class contained ∼106 as many sites as the ‘active’
class, we selected a random subset of ∼2.5% of the ‘inactive’ sites for each nuclease in order
to reduce the computational resources required for the machine learning process. Since a
nuclease typically had several bona fide off-target sites, the number of off-target sites in the
‘active’ class outnumbered the on-target sites. In order to help guide the machine towards
recognizing the baseline biological assumption that all on-target sites should be classified
as ‘active’, we added in additional ‘spike-in’ examples of on-target sites into the datasets.
5.3.3.1 ZFNs
The ‘active’ class of our ZFN dataset consisted of 134 bona fide off-target sites gathered
from 11 different ZFNs, the on-target sites for those ZFNs, and 50 additional ‘spiked-in’
on-target sites (Figure 5-1). ∼35, 000 ‘inactive’ sites are drawn from genomic sequences
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with homology to the intended target sites. The off-target sites were uncovered using a
variety of methods and the number of off-target sites per nuclease shows only a moderate
positive skew (non-parametric skew of 0.384). Taken together, this should result in a model
that can be broadly applied to accurately predict off-target sites for any given ZFN.
5.3.3.2 TALENs
Several publications have sought to investigate off-target activity by designing TALENs
to sites that have additional highly homologous sites in the genome. While this acts as
an effective model system to examine what may affect levels of off-target activity, these
sites are trivial to locate by any off-target prediction method. Therefore, while they are
included in the ‘active’ class of TALEN sites in our dataset, any site with >87% homology
to the intended target is marked as a ‘trivial’ off-target site to denote the fact that it is not
appreciably contributing to the diversity of off-target sites in our dataset.
The ‘active’ class of our TALEN dataset consisted of 43 bona fide off-target sites gath-
ered from 14 different TALENs, the on-target sites for those TALENs, 33 ‘trivial’ off-target
sites, and 50 additional ‘spiked-in’ on-target sites (Figure 5-1). ∼35, 000 ‘inactive’ sites are
drawn from genomic sequences with homology to the intended target sites. The off-target
sites were uncovered using a variety of methods and the number of bona fide off-target sites
per nuclease shows only a moderate positive skew (non-parametric skew of 0.381). Taken
together, this should result in a model that can be broadly applied to accurately predict
off-target sites for any given TALEN.
5.4 Results
5.4.1 Hyperparameter Tuning
After testing several different machine learning algorithms, we determined that a support
vector classifer (SVC) employing a radial basis function (RBF) kernal achieved the best re-
sults on the ZFN dataset while a stochastic gradient descent (SGD) logarithmic regression
classifer employing an elastic net penalty achived the best results on the TALEN dataset. In
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Figure 5-1: Machine learning datasets
order to further refine the classifiers, we performed a grid search over a range of hyperpa-
rameters. For ZFNs, we found that setting C = 105 and γ = 10−4 achieved the best results
(Figure 5-2a). For TALENs, we found that setting α = 10−6 and the L1/L2 ratio at 0.01
achieved the best results (Figure 5-2b).
5.4.2 Training Results
After optimizing the choice of machine hyperparameters, we trained the models on the ZFN
and TALEN datasets using 4-fold cross-validation. By plotting the Precision-Recall curves
for each of the folds, we observed that each fold was clustered relatively closely around the
average of all of the folds, providing evidence that the model was not overtraining to the
dataset (Figure 5-3).
5.4.3 Performance on Hold-Out Test Set
Prior to the onset of any experiments, 10% of each dataset (ZFNs and TALENs) was set
aside to use for a hold-out test set on the final classifiers to asses the performance of the
off-target prediction models. Due to the relatively small size of the overall training sets, the
hold-outs were also limited in size (13 and 6 bona fide for ZFNs and TALENs respectively),
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Figure 5-2: Hyperparameter Tuning. Results of a grid search over a range of hyperpa-
rameters. (a) Tuning a support vector classifier using a radial basis function kernal on the
ZFN dataset. (b) Tuning a stochastic gradient descent logarithmic regression classifer with
an elastic net penalty on the TALEN dataset.
Figure 5-3: Cross-validation on training set. Performance of individual cross-validation
folds compared to the average of all folds for the ZFN (a) and TALEN (b) classifiers.
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Figure 5-4: Testing performance of classifiers on hold-out datasets. Performance on
the full training set, the hold-out test set, and the average performance across folds of the
cross-validation for the ZFN (a) and TALEN (b) classifiers.
resulting in a somewhat coarse-grained Precision-Recall plot. Nevertheless, we observed
relatively high concordance between the performance of the models on the training and
test sets (Figure 5-4), increasing our confidence that the classifiers were not overtrained
and that these results can be used to estimate their performance on future off-target studies
of nucleases.
5.4.4 Cross-Validation by Nuclease
In addition to performing standard cross-validation on the whole dataset, we performed an
additional type of cross-validation based on the off-target sites of the individual nucleases.
Rather than dividing the training set into random folds for cross-validation, we trained
the classifier on all sites except for those of a particular nuclease, and then assessed the
performance of the classifier on that nuclease (Figure 5-5). As expected, the precision-
recall curves for any individual nuclease are less smooth than the average performance, but
overall the classifier seemed to have similar performance across a wide variety of nucleases.
To quantify the performances, we calculated the coefficient of variation (CV)—the standard
deviation divided by the mean—of the AUC. For ZFNs, the CV across all nucleases was
50%, but if two extreme outliers (the GFP ZFNs and the Li Mouse Albumin ZFNs) are
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excluded, then the CV drops to 35%. The CV across all TALENs was 29%.
5.4.5 Comparison to Other Off-Target Prediction Algorithms
After validating that the classifiers were not over-trained, we compared their performance
to the previous algorithms developed in Chapter 3. Specifically, we used three metrics to
measure algorithm performance. As in Chapter 3, we calculated the precision within the
top 16 rankings (taking the mean across all nucleases) and also the percentage of all bona
fide sites found within the search limit for each nuclease (the search limit is defined by the
number of sites interrogated in the original study that uncovered the bona fide sites). Addi-
tionally, we calculated the average precision (the area under the Precision-Recall curve) of
the classifier for each nuclease.
The ‘ZFN 02’ classifier developed through machine learning represented a 14% im-
provement over the best previously developed algorithm (Figure 5-6a). Delving deeper
into the individual metrics, the ‘ZFN 02’ classifier outperformed all previous algorithms in
all three measurements (Figure 5-6b).
The ‘TALEN 04’ classifier developed through machine learning represented a more
modest, but still readily observed, 7% improvement over the best previously developed
algorithm (Figure 5-6c). Looking at the individual metrics, the ‘TALEN 04’ classifier out-
performed all previous algorithms in terms of average precision and the percentage of bona
fide sites within the search limit, but several other algorithms had slightly better perfor-
mance in terms of the precision within the top 16 rankings (Figure 5-6d).
5.4.6 Insights from Feature Weightings
Because the TALEN classifier was constructed using a logarithmic regression algorithm,
each feature is assigned a discrete value during training. These weighting values provide
insight into what the most influential features are—what has the most impact on TALEN
specificity. Previous experimental data had provided evidence that there can be a ‘polarity’
effect where mismatches in the 5’ region of the TALEN binding site less well tolerated
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Figure 5-5: Cross-Validation by Nuclease. Performance of classifiers trained on all data
except the indicated nuclease and then tested on that nuclease for ZFNs (a) and TALENs
(b). Average performance of all classifiers is shown by the thicker brown line.
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Figure 5-6: Performance of different off-target prediction algorithms. Comparing the
overall performance across all nucleases of different predictive algorithms for ZFNs (a, b)
and TALENs (c, d).
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Figure 5-7: Positional feature weightings of the TALEN classifier. Weightings assigned
to different features of the ‘TALEN 04’ classifier along the axis of the target site beginning
with the 5’ base and ending with the RVD closest to the FokI nuclease (Fn) domain.
than mismatches in the 3’ region of the binding site [75]. Looking at the features in this
classifier, we were able to see a clear trend matching this experimental observation in that
the RVDs in positions 1 to N-5 were weighted very highly, RVDs in positions N-4 to N-
1 less so, and the last RVD (furthest in the 3’ direction) substantially lower (Figure 5-7).
However, we also observed a low weighting assigned to the 5’ base by the classifier.
5.5 Discussion
Evidence from the cross-validation analyses indicated that these algorithms do not appear
to be over-trained, and that their performance on these test-sets provides a close approx-
imation to how the algorithms will perform on future ZFNs and TALENs. The internal
cross-validation analysis found relatively low variance between the different folds using
the optimized hyperparameter settings (Figure 5-3). Furthermore, testing the algorithms on
the ‘hold-out’ datasets showed only a slight reduction in performance compared to the av-
erage performance of the internal cross-validation (Figure 5-4). However, the small size of
the ‘hold-out’ datasets (an unavoidable limitation given the current number of total known
ZFN and TALEN off-target sites) somewhat limits the interpretation of those findings.
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Since the overall goal of the algorithms is to be able to predict the off-target behavior
of a novel ZFN or TALEN solely based in information gathered about other nucleases,
we sought to also cross-validate the algorithms by testing their performance using each
different nuclease as a test-set. Although the performance differences between individual
nucleases were certainly greater than the randomized subdivisions used for the standard
cross-validation procedures, the CVs for the two algorithms were both < 50%. The small
number of off-target sites for some individual nucleases likely contributed to the larger vari-
ability observed in this cross-validation approach. The overall lower average precision val-
ues (the area under the curve) for the ‘by nuclease’ cross-validation approach—compared
to the standard cross-validation approach—are due to the fact that additional ‘spike-in’
on-target sites were not present in the test-sets of the ‘by nuclease’ approach.
The algorithms derived from the machine learning approach outperformed the previ-
ously developed algorithms (Figure 5-6), however the gain in predictive power was more
modest than originally anticipated. These findings may reflect the limitation imposed by
the number of known off-target sites available as training data. While the two previously
developed performance metrics (the percentage of total bona fide off-target sites found
within the search limits and the precision within the top 16 rankings) are more intuitive,
we believe that average precision is a more appropriate performance metric as it is well es-
tablished in the machine learning community and better reflects the aggregate performance
of the predictive algorithm. We note that while some TALEN algorithms outperformed the
new ‘TALEN 04’ algorithm developed through machine learning in terms of the precision
within the top 16 rankings, none of the previous algorithms achieved as high of an average
precision score (Figure 5-6d).
In our analysis here of an expanded dataset of off-target sites, the ‘v2.0’ algorithms
did not retain the performance advantage over the first-generation algorithms that was pre-
viously observed (Figure 3-6). Although the ZFNv2.0 and TALENv2.0 algorithms still
performed comparably or better than the first-generation algorithms (Figure 5-6), they was
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not clearly superior. We speculate that the less sophisticated validation approaches used in
developing the ‘v2.0’ algorithms may have led them to be somewhat over-trained.
The weightings assigned by machine learning algorithms to different features can pro-
vide a variety of useful information. On one hand, the weightings can offer insight into
potential new mechanisms of how the phenomenon in question operates, which can guide
researchers towards testable hypotheses. On the other hand, if certain factors have al-
ready been experimentally validated, then seeing whether the feature weightings recapitu-
late those findings can be used as an assessment of how well the algorithm is capturing the
underpinnings of the problem in question. In our case, we observed consensus with previ-
ous publications [75] that mismatches towards the 3’ end of TALENs are better tolerated
than mismatches towards the 5’ end (Figure 5-7), indicating that the algorithm appropri-
ately captured that aspect. However, the weighting of the 5’ base was substantially lower
than the weightings of the RVDs in the 5’ region; most published evidence [79] suggests
that the 5’ base has a very high impact on TALEN binding. This could reflect an issue with
our choice of extracted features or could simply be that the weighting of the impact of a
single base and the weighting of 5 grouped RVDs are not directly comparable.
5.6 Conclusion
Using the most comprehensive list of ZFN and TALEN off-target sites compiled to date,
we successfully applied machine learning techniques to create algorithms with abilities
to predict bona fide off-target sites de novo solely based on the intended target site that
are superior to any algorithms previously developed. Although the overall improvement
in algorithm performance gained through the machine learning process was incremental
rather than transformative, we have developed a robust framework that should continue
to provide performance improvements as more bona fide off-target sites are added to the
training datasets through future investigations.
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CHAPTER VI
QUANTIFYING GENOME-EDITING OUTCOMES AT
ENDOGENOUS LOCI WITH SMRT SEQUENCING1
6.1 Abstract
Targeted genome editing with engineered nucleases has transformed the ability to introduce
precise sequence modifications at almost any site within the genome. A major obstacle
to probing the efficiency and consequences of genome editing is that no existing method
enables the frequency of different editing events to be simultaneously measured across a
cell population at any endogenous genomic locus. We have developed a novel method
for quantifying individual genome editing outcomes at any site of interest using single
molecule real time (SMRT) DNA sequencing. We show that this approach can be applied
at various loci, using multiple engineered nuclease platforms including TALENs, RNA
guided endonucleases (CRISPR/Cas9), and ZFNs, and in different cell lines to identify
conditions and strategies in which the desired engineering outcome has occurred. This
approach facilitates the evaluation of new gene editing technologies and permits sensitive
quantification of editing outcomes in almost every experimental system used (Figure 6-1).
6.2 Introduction
Genome editing with engineered nucleases is a transformative technology for efficiently
modifying essentially any genomic sequence of interest [74]. This technology utilizes en-
gineered nucleases to generate site-specific double-strand breaks (DSB) at desired genomic
1Modified from: Hendel A*, Kildebeck EJ*, Fine EJ* et al. (2014). Quantifying Genome-Editing
Outcomes at Endogenous Loci with SMRT Sequencing. Cell Reports [48]. * These authors contributed
equally to the work.
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Figure 6-1: Graphical Abstract
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locations followed by resolution of DSBs using the endogenous cellular repair mecha-
nisms of nonhomologous end-joining (NHEJ) and homology directed repair (HDR) [91].
A variety of desired genetic modifications can be achieved with this approach, includ-
ing mutation of a specific site through mutagenic NHEJ and precise change of a genomic
sequence to a new sequence through HDR. There are currently four principal families of
engineered nucleases used for gene editing: Zinc Finger Nucleases (ZFNs) [91], Transcrip-
tion Activator-Like Effector Nucleases (TALENs) [10], Clustered Regularly Interspaced
Short Palindromic Repeats (CRISPR/Cas9) or RNA-guided endonucleases (hereafter called
“RGENs”) [38, 73], and engineered meganucleases [106]. The rapid development of these
technologies is allowing for the precise alteration of genomes for numerous applications,
including plant engineering [67], generation of cell lines for basic science [107], human
gene therapy [120], and industrial applications [33].
When a new set of gene editing reagents is developed for a custom application, the
activity levels of nucleases and the frequency of the desired gene editing event at the tar-
get locus must be determined and often need to be optimized for the specific cell type and
system being used. This need has previously been met by a variety of methods including
gel-based assays to measure mutagenic NHEJ [45], gene addition of fluorescent reporters
to measure HDR [90, 109], analysis of large numbers of single cell clones, and the use of
optimization assays to measure NHEJ and HDR at engineered reporter loci [15]. While
each of these assays have their utility, each have important limitations including a lack of
sensitivity required for difficult applications (gel based assays), the use of an indirect rather
than a direct measure of genome editing (targeted gene addition of fluorescent reporters),
and the need to generate reporter cell lines (Traffic Light Reporter system). The Traffic
Light Reporter (TLR) system [15] is the only one of these assays that allows simultaneous
measurement of NHEJ and HDR by expressing GFP in cells that undergo HDR-mediated
correction of a GFP gene and expressing mCherry in cells with NHEJ-induced frameshift
mutations. While the TLR is a very sensitive assay for measuring DSB repair (DSBR)
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pathway choice, the need to generate a fluorescent reporter locus precludes measurement
at endogenous target loci and thus far has prevented the use of the TLR in human primary
cells. High-throughput sequencing of endogenous loci overcomes these limitations, but
the range of outcomes that can be measured is limited by sequencing read-lengths. Illu-
mina [132] and 454 [92] sequencing have recently been used to measure HDR and NHEJ
outcomes when single-stranded oligodeoxynucleotides (ssODNs) or plasmids with short
homology arms are used as donor templates, but the read-length limitations of these plat-
forms do not allow analysis of longer arms of homology that drive more efficient HDR and
provide the flexibility to target long gene cassettes.
Here, we present a new method for measuring genome editing outcomes at endogenous
loci using single molecule real time (SMRT) DNA sequencing, which provides read-lengths
approaching 15 kb and is an affordable approach that can be widely used. This technique
allows for analysis of gene editing frequencies when donor templates with long arms of
homology are used, which is a common strategy to increase HDR efficiency in primary
cells and for the addition of large gene inserts. Using this method, we were able to measure
simultaneous frequencies of NHEJ and HDR in primary cells and cell lines with greatly
improved detection sensitivity. We describe the use of SMRT sequencing analysis to mea-
sure genome editing outcomes and rare large insertions generated by TALENs, ZFNs, and
RGENs at the endogenous IL2RG, HBB, and CCR5 loci. In addition, we use this system




IL2RG TALENs were synthesized (Genscript) using the ∆152 N-terminal domain and the
+63 C terminal domain as previously described [77] and fused to the FokI nuclease domain
and cloned into pcDNA3.1 (Invitrogen). HBB TALENs were previously described in Voit
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et al. [125]. CCR5 TALENs containing the same RVDs as previously described in Mus-
solino et al. [80] were made using a Golden Gate cloning strategy [14] and cloned with the
same N- and C- termini and nuclease domain into pcDNA3.1. CCR5 ZFNs were previously
described in Perez et al. [89]. For generating RGEN expression vectors, the bicistronic ex-
pression vector (pX330, provided by Dr. Feng Zhang, and also available through Addgene
#42230) expressing Cas9 and sgRNA were digested, and the linearized vector was gel pu-
rified. Oligo pairs for the IL2RG and HBB sites were annealed, phosphorylated, and ligated
to linearized vectors.
The IL2RG, HBB, and CCR5 targeting vectors were constructed by PCR amplifying
arms of homology from the corresponding loci using genomic DNA isolated from K562
cells. The point mutations that, upon successful homologous recombination, would be
stably integrated into the genome and prevent binding and cleavage by the engineered nu-
cleases were added as part of the PCR primers used to generate the arms of homology. The
homology arms were then cloned into a ∼2900 base pair vector based on pBlueScript SK+
using standard cloning methods.
6.3.2 Cell Culture
K562 cells (ATCC) were maintained in RPMI 1640 (Hyclone) supplemented with 10%
bovine growth serum, 100 units/ml penicillin, 100 µg/ml streptomycin and 2mM L-glutamine.
Human CD34+ hematopoietic stem/progenitor cells (HSPCs) were purchased from Lonza
(2M-101B) and thawed per the manufacturers instructions. CD34+ HSPCs were maintained
in X-VIVO15 (Lonza) supplemented with SCF (100 ng/ml), TPO (100 ng/ml), Flt3-Ligand
(100 ng/ml), IL-6 (100 ng/ml), and StemRegenin1 (0.75 µM). hESC line H1 (WiCell) was
maintained in feeder-free culture conditions in mTeSR1 (Stem Cell Technologies) on a thin
layer of Matrigel (BD). Cultures were passaged every 3-5 days enzymatically with Accu-
tase (Innovative Cell technologies). Cells were transfected between passage 45 and 47.
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6.3.3 Transient Transfection for Genome Editing
1 ∗ 106 K562 cells were transfected with 2 µg TALEN-encoding plasmid and 5 µg donor
plasmid (unless otherwise indicated) by nucleofection (Lonza) using program T-016 and a
nucleofection buffer containing 100 mM KH2PO4, 15mM NaHCO3, 12 mM MgCl2·6 H2O,
8mM ATP, 2mM glucose, pH 7.4. 4∗105 CD34+ HSPCs were nucleofected with an Amaxa
4D Nucleofector with the P3 Primary Cell Nucleofector Kit (V4XP-3032) and program
EO-100 per the manufacturers instructions. 1 ∗ 106 H1 cells were transfected with 0.5 µg
or 2.5 µg of each TALEN-encoding plasmid and 4 µg donor plasmid (unless otherwise in-
dicated) by nucleofection (Lonza) using an Amaxa 4D Nucleofector (program B-105) with
the P3 Primary Cell Nucleofector Kit (V4XP-3032) and following manufacturers instruc-
tions.
6.3.4 Flow Cytometry
Samples were collected 72h post-nucleofection and analyzed for fluorescence using an Ac-
curi C6 flow cytometer. GFP expression was measured using a 488-nm laser for excitation
and a 530/30 bandpass filter for detection.
6.3.5 Restriction Fragment Length Polymorphism Assay
Restriction fragment length polymorphism assay was performed as previously described
[16]. Briefly, Genomic DNA was extracted from transfected cells with DNeasy Blood
& Tissue Kit (Qiagen). Genomic DNA was then PCR amplified with primers flanking
the donor target region. The amplification was carried out with Accuprime polymerase
(Invitrogen), using the following cycling condition: 95°C for 5 min for initial denaturation;
30 cycles of 95°C for 30 s, 67°C for 45 s and 68°C for 120 s; and a final extension at 68°C
for 5 min. PCR products were digested with 20 U of AfIII at 37°C for ∼2h and resolved
with PAGE.
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6.3.6 Single cell clone analysis
Single-cell cloning was performed by flow cytometry cell sorting on a BD FACSAria. Ge-
nomic DNA was isolated from single clones using the Qiagen DNeasy kit (Qiagen). The
IL2RG target region was PCR amplified with Accuprime polymerase (Invitrogen) and the
following cycling condition: 95°C for 5 min for initial denaturation; 30 cycles of 95°C for
30 s, 67°C for 45 s and 68°C for 120 s; and a final extension at 68°C for 5 min. PCR
amplicons were sequenced using standard Sanger sequencing. Sequences were analyzed
using the ApE plasmid editor by M. Wayne Davis.
6.3.7 SMRT Sequencing
Genomic DNA containing IL2RG alleles was harvested from cultured K562, CD34+ HSPC,
and hESC samples using the DNeasy Blood & Tissue Kit (Qiagen). IL2RG alleles were am-
plified with Accuprime polymerase (Invitrogen) and the following cycling condition: 95°C
for 5 min for initial denaturation; 30 cycles of 95°C for 30 s, 67°C for 45 s and 68°C for
60 s; and a final extension at 68°C for 5 min for the K562 samples and 95°C for 5 min for
initial denaturation; 30 cycles of 95°C for 30 s, 67°C for 45 s and 68°C for 90 s; and a final
extension at 68°C for 5 min for the HSPC, and hESC samples. Sequencing libraries were
constructed, as previously described [117], using the DNA Template Prep Kit 1.0 (Pacific
Biosciences, Menlo Park, CA). SMRTbell libraries contained amplicons that were pooled
together, with different barcodes appended to allow multiplex analysis. Purified, closed
circular SMRTbell libraries were annealed with a sequencing primer complementary to a
portion of the single-stranded region of the hairpin. For all SMRTbell libraries, annealing
was performed at a final template concentration between 30 and 60 nM, with a 20-fold
molar excess of sequencing primer. All annealing reactions were carried out at 80°C for 2
min, with a slow cool to 25°C at a rate of 0.1°C/second. Annealed templates were stored
at -20°C until polymerase binding. DNA polymerase enzymes were stably bound to the
primed sites of the annealed SMRTbell templates using the DNA Polymerase Binding Kit
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2.0 (Pacific Biosciences). SMRTbell templates (3 nM) were incubated with 6 nM of poly-
merase in the presence of phospholinked nucleotides at 30°C for 2 h. Following incubation,
samples were stored at 4°C. Sequencing was performed within 72 h of binding using final
on plate concentration of 0.3 nM. Each sample was sequenced as previously described [96]
using DNA Sequencing Kit 2.0 (Pacific Biosciences). Sequencing data collection was per-
formed on the PacBio® RS (Pacific Biosciences) using C2/C2 chemistry and movies of 55
min in each case.
6.3.8 SMRT Analysis Pipeline
A SMRT library can contain amplicons from different genomic loci, with different barcodes
appended to allow multiplex analysis, with indels resulting from NHEJ, or with SNPs intro-
duced through dHDR. To separate out all of these components, as well as deal with variable
read quality and other artifacts introduced by the sequencing process, we implemented an
analysis pipeline using Perl (Figure 6-2).
6.3.8.1 Determining amplicon source
To begin, we take the FASTQ output files (Figure 6-2a) of the SMRT consensus sequence
generation algorithm that is provided by the PacBio RS instrument. These files are labeled
with the extension “.ccs.fastq” and contain the assigned DNA bases for each sequencing
read as well as Phred quality values (QV) indicating the degree of confidence in the as-
signment of each base. Using the wild-type amplicon sequences (excluding barcodes) that
would be expected to be contained in the SMRT library (Figure 6-2b), a BLAST database
is constructed (Figure 6-2c). All sequence reads are BLASTed against this database to
determine the amplicon from which they originated (BLAST Parameters: gapOpen 2,
gapExtend 1, reward 1, penalty -1) and also to align the read in the proper ori-
entation (because the SMRT polymerase can initially bind to either strand of DNA, some
reads are in the “sense” orientation while others are “anti-sense”). Due to trace levels of
contamination or non-specific PCR amplification, a small fraction (typically <0.5%) of the
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Figure 6-2: SMRT Analysis Pipeline
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raw sequence reads do not have a significant BLAST match to any of the expected ampli-
con sequences (Figure 6-2d) and are subsequently discarded. After all BLAST queries are
completed, each read has been mapped to a genomic site (Figure 6-2e).
6.3.8.2 Initial quality filtering
After reads have been mapped to a genomic site, reads are pairwise aligned to the expected
amplicon sequence for further analysis (Figure 6-2f). The alignment is performed using
the Needleman-Wunsch algorithm obtained from the mEmboss server (all pairwise align-
ments are performed with the parameters: gapOpen 10, gapExtend 1). PCR and the
sequencing process sometimes generate reads that are missing large segments of the 5’ or
3’ ends of the amplicon or have concatemerized amplicons together. To remove these arti-
facts, the 40 proximal bases of the 5’ and 3’ ends of the pairwise alignments are scanned
for “gaps” between the sequencing read and the expected amplicon. If more than 30 gaps
are observed at either end of the alignment, the read is discarded (Figure 6-2g); typical
loss at this step is 4%-15% of the sequencing reads. To decrease the computing require-
ments of the pipeline, a simple quality filter is applied to the reads (Figure 6-2h) and all
those with a mean Phred QV of less than 40 are discarded (Figure 6-2i); typical loss at this
step is 20%-40% of the remaining sequencing reads. Skipping this initial QV filter would
be expected to have negligible effect on the final results because low quality reads would
be removed in downstream quality filters (Figure 6-2n,y). The threshold of 40 was found
through empirical testing to be optimal for decreasing total analysis time while minimizing
the number of reads discarded using this simple preliminary filter that would have passed
through later, more complex, quality filters (Figure 6-2n,y).
6.3.8.3 De-multiplexing experimental conditions
For investigation of multiple experimental conditions at a single genomic locus, amplicons
can be barcoded and pooled together in the same SMRT library for multiplex analysis. To
determine the barcode of each sequencing read (Figure 6-2j), the 5’ and 3’ ends of the
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read are pairwise aligned against all barcode sequences for that amplicon in the library.
An additional two bases of the sequence read are included in the alignment to allow for
small errors generated during sequencing (i.e. for a 10 bp barcode, 10 + 2 = 12 bp of the
edges of the sequencing read would be aligned to each 10 bp barcode). The alignments
are analyzed for matches between a given barcode and the sequencing read. If more than
three gapped bases occur in the alignment, it is determined that that barcode does not
match the sequence. If ≥80% of the bases align in both the left and right barcodes, that
sequence is counted as a match for that barcode set. Due to sequence similarity between
barcodes and small sequencing errors, there are rare cases (0%-0.01% of sequencing reads)
where a sequencing read can match (at the ≥80% threshold) more than one barcode. Any
reads that match more than one barcode or are not matched to any barcode are discarded
(Figure 6-2k); typical loss due to reads not matching any barcode is 4-15% of the remaining
sequencing reads. The 80% threshold was found through empirical testing to be optimal
for reducing the number of reads matching no barcode while keeping the number of reads
matching to more than one barcode very close to zero. A further filter is applied to remove
any reads that have an initial gap of more than six bases at the 5’ or 3’ ends of the alignment
(Figure 6-2l); removal of reads by this filter is very rare (0%-0.1% of sequencing reads).
After all these steps are completed, the sequencing reads have been separated using the
barcodes to determine what experimental condition each read originated from (Figure 6-
2m).
6.3.8.4 Secondary quality filtering
The processivity of the polymerase used in the SMRT sequencing process is highly stochas-
tic, which leads to a wide distribution of the number of passes around the SMRTbell and
therefore a wide distribution of the quality of the consensus sequence reads. Low quality
reads containing small insertions, deletions, and substitutions must be removed so that they
do not produce false positive reports of a sequence read showing evidence of mutNHEJ
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or dHDR. Several approaches to filter low quality sequences using the Phred QV scores
were attempted, but background noise still persisted, perhaps due to the lack of a 1:1 cor-
respondence between calculated QV scores and measured empirical accuracy (Travers et
al. Figure 5 [117]). Consequently, a filter to remove low fidelity sequences (Figure 6-2n)
was constructed based on empirical comparison of the sequencing read to the expected
sequence. The sequencing read is expected to match the wild-type genomic sequence in
the positions flanking the nuclease cleavage site and excluding any SNPs introduced by the
DNA Donor Template. Therefore, the accuracy of the sequencing read in these constant
regions was used as a proxy for the accuracy of the sequence in the variable regions of the
amplicons. Specifically, the reads were scanned for substitutions, insertions, and deletions
(indels), relative to the wild type sequence that did not overlap any regions within ten bases
of DNA Donor SNPs or nuclease binding sites. The sum of the squares of the lengths of
the indels was divided by the length of the total search sequence and if the quotient was
greater than 0.03, the read was discarded (Figure 6-2o). For example, a read containing a
one bp indel and a 3 bp indel out of a total sequence length of 500 would be calculated as:
12+32
500
= 0.02; since 0.02 ≤ 0.03, this read would meet acceptable quality standards for this
filter and would remain in the pipeline. Typical loss at this step is 4%-10% of the remaining
sequencing reads.
6.3.8.5 Allele assignment
The next step in the pipeline is to determine if a sequencing read originated from an allele
that had undergone homology directed repair using the DNA Donor as a template (dHDR)
or from an allele that was the wild-type (WT) genomic sequence (Figure 6-2p). To perform
this comparison, the read is pairwise aligned to both the expected WT and dHDR amplicon
sequences (in separate steps). For each alignment, the positions of the SNPs introduced by
the DNA Donor Template are examined. If the position of the SNP, in addition to the two
flanking bases on each side (a total of five bases), contains no gaps or substitutions in the
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pairwise alignment, that SNP is counted as a match. If the percentage of matching positions
is ≥80%, then a read is declared as a match for that allele. Similar to the barcode analysis
(Figure 6-2j), in rare cases (0-0.01%), a read will be declared as matching both alleles
due to small sequencing errors; these reads are discarded from further analysis (Figure 6-
2q). Another subset of reads will not meet the threshold to match either allele (Figure 6-
2r); these are typically 0.1%-1.5% of the remaining sequencing reads. While sometimes
these reads simply do not have the necessary sequence fidelity to be confidently matched, a
substantial fraction consists of reads with a large deletion that has removed the entire region
where the SNPs exist. As these large deletions are typically resulting from a mutNHEJ
event, these reads are saved for further analysis (Figure 6-2s,t).
6.3.8.6 Detecting unanticipated SNPs
When testing different cell lines, there may often be unknown SNPs present in the cell
line that are not in the reference genome which could interfere with accurate sequence
fidelity, mutNHEJ, and dHDR analysis. To identify any unanticipated SNPs, all the se-
quencing reads in each barcode set are compiled together in a multiple sequence alignment
(Figure 6-2u) which allows analysis of the base in each sequencing read that was pairwise
aligned to a position in the expected amplicon sequence. In the unanticipated SNP analy-
sis (Figure 6-2v), any positions where 40% or more of the bases in the reads are different
than the expected base are flagged for manual inspection. In some cases, a homozygous
SNP relative to the reference genome is identified (Figure 6-2x) and the expected amplicon
sequence can be adjusted accordingly and the analysis re-run. In other cases, the SNP is
heterozygous and is simply noted for downstream steps in the pipeline. Bases flagged as
SNPs that occur near the nuclease cleavage site should be inspected very carefully, espe-
cially if the SNP analysis showed that most reads had a deletion instead of the expected
base, to determine if this “SNP” may actually be the result of high levels of mutNHEJ
modifying that position.
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6.3.8.7 Final quality filtering
Once all SNPs have been identified, a final sequence fidelity filter can be applied to prune
any remaining low quality sequences (Figure 6-2y). This filter works similarly to (Figure 6-
2n) in that it searches for indels in the pairwise alignment and calculates an “error score”.
It differs in a few aspects though: any positions where a SNP was identified are not counted
as an indel if the base matches the alternate SNP base, only the 100 bases flanking each side
of the nuclease binding site are searched instead of the whole sequence, indels overlapping
any region except the nuclease binding site and the DNA Donor SNPs are counted instead
of allowing ten bases of “buffer” surrounding those regions in which indels would also not
be counted, and the quality threshold for excluding low fidelity sequences is set at the more
stringent 0.01 level (instead of 0.03). The 100 flanking bases are used for this filter instead
of the whole sequencing read because different portions of a longer read may have different
levels of quality and the regions flanking the nuclease binding site are presumed to be a
better proxy for the sequence quality in the binding site than regions further away. Any
reads not meeting the 0.01 error threshold are discarded (Figure 6-2z); typical loss at this
step is 5%-20% of the remaining sequencing reads.
6.3.8.8 NHEJ analysis
Once the final set of high fidelity sequencing reads has been filtered, they can be analyzed
for the presence of indels caused by mutNHEJ (Figure 6-2aa). Some indels in the sequenc-
ing reads may be due to errors in the SMRT sequencing process, so a set of guidelines was
developed to characterize indels that would result from mutNHEJ but not from sequencing
errors. For an indel to be considered to be caused by mutNHEJ, the initial requirements
are that the indel must overlap the spacer region between the nuclease binding sites and
be at least three bases long. If those criteria are met, then the following characteristics are
considered:
a) If the indel is larger than four bases, it is considered mutNHEJ
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b) If the indel consists entirely of deleted sequence, it is considered mutNHEJ
c) If the indel consists entirely of inserted sequence AND is a tandem repeat of either the
immediately adjacent 5’ or 3’ flanking sequence or allowing up to a one base separation.
Examples:
Wild-type Sequence: ACACCCAGGGAATGAAGAGCAAGCGCCATGTTGAAGCCATCATT
3 bp tandem repeat: ACACCCAGGGAATGAAGagcAGCAAGCGCCATGTTGAAGCCATC
4 bp tandem repeat: ACACCCAGGGAATGAAGagcaAGCaAGCGCCATGTTGAAGCCAT
1 base separation: ACACCCAGGGAATGAAGgcaAGCAAGCGCCATGTTGAAGCCATC
Sequencing reads previously identified in step (Figure 6-2p) as originating from dHDR
alleles theoretically should not have any mutations indicative of mutNHEJ due to the SNPs
in the nuclease binding site that should inhibit binding and cleavage. However, these reads
are still analyzed for evidence of mutNHEJ by the pipeline to ensure that this is the case. To
date, we have not observed any reads that were identified as dHDR that showed evidence
of mutNHEJ.
Once all sequencing reads have been analyzed for indels, the rates of mutNHEJ and
dHDR for each barcoded experimental condition can be determined (Figure 6-2ab). Reads
that had previously been unable to be definitively assigned as either originating from a
dHDR or WT allele (Figure 6-2r) are analyzed for indels in two configurations: pairwise
aligned to the dHDR allele (Figure 6-2s) and pairwise aligned to the WT allele (Figure 6-
2t). Only sequencing reads that show evidence of mutNHEJ in BOTH pairwise alignments
are considered to have been originally WT alleles in which mutNHEJ occurred. If indels
indicative of mutNHEJ only occur in one of the pairwise alignments, then it is possible that
it is due to small sequencing errors combined with alignments with the incorrect allele. If
indels indicative of mutNHEJ do not occur in either pairwise alignment, it is still unknown
which allele the read originated from and so it cannot be appropriately assigned. The rates
of mutNHEJ and dHDR for a given barcode set are calculated as follows:
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Let R be the number of reads from (Figure 6-2r) with mutNHEJ indels in both
alignments.
Let W be the total number of reads assigned to the WT allele.
Let N be the number of reads in W with mutNHEJ indels.





6.3.8.9 Indel spectrum analysis
After the sequencing reads with mutNHEJ have been identified, the sizes of the different
indels are analyzed to produce a mutation spectra showing the distribution of indels created
(Figure 6-2ac). For indels consisting of both insertions and deletions, the resulting total
change in the amplicon size is used for the distribution (i.e. an indel consisting of a +7
insertion and a -3 deletion would be recorded as a +4 overall insertion). Mutation spectra
are displayed as cumulative distribution functions representing the fraction of all mutation
sizes observed that are more negative than the given value.
6.3.8.10 Systemic biases
Certain steps in the analysis pipeline introduce small amounts of systemic bias in the mea-
surements of mutNHEJ and dHDR. From the comparison of the SMRT pipeline to single
cell clone analysis, it appears that these small biases largely cancel each other out to yield
highly accurate results (Figure 6-4). However, for special applications of this pipeline,
certain biases may become more prominent and should be kept in mind. Any biases intro-
duced by the different steps are denoted at the end of the paragraphs as either increases (↑)
or decreases (↓) to the measurements of mutNHEJ or dHDR.
SMRT sequencing process:
The diffusion mechanics of the SMRT sequencing process cause shorter amplicons to be
slightly overrepresented and longer amplicons to be slightly underrepresented in the raw
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sequencing reads (Figure 6-2a). Therefore, amplicons with a large deletion caused by
mutNHEJ will be slightly overrepresented compared to wild-type amplicons while those
with large insertions caused by mutNHEJ will be slightly underrepresented. Similarly,
longer amplicons tend to have lower average sequence quality than shorter amplicons. This
is due to the reduced number of passes around the SMRTbell that can be achieved with a
given read length for longer compared to shorter amplicons. This results in reads with large
insertions tending to be discarded at a slightly higher frequency than wild-type amplicons
and reads with large deletions discarded at a slightly lower frequency (Figure 6-2 i,o,z).
↑mutNHEJ, ↓mutNHEJ
Allele analysis:
In determining whether a sequencing read originated from a dHDR allele or a WT allele
(Figure 6-2p), there are a small fraction of reads that do not contain enough SNPs for
definitive matching to either allele (Figure 6-2r). A large fraction of these reads contain
large deletions resulting from mutNHEJ that removed the entire sequence containing the
SNPs from the allele. These reads with mutNHEJ are later recovered in the indel anal-
ysis step (Figure 6-2aa), but the only way to determine if a read from (Figure 6-2r) was
originally WT or dHDR is by making the assumption that mutNHEJ can only occur in
WT alleles. Therefore, no reads can be recovered from (Figure 6-2r) that did not have
mutNHEJ which means that in the final determination of the rate of mutNHEJ in (Fig-
ure 6-2ab), the numerator and denominator are always increased simultaneously; there are
no cases where only the denominator is increased. This results in a slight overestimation
of the rate of mutNHEJ. Excluding these reads would result in an underestimation of the
rate of mutNHEJ and would also make the mutation spectra inaccurate. Since the mutation
spectra is an analysis of the types of mutations and not the overall rate of mutation, includ-




In determining whether or not a sequencing read has indels indicative of mutNHEJ, some
small types of indels are ignored. Because the predominant error mode of SMRT sequenc-
ing is single inserted and deleted bases, these are discounted in the indel analysis to remove
background noise. However, this reduction in background noise comes at the cost of a
slight underestimation in the rate of mutNHEJ since it is known that mutNHEJ can pro-
duce small one or two base indels.
↓mutNHEJ
6.3.9 Statistical analysis
To calculate confidence intervals, t-statistics were calculated as previously described [88].
90% confidence intervals were calculated by determining the upper and lower bounds of the
mutation rates that would yield P values of 0.05. 66% confidence intervals were calculated
similarly using a target P value of 0.32.
6.4 Results
6.4.1 Measurement of Gene Editing Outcomes at the Endogenous IL2RG Locus
To develop a method for quantitatively and rapidly measuring the different gene alterations
occurring at an endogenous locus of interest, we used a highly active TALEN pair to stim-
ulate DSBs at the endogenous IL-2 receptor common γ-chain gene (IL2RG), mutations in
which are responsible for the congenital primary immunodeficiency SCID-X1 [58, 105].
For the introduction of precise sequence alterations at this locus, we designed a donor tem-
plate with approximately 400bp arms of homology 5’ and 3’ of the TALEN cut site (Fig-
ure 6-3a). Within the 3’ arm of homology we introduced seven point mutations that, upon
successful HDR, are stably integrated into the IL2RG gene and prevent binding and cleav-
age by the TALEN pair (Figure 6-3a,b). To measure the frequency of mutagenic NHEJ
and HDR with this system, we developed a strategy based on single molecule real time
(SMRT) DNA sequencing, a high-throughput sequencing technology capable of analyzing
long DNA fragments. First, the IL2RG locus was amplified using a forward primer that is
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5’ and outside the start of the 5’ homology arm and a reverse primer that is downstream of
the TALEN pair target site (Figure 6-3c). With this approach, non-integrated and randomly
integrated donor templates are not amplified, removing common sources of background
noise. The SMRT DNA sequencing technology allows for the determination of DNA se-
quence from individual DNA templates [31, 98]. Single-molecule read lengths approaching
15 kb were reached in this study, with an average read length approaching 3 kb. For DNA
fragments shorter than the read limit of the polymerase, improved sequence accuracy (fre-
quently reaching an average Phred QV score of 40, denoting 99.99% accuracy) is achieved
by iteratively sequencing the same circular DNA template [117] (Figure 6-3c).
To induce sequence alterations in IL2RG we expressed the IL2RG TALENs from plas-
mid DNA with or without introduction of donor DNA, and then analyzed cell popula-
tions by SMRT DNA sequencing. Following transfection with TALENs alone we detected
unmodified alleles and alleles with deletions or insertions indicative of mutagenic NHEJ
(Figure 6-3d). When cells were transfected with both the TALENs and donor DNA, we
detected unmodified alleles, alleles with deletions or insertions, and alleles with the 7 point
mutations precisely integrated into IL2RG by HDR. Notably, no alleles were detected with
both the 7 point mutations and indels indicative of NHEJ, validating the ability of the point
mutations to prevent TALEN cleavage of HDR-modified alleles. High frequencies of ‘on-
target’ IL2RG modification were observed in K562 cells under these conditions, with 18%
of alleles mutated by NHEJ and 17% of alleles precisely modified by HDR (Figure 6-3d).
Due to the PCR strategy being used, where one primer is outside of the donor template
arm of homology, essentially no background signal was detected from amplification of
non-integrated or randomly integrated donor template. Control experiments (either mock
or donor only transfections) had low background frequencies of NHEJ and HDR reads
resulting from PCR or DNA sequencing errors, which ranged from 0.00% to 0.03% for
individual samples with average frequencies of 0.007% NHEJ and 0.001% HDR. This low
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Figure 6-3: Measuring gene editing at an endogenous locus with SMRT sequencing.
(a) Sequence of the TALEN target site at the IL2RG locus and the IL2RG donor template.
The donor template harbors seven point mutations that, when integrated into IL2RG, create
silent mutations and a novel AflII restriction site. These substitutions alter the right TALEN
binding site and provide a signature for alleles precisely modified by HDR. (b) Diagram of
gene editing at an endogenous locus. TALENs create a double strand break (DSB), which
can lead to no modification, insertion or deletion mutations, or integration of point muta-
tions from the donor template. (c) Schematic of SMRT DNA sequencing analysis. The
endogenous locus is amplified by PCR, with at least one primer outside the arms of homol-
ogy of the donor template, and SMRT adapters are added to PCR amplicons. Individual
DNA molecules are sequenced by SMRT sequencing, with read lengths averaging ∼3kb in
length and approaching ∼15kb. (d) Measurement of gene editing outcomes at the IL2RG
locus in K562 cells. Modification frequencies are normalized to transfection efficiency.
Bars represent three independent biological replicates; error bars, s.d.
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level of background noise, coupled with the high-throughput nature of this approach, pro-
duces a high level of sensitivity and creates new possibilities for studying rare DNA repair
events.
6.4.2 Reliability of SMRT Sequencing Analysis at a Single Endogenous Locus
To validate the accuracy of the SMRT DNA sequencing strategy, we compared our high-
throughput results with standard gel-based assays and single cell clone analysis of K562
cells. First, we used a restriction fragment length polymorphism (RFLP) assay to measure
the frequency of HDR by measuring the presence of an AflII restriction site that is created
when the 7 point mutations within the donor template are precisely incorporated into the
target locus (Figure 6-4a). Using the RFLP assay, the AflII restriction site was detected in
an average of 14.3% of alleles normalized for transfection efficiency compared to 16.8% of
alleles by SMRT sequencing analysis of the same populations. The most commonly used
methods for determining the frequency of NHEJ measure any small deletion or insertion
events, which is confounded by sequence alterations introduced by HDR. To independently
determine the true frequency of alleles modified by NHEJ and HDR, we grew single cell
clones from a representative sample. Analysis of these clones showed that 11.3% of alle-
les had undergone mutagenic NHEJ and 11.1% of alleles had been precisely modified by
HDR, compared to frequencies of 11.2% and 11.0% respectively as measured by SMRT
sequencing analysis of the same population (Figure 6-4b); SMRT frequencies represent the
total population frequency, not normalized to transfection efficiency, in order to directly
compare to the clonal analysis. To confirm the reproducibility of SMRT sequencing analy-
sis, we analyzed a single targeted population eight times and found standard deviations for
NHEJ and HDR of 0.66% and 0.79% respectively (Figure 6-4c). This experimental vari-
ance between samples was only slightly higher than the expected statistical variance for the
number of sequences analyzed, demonstrating the reliability of this approach (Figure 6-4d).
137
Figure 6-4: Reliability of SMRT sequencing analysis for measuring gene editing out-
comes at an endogenous locus. (a) RFLP analysis of K562 cells targeted with 1 µg of each
TALEN and 5 µg donor in triplicate. The frequency of HDR in each sample as measured by
RFLP and SMRT sequencing analysis is shown. (b) Quantification of NHEJ and HDR fre-
quencies in single cell clones grown from a representative population of K562 cells. Error
bars represent 90% confidence intervals. (c) A representative sample of targeted K562 cells
was analyzed by SMRT sequencing 8 separate times to determine the variability introduced
by PCR, SMRT library synthesis, and sequencing. Error bars represent 90% confidence in-
tervals. (d) Quantification of the observed experimental variation compared to the expected
statistical variation for the number of sequences analyzed for the 8 replicates. Error bars
for experimental variation represent standard deviation. Error bars for statistical variation
represent 68% confidence intervals (corresponding to the fraction of the normal distribution
covered by ±1 standard deviation).
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6.4.3 Quantification of Gene Editing at the IL2RG Locus in Primary Cells
For novel gene editing applications, moving from known conditions in commonly-used cell
lines to more difficult experimental platforms, such as induced pluripotent stem cells or pri-
mary cells, poses a significant challenge. Using the gene editing tools previously described,
we next tested our ability to measure gene editing events in CD34+ hematopoietic stem/pro-
genitor cells (HSPCs) and human embryonic stem cells (hESCs), both of which are difficult
to target, but important cell types for basic research and gene therapy. After introducing
TALENs and donor DNA into CD34+ HSPCs, SMRT sequencing analysis showed frequen-
cies of mutagenic NHEJ and HDR of 7% and 1% respectively at the endogenous IL2RG
locus (Figure 6-5a). In hESCs, which commonly require enrichment of targeted clones
due to low gene editing efficiencies, addition of our gene editing reagents resulted in muta-
genic NHEJ and HDR frequencies of 0.10% and 0.14% respectively (Figure 6-5b). Control
hESC samples transfected with only donor DNA showed background frequencies of 0.02%
NHEJ and no HDR, illustrating the very low level of background noise for this technique.
Our transfection efficiency for these hESC populations was approximately 20%, suggest-
ing that with enrichment for transfected cells we would generate modification frequencies
of 0.5-0.7%. These numbers are consistent with the numbers published by Soldner et al.
[107], who showed that after sorting for highly transfected hESCs targeting frequencies
of 0.4-0.8% were obtained. Importantly, since IL2RG is silent in both of these cell types,
these results demonstrate the ability of this approach to provide quantitative and sensitive
measures of gene editing and DNA damage repair at a silent endogenous locus in primary
cells.
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Figure 6-5: Measurement of genome editing at an endogenous locus in human pri-
mary cells. (a) Measurement of gene editing outcomes at IL2RG in CD34+ HSPCs us-
ing the high-expression TALEN plasmids. (b) Measurement of gene editing outcomes at
IL2RG in hESCs using the high-expression TALEN plasmids.
Bars represent three independent biological replicates; error bars, s.d.
6.4.4 Analysis of Gene Editing with TALENs, RGENs, and ZFNs at the Endogenous
IL2RG, HBB, and CCR5 Loci
The extraordinary expansion of gene editing technologies over recent years has created a
plethora of opportunities for researchers attempting to modify genomes. With the introduc-
tion of TALENs and RGENs, it is now possible to generate tens to hundreds of candidate
nucleases in a matter of weeks, or even days, and target multiple genomic sites simulta-
neously [11, 19, 61, 97, 131]. Via simultaneous analysis of different genomic sites and
conditions in a single SMRT sequencing run, this approach has the potential to rapidly
expedite the process of characterizing nuclease activities and optimizing targeting param-
eters. To determine the ability of this method to measure the activities of different classes
of nucleases at multiple genomic sites, we treated cells with TALENs, RGENs, and ZFNs
designed to target the IL2RG, HBB, and CCR5 genes and analyzed gene modification.
To test the relative activity of TALENs and RGENs at the IL2RG locus we first con-
structed an RGEN with a target site overlapping the target site of the IL2RG TALENs
(Figure 6-6a). Expression of the RGEN in K562 cells generated targeted mutations in 37%
of IL2RG alleles compared to only 13% of alleles using TALENs. Introduction of donor
140
template DNA with either the RGEN or TALENs produced alleles modified by mutagenic
NHEJ and alleles precisely modified by HDR. As expected, the more active RGEN stim-
ulated a higher level of HDR than the TALENs with 33% and 22% of alleles harboring
the integrated SNPs respectively. Moving to a different genomic locus, we used a TALEN
pair and an RGEN targeting the HBB gene, mutations in which are responsible for sickle
cell anemia and thalassemia [40] (Figure 6-6b). At HBB, the RGEN again produced sig-
nificantly higher frequencies of gene disruption than the TALENs and stimulated higher
frequencies of HDR upon the introduction of donor template. When expressed with donor
template, the HBB RGEN mutated 41% of HBB alleles while the IL2RG RGEN mutated
21% of IL2RG alleles, suggesting that more DSBs were being created at the HBB locus.
Despite this increase in mutagenesis, the simultaneous level of HDR was only 14% at HBB
compared to 33% at IL2RG. Thus, total modification levels at HBB and IL2RG were highly
similar, 55% and 54% respectively, but the ratio of HDR to NHEJ was markedly lower at
HBB (0.34:1) than at IL2RG (1.6:1) (Figure 6-6a,b). This large difference in the efficiency
of precise gene targeting suggests that there could be intrinsic differences between these
loci affecting their ability to participate in plasmid-mediated gene targeting by HDR.
To further confirm the utility of SMRT sequencing analysis to measure targeted ge-
nomic modifications for multiple classes of nucleases, we compared the activity of previ-
ously reported ZFNs and TALENs designed to target the CCR5 locus [80, 89]. As seen at
IL2RG and HBB, addition of nucleases led to targeted disruption of the endogenous gene
by NHEJ and the further addition of donor template DNA stimulated targeted integration
through HDR (Figure 6-6c). The CCR5-specific ZFNs, variants of which are currently
being used in clinical trials for HIV [89, 115], produced higher levels of modification at
the endogenous CCR5 locus than TALENs designed to an overlapping target site. It is
important to note that in this study, stable modifications in K562 cells were measured for
TALENs, RGENs, and ZFNs 14 days post-transfection. The absolute genome editing fre-
quencies reported here are thus somewhat different than published results for previously
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described nucleases where nuclease activity was measured at different time points, in dif-
ferent cell types, and with different nuclease levels [80, 89, 126]. Nuclease-induced NHEJ
is typically measured with high nuclease levels 3 days post-transfection to detect maximal
NHEJ levels, but these modifications decrease over time due to toxicity [29, 30, 59, 70].
Instead of measuring NHEJ and HDR separately or with different transfection conditions,
SMRT DNA sequencing provides a simple alternative for comparing stable NHEJ and HDR
frequencies simultaneously.
6.4.5 Optimization of Gene Targeting Parameters
In addition to comparing different nuclease platforms, we have also used the SMRT DNA
sequencing approach to study different variables that might affect genome editing out-
comes. To explore how varying the dose of TALENs effects gene editing frequencies we
measured frequencies of NHEJ and HDR at IL2RG while progressively decreasing the
amount of TALENs transfected in K562 cells. Keeping the amount of donor DNA constant
and titrating down the amount of TALENs by 100-fold, we saw a progressive decrease in
both mutagenic NHEJ and HDR events while their relative frequencies remained largely
unchanged (Figure 6-7a). Using this approach we were able to reliably detect gene editing
outcomes at frequencies ranging from >20% at high TALEN levels to ≤0.1% at very low
TALEN levels. Even at modification frequencies of 0.1-0.4%, relative activity levels were
easily distinguished with this approach. Next, to test conditions for maximizing the fre-
quency of HDR at IL2RG, we investigated the effect of the amount of donor template DNA
on gene modification. Keeping the amount of TALENs constant and titrating the amount of
donor DNA, we saw the overall level of modification at IL2RG remain relatively constant
while the total level of HDR rose from 1.6% to 17.8% at optimal levels (Figure 6-7b). With
this rise in the contribution of HDR, the ratio of HDR to NHEJ increased from 0.12 to 1.37
with increasing abundance of donor DNA (Figure 6-7c).
Another important variable for efficient HDR-mediated DNA repair is the length of
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Figure 6-6: Measuring gene editing with different engineered nuclease platforms at
different genomic targets. (a) Left; IL2RG target site for TALENs and RGEN guide
sequence. The IL2RG start codon is shown in cyan. Right; Modification of the IL2RG
locus in K562 cells. (b) Left; HBB target site for TALENs and RGEN guide sequence. The
HBB start codon is shown in cyan. Right; Modification of the HBB locus in K562 cells. (c)
Left; CCR5 target site for TALENs and ZFNs in exon 3. Right; Modification of the CCR5
locus in K562 cells.
Bars represent three independent biological replicates; error bars, s.d.
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the homologous regions in donor DNA, which has been shown to vary between species
and in different cell types of the same species [8, 83, 127]. To determine the effect of
homology arm length on HDR efficiency with plasmid donors, we constructed a series of
donor templates with a range of homology arm lengths from 800bp to 100bp (Figure 6-
7d). At the IL2RG locus in K562 cells, homology arms 100bp or 200bp in length were
found to be significantly less effective for HDR than plasmid donor templates with 400bp
or 800bp homology arms. As would be predicted, the homology arm length did not change
the frequency of mutagenic NHEJ. In this cell type, 400bp arms of homology actually
resulted in the same levels of HDR as more commonly used 800bp arms, suggesting that
for gene targeting in some human cell types maximal levels of HDR may be achieved
with relatively short 400bp arms of homology. For all areas of optimization, however, the
specific setting of the cell type and the chromosomal locus under investigation should be
taken into consideration.
6.4.6 SMRT Sequencing of Genome Editing Outcomes Reveals Genomic and Plas-
mid DNA Sequences Captured into Targeted Sites
A unique feature of the SMRT sequencing method is the combination of high-throughput
with long sequence read-lengths. This combination allowed us to see rare mutations in-
cluding large insertions and deletions hundreds of base pairs (bp) in length. Analysis of
mutations at the IL2RG, HBB, and CCR5 loci showed a wide range of insertions and dele-
tions ranging from +334 bp to -412 bp. Interestingly, when we BLASTed the inserted
sequences that were >30 bp against NCBI non-redundant nucleotide databases, we were
able to identify sequences originating from the same chromosome as the target site, nonho-
mologous chromosomes, plasmid DNA, and the E. coli genome. Representative samples of
such insertion events can be seen in Figure 6-8. At each end of an insertion event, there is a
junction with the chromosomal segment on one side and the inserted segment on the other
side. Processing of the chromosomal sides of the junctions can be tracked by examining
the sequences at these sites. NHEJ-mediated DSBR commonly involves deletion of a few
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Figure 6-7: Optimization of gene editing parameters at IL2RG with SMRT sequenc-
ing. (a) Titration of TALEN amount in K562 cells with amount of donor DNA held con-
stant at 5 µg. (b) Titration of donor DNA amount in K562 cells with TALEN DNA amount
held constant at 1 µg each TALEN. (c) Ratio of HDR to NHEJ for samples in (b). (d) Left;
Schematic of donor templates with varying arm of homology lengths. Right; Quantifica-
tion of effect of homology arm length on gene editing frequencies in K562 cells.
Bars represent three independent biological replicates; error bars, s.d.
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nucleotides. Surprisingly, of the 42 long insertions we found only 7 that involved dele-
tions of nucleotides. The remaining 35 did not involve even single nucleotide deletions.
This finding suggests that the insertion event may have a role in protecting chromosomes
from harmful deletions during DSBR. Microhomology is known to drive some small inser-
tion and deletion events during NHEJ. But analysis of the sequences flanking the external
sources of these long insertion events did not reveal any trends suggesting that these events
were driven by flanking microhomologous sequences.
6.5 Discussion
While the simplicity and flexibility of engineering TALENs and RGENs has transformed
gene editing over recent years, many questions remain about DSBR processes and gene
targeting in different cell types and at different genomic sites. Here, we present a rapid,
accurate, and sensitive strategy for analyzing gene editing outcomes and DSBR pathway
choice at endogenous loci in potentially any cell type using any type of engineered nucle-
ase. The SMRT DNA sequencing strategy offers three principle advantages over currently
available techniques:
1) Sensitive measurement of genome editing in any cell type, including primary stem cells,
without the need to make a stable reporter cell line
2) Measurement of modifications at endogenous loci regardless of transcriptional status
3) Long sequencing read-lengths that allow insight into a wide range of DNA repair out-
comes when donor templates with long arms of homology are used
Without generating reporter cell lines, we used the SMRT DNA sequencing strategy
to measure gene editing outcomes in CD34+ HSPCs, hESCs, and K562 cells. Measure-
ment at the IL2RG locus was not inhibited by the lack of transcription of this gene in
CD34+ HSPCs and hESCs, demonstrating the ability of this method to provide quantitative
and sensitive analysis of silent endogenous loci. Epigenetic status is known to affect all
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Figure 6-8: DNA repair by insertion of large sequences from various sources. (a) An
event from the IL2RG RGEN-only transfections where the insert is an exact repeat—in the
inverse orientation—of a sequence near the cleavage site. (b) Reads from the IL2RG RGEN
and Donor transfections containing inserts derived from the E. coli genome, an intronic se-
quence in chromosome 12, and a Donor plasmid. (c) Several representative SMRT reads
from the HBB TALENs-only transfections were recovered containing inserts derived from
a repetitive genomic element, one of the TALEN plasmids, and a region in chromosome
11 on the opposite arm from the HBB gene. (d) Reads from the HBB RGEN and Donor
transfections containing inserts derived from the E. coli genome and a region in chromo-
some 11 on the opposite arm from the HBB gene. (e) Reads from the CCR5 TALENs-only
transfections containing inserts derived from a TALEN plasmid and an unknown plasmid.
Wild-type (WT) sequences are shown with nuclease binding sites highlighted in yellow. In-
serted sequences in the SMRT reads are lowercase and highlighted in blue with the size and
source listed below. Deleted bases, likely resulting from sequencing errors, are represented
by hyphens highlighted in red.
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DNA-metabolism processes including transcription, replication, and repair [13, 86]. The
importance of transcriptional activation and epigenetic status for gene editing efficiency
is still largely unknown, but epigenetic modification was recently shown to impact DSBR
pathway choice [24, 63, 122, 123, 124]. The SMRT DNA sequencing strategy could be
used to further study how chromatin status influences DSBR pathway choice and gene
editing efficiency by providing analysis in a broader range of cell types in which the chro-
matin state of the targeted site is known. One other potentially important variable for gene
editing efficiency, particularly when working between different cell types, is the method of
delivery and this strategy could be used to quantitatively measure the impact of using dif-
ferent delivery methods including electroporation-based techniques, viral-based strategies,
and lipid or nanoparticle-based methods.
Genome editing with engineered nucleases can be used to create many types of changes
to a genome, and any site within an organisms genome is now a potential target. The ver-
satility of this approach, combined with the ease of synthesizing new nucleases, creates a
need for a method to evaluate different types of nucleases at different genomic locations.
In this study we used SMRT DNA sequencing analysis to measure genome editing at sites
within the IL2RG, HBB, and CCR5 genes using the three most widely used classes of en-
gineered nucleases. For the specific nucleases we investigated in K562 cells, we found that
at both the IL2RG and HBB loci the RGEN generated significantly higher frequencies of
mutagenic NHEJ than TALENs designed to overlapping sites. When transfected alone, the
IL2RG-specific and HBB-specific RGENs created very similar levels of mutagenic NHEJ,
suggesting that a similar amount of DSBs are being created at the two loci. Despite this, the
HBB-specific RGEN stimulated a significantly lower frequency of HDR than that seen at
IL2RG. Whether this difference in repair pathway utilization is the result of different chro-
matin status or the sequence composition of the target sites and corresponding donor DNA
is still unclear, but this technique could be applied to further elucidate how spatial param-
eters affect DNA repair. Additionally, moving between genomic loci we have encountered
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single nucleotide polymorphisms (SNPs) that confound measurement of NHEJ using stan-
dard mismatch detection assays [45], including one at HBB in K562 cells. The ability to
use SMRT DNA sequencing to quantify mutation frequencies even in the presence of SNPs
is another advantage of this system.
In addition to the gamut of new nucleases and target sites, molecular and genetic strate-
gies to influence DSBR pathway choice can play a significant role in achieving a desired
outcome or minimizing unwanted outcomes. By titrating the amount of donor template in
K562 cells we were able to optimize conditions for generating HDR events and alter the
ratio of HDR to NHEJ significantly. Furthermore, the long read-lengths of SMRT DNA se-
quencing allowed us to measure gene editing outcomes using donor templates with 800bp
arms of homology. These data demonstrate the advantage of using long arms of homology
to stimulate higher frequencies of HDR with plasmid donors, and this technique could fur-
ther be used to directly compare gene editing outcomes with different donor architectures
including plasmids, minicircle DNA, viral vectors, and ssODNs [16, 17, 70]. Beyond tar-
geted gene editing, this method offers a new experimental system for studying DNA repair
pathway utilization when DSBs occur at endogenous genomic loci following manipula-
tion of DNA repair genes. As was shown in this study, and previous studies, parameters
like nuclease properties, donor template architecture, cell type, and the site being modified
can influence DSBR. The SMRT DNA sequencing method thus opens up new possibilities
for studying DSBR with engineered nuclease-induced breaks, where previous work has
focused significantly on breaks induced by I-SceI at defined sites within reporter cell lines.
One area where application of SMRT DNA sequencing is challenging is the quantifi-
cation of gene modifications that result in differently sized alleles, such as when entire
linear donor templates are captured by NHEJ at ‘on-target’ and ‘off-target’ DSBs [23, 37].
PCR bias when amplifying WT and modified loci with significantly different sizes can fa-
vor shorter alleles and confound quantification, which is further effected by loading bias
for shorter molecules in the SMRT sequencing cells. For analysis of large gene inserts
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mediated by HDR, we have overcome this obstacle using embedded primers that distin-
guish between targeted and WT allele sequences while producing similar PCR amplicon
sizes [125]. Simultaneous measurement of amplicons with different lengths has also been
achieved by adding a size standard ladder to the SMRT sequencing reaction, and a sim-
ilar strategy could be used for quantification of large gene additions or NHEJ-mediated
integrations of the donor template [71].
By analyzing thousands of alleles within cell populations modified by TALENs and
CRISPRs, this technique revealed the presence of rare insertional events where large stretches
of DNA from other sources were integrated at nuclease cleavage sites. Choosing a cutoff
of >30bp to exclude sequences generated by DNA polymerase, we analyzed these inserted
sequences and found matches to the donor template and nuclease expression plasmids intro-
duced for gene targeting, sequences from nearby chromosomal sites, sites on other chromo-
somes, and sites within the E. coli genome that may have originated from trace impurities
from the plasmid purification process. The presence of these events highlights the impor-
tance of minimizing the amount of exogenous DNA added for gene targeting and illustrates
the potential for SMRT DNA sequencing to measure large, rare sequence alterations at sites
throughout the genome.
6.6 Conclusion
The recent explosion in custom gene editing technologies is ushering in a new age of
genome engineering where scientists across fields of study and using different organisms
and cell types can precisely modify essentially any locus they desire. Here we show that
SMRT DNA sequencing provides a simple, rapid, quantitative, and sensitive strategy for
measuring genome editing outcomes with different cell lines, at any endogenous loci, in-
cluding transcriptionally silent loci, and using multiple nuclease platforms. Moreover, our
strategy offers a new approach for studying DNA repair pathway utilization when DNA
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breaks occur within genomic sites that have been difficult to study using previous method-
ologies. With the flexibility to evaluate new engineered nucleases and targeting constructs
directly at desired loci without the development of reporter systems, SMRT DNA sequenc-
ing can streamline the development of genome editing projects and hasten the expansion
of these technologies to a wider range of applications.
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CHAPTER VII
FURTHER ANALYSIS OF NHEJ VS HDR
7.1 Introduction
With the new tool developed in Chapter 6 to simultaneously analyze the NHEJ and HDR
repair pathways at endogenous loci, we conducted a variety of different experiments aimed
at further understanding how to optimize gene repair therapeutic strategies.
7.2 Comparing mRNA vs Plasmid Delivery of TALENs1
There have been previous comparisons of the performance of nucleases encoded as mRNA
vs plasmids (DNA) in microinjection experiments [116], but very limited data on the per-
formance in bulk cell populations. mRNA tends to be better tolerated by cells than plasmid
DNA and can therefore be given in higher doses, which would lead to higher expected
nuclease activity. On the other hand, expression from mRNA is much more transient than
from DNA plasmids, which would lead to lower expected nuclease activity. We sought to
determine the overall effect on nuclease activity as well as to observe if any differences in
the HDR:NHEJ ratio occurred.
We nucleofected K562 cells with mRNA (synthesized by TriLink Biotechnologies, San
Diego CA) or plasmid DNA encoding TALENs targeting the IL2RG gene along with a
donor plasmid (as described previously in Figure 6-3a). SMRT analysis was used to deter-
mine the rates of HDR and NHEJ repair.
We found that the was no significant difference in HDR:NHEJ ratios between the two
different methods, however mRNA delivery resulted in substantially higher levels of both
NHEJ and HDR (Figure 7-1).
1In collaboration with Dr. Eric Kildebeck and Dr. Matthew Porteus, Stanford University.
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Figure 7-1: mRNA vs Plasmid Delivery of TALENs. n=3, error bars are s.t.d.
153
While synthesized mRNA remains much more expensive than plasmid DNA, the marked
increase in nuclease activity makes mRNA a promising option for more critical experi-
ments, such as those in primary CD34+ cells.
7.3 Enrichment of Gene Modified CD34+ Cells through FACS2
Rates of HDR in primary cells are typically much lower than in immortalized cell lines
such as the K562 model system. Therefore, an area of growing interest is the ability to
enrich the subpopulation of HDR-modified primary cells.
We constructed a donor plasmid which would fuse the gene for the mCitrine fluores-
cent protein to the HBB sequence such that expression of mCitrine would only occur from
the endogenous HBB locus (and not from the donor plasmid itself). CD34+ cells were nu-
cleofected with the TALENs previously described (Figure 6-6b) with or without the donor
plasmid. The cells were then put through a two-week erythroid differentiation protocol
so that the HBB locus would be actively expressed. At that point, a portion of the bulk
population was set aside, and the remaining cells were sorted using FACS into mCitrine+
and mCitrine- sub-populations. Genomic DNA was harvested from the cells and cDNA
libraries were created from the RNA. Both the DNA and the RNA were analyzed using the
SMRT analysis pipeline previously described [48].
Modified alleles and RNA transcripts were observed at low rates in the bulk cell popula-
tion (Figure 7-2). After FACS selection, the percentage of HDR-modified alleles increased
∼40-fold while the percentage of NHEJ-modified alleles stayed roughly equal; selective en-
richment of only HDR-modified alleles was expected because mCitrine is only integrated
in the case of HDR. While the percentage of HDR-modified alleles in the mCitrine+ pop-
ulation was ∼25%, the percentage of HDR-modified transcripts was much higher—nearly
90%. This was an unexpected result since our original hypothesis was that the percentage
2In collaboration with Dr. Adam Hartigan (Harvard), Dr. Amy Wagers (Harvard), Gabriel Washington
(Stanford), and Dr. Matthew Porteus (Stanford).
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of modified transcripts would roughly mirror the percentage of modified alleles. Possi-
ble reasons for this observation include preferential gene modification of the more highly
expressed allele and/or bias during the FACS process for selecting cells where one allele
(containing mCitrine) is expressed at much higher levels than the other allele (therefore
giving a stronger fluorescent signal). These possibilities will require further investigation.
7.4 Analysis of Many HBB Nucleases
In order to further advance gene therapy approaches for correcting sickle cell anemia, we
analyzed the HDR:NHEJ ratios of many different classes of nucleases all targeting HBB.
In addition to determining an optimal nuclease to move forward with for further sickle cell
experiments, this study also provides a direct comparison different types of nucleases all at
the same genetic locus to control for location-dependent effects.
7.4.1 Methods
7.4.1.1 Preliminary SMRT Investigation
200,000 K562 cells were nucleofected with 1000 ng of total DNA, consisting of 200 ng of
total nuclease plasmid and 800 ng of donor plasmid (or pUC control). Nucleofections were
performed in simultaneous triplicate (separate nucleofections of cells taken from the same
cultured population). After 72 hours, genomic DNA was harvested and the HBB locus was
analyzed using SMRT sequencing as described in Chapter 6.
7.4.1.2 Follow-up Illumina Investigation
200,000 K562 cells were nucleofected with 1400 ng of total DNA, consisting of 400 ng
of total nuclease plasmid and 1000 ng of donor plasmid (or pUC control). Nucleofections
were performed in biological triplicate with each replicate performed on different weeks.
After 72 hours, genomic DNA was harvested and the same sequence of the HBB locus
as described in Chapter 6 was amplified; however, the primers contained additional 5’
sequences to facilitate binding to the Illumina flow cell. Dual i5/i7 Illumina barcodes were
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Figure 7-2: Analysis of CD34+ DNA and RNA.
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added to each amplicon to facilitate multiplexing 128 samples into a single MiSeq run.
250-bp paired end (PE) sequencing was used.
Because Illumina sequencing only provides the sequences at the edges of the amplicons,
as opposed to SMRT sequencing which provides the full sequence of the amplicon, several
alterations needed to be made to the previously described analysis pipeline (Figure 6-2).
Since the total HBB amplicon length is ∼600 bp, the two 250 bp Illumina sequencing reads
do not overlap and are therefore handled separately by the modified pipeline. The following
modified initial steps were changed to accommodate the Illumina data:
1) Reads were de-multiplexed according to their i5/i7 barcodes by the internal Illumina
analysis software.
2) If the average FASTQ score of either read is below 25, the reads are discarded.
3) The 20 bp at the 5’ end of each read must exactly match the expected template sequence.
4) The read distal from the nuclease target site was pairwise-aligned to the expected HBB
sequence and the 5’ 100 bp were checked to ensure ≥80% match to the template se-
quence.
5) The 3’ 50 bp of the read proximal to the nuclease target site were also checked by
pairwise alignment to ensure ≥80% match to the template sequence.
6) If all those requirements were met, the remaining expected template sequence 3’ of the
end of the proximal read was computationally appended to the sequencing read to make
the data more closely resemble a SMRT read (which consists of the full amplicon) and
then the reads were fed into the previously developed pipeline at the allele analysis step
(Figure 6-2p) for subsequent analysis.
7.4.1.3 Donors and Nucleases
Several different repair donors were tested (Figure 7-3). In the preliminary SMRT investi-
gation, the ‘EcoRI Donor’ (which introduces an EcoRI restriction site that can be assayed
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Wild-Type: 5’-ATGgtgcacctgactcctgaggagaagtctgccgttactgccctgtggggcaaggtgaacgtggatgaagttggtggt-3’
EcoRI Donor: ←400 bp-ATGgtgcacctgactcctgaggagaagtctgccgttactgGAAtTCggggcaaggtgaacgtggatgaagttggtggt-400 bp→
"M4" Donor: ←400 bp-ATGgtgcaTctTacGccAgaggagaagtctgcAgttactgcGctgtggggcaaAgtTaaTgtTgaCgaagttggtggt-400 bp→








5’-TGCACCTGACTCCTGt - L4 TALEN
5’-TCTGCCGTTACTGCCCTGT - S136 TALEN
4F-ZFN - GGGGCAAGGTGA-3’
ZFN & TALEN 5’-ATGGTGCACCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATGAAGTTGGTGGTGA-3’
Binding Sites 3’-TACCACGTGGACTGAGGACTCCTCTTCAGACGGCAATGACGGGACACCCCGTTCCACTTGCACCTACTTCAACCACCACT-5’
R4 TALEN - ATGACGGGACACCCCGTT-5’
S120 TALEN - TACTTCAACCACCACT-5’
3’-ACGGCAATGACG - 4F-ZFN
Figure 7-3: HBB Donors and Nucleases. (upper panel) The wild-type HBB sequence
beginning with the start codon in green, followed by the corresponding sequence of differ-
ent donor plasmids with mismatches highlighted in red—all three donor plasmids had ∼400
bp flanking arms of homology to the endogenous HBB sequence on either side. (middle
panel) CRISPR/RGEN binding sites within HBB are given. PAM sequences are under-
lined and a mismatched 5’ base in the guide strand is signified by a lowercase ‘g’. (lower
panel) ZFN and TALEN binding sites within HBB are given. The L4 TALEN targets a
mismatched base relative to the wild-type HBB sequence, signified by a lowercase ‘t’—it
is designed to target the sickle mutation.
using RFLP) was used. While this donor blocked the binding of all of the nucleases (or at
least one element of each nuclease pair) tested in the preliminary study, its SNPs did not
block all of the nucleases planned for the followup study; therefore, a donor was made with
synonymous SNPs spread throughout exon 1 (“M4” Donor). In parallel to the development
of “M4”, our collaborators created the “AfeI Donor” which also contains a larger number
of synonymous SNPs as well as an AfeI restriction enzyme site.
Several different nucleases were tested (Figure 7-3). The R7, R1, R3, and R2 CRISPR
/ RGEN guide sequences have been previously described [21] while the R2d3 guide strand
is a truncated version of R2 following the findings of Fu et al. [36]. The L4/R4 TALEN
pair is the same as was used in Chapter 6. The 4F-ZFN pair is the same as was used in
Chapter 3. The S136/S120 TALEN pair was previously described by Lin et al. [69].
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7.4.2 Results
7.4.2.1 Preliminary SMRT Investigation
A wide range of performance was observed across the different types of nucleases (Fig-
ure 7-4). The L4/R4 TALENs outperformed the ZFNs, the S136/S120 TALENs, and an-
other version of the L4/R4 TALENs utilizing a bi-partite nuclear localization signal (NLS)
generated by a collaborator in terms of NHEJ, but none of those nucleases had appreciable
HDR activity above background levels. The “RH” CRISPR paired nickases (employing the
H840A mutation) performed poorly, consistent with previous results [95], in contrast to the
“RN” CRISPR paired nickases (employing the D10A mutation) which had extremely high
NHEJ and activity and moderate HDR activity as well. The single CRISPR nucleases (R2
and R3) had the highest rates of HDR as well as the most favorable HDR:NHEJ ratios. The
truncated guide strand (R2d3) showed slightly reduced NHEJ activity compared to the full
length guide strand (R2) but much lower HDR activity.
7.4.2.2 Follow-up Illumina Investigation
In order to examine some of the trends observed in the preliminary SMRT investigation in
more detail, a more comprehensive set of experiments was conducted. In order to reduce
sequencing costs for the 128 total samples, we modified the approach to be compatible with
the Illumina sequencing approach.
Because analyzing the Illumina sequencing data required modifications to the previ-
ously developed bioinformatics pipeline, we performed side-by-side comparisons of the
two different analysis methods on the same genomic DNA (Figure 7-5). Overall, the same
trends were observed between the two different analysis methods; both reported that the
RN1/RN2 paired CRISPR nickases induced high levels of NHEJ and lower levels of HDR
and that the R3 CRISPR nuclease had higher levels of HDR than NHEJ. However, the exact
reported values different slightly between the two methods and the Illumina method was
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Figure 7-4: Preliminary SMRT Investigation of HBB nucleases. Several different
types of nucleases were nucleofected into K562 cells, including ZFNs, TALENs, CRISPR
nucleases (R2 and R3), CRISPR nucleases with truncated guide strands (R2d3), D10A
paired CRISPR nickases (RN1/RN2 and RN7/RN2), and H840A paired CRISPR nickases
(RH7/RH2). n=3, error bars are s.t.d.
characterized by much higher variability in the measurements (indicated by higher stan-
dard deviations of the replicates). Overall, while the current Illumina analysis pipeline has
clearly not reached the same level of refinement and precision as the SMRT pipeline, it
appears to provide reasonably accurate results and warrants some, but not complete, confi-
dence in the results obtained for the following experiments.
Two pairs of TALENs and a pair of ZFNs were analyzed. As in the preliminary SMRT
analysis, only moderate levels of activity were observed (Figure 7-6). In contrast to the
robust NHEJ activity observed for the S136/S120 TALENs in 293T cells (∼60% modified
alleles [69]), extremely low activity was seen under these conditions in K562 cells. The
levels of NHEJ for the L4/R4 TALENs were relatively constant in the presence or absence
of a donor. However, the HDR activity using the AfeI donor was much higher than when
using the “M4” donor.
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Figure 7-5: Comparing SMRT and Illumina Analysis Methods. The same 6 genomic
DNA samples (3 replicates of each experiment) were analyzed by SMRT and by Illumina
for HDR and NHEJ repair. n=3, error bars are s.t.d.
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Figure 7-6: TALEN and ZFN Analysis. Two pairs of TALENs and a pair of ZFNs were
analyzed, in the presence or absence of either the “M4” or AfeI donors. n=3, error bars are
s.t.d.
Working with collaborators3, we tested the performance of a “mini-circle” version of
the AfeI donor. Mini-circles are plasmids that are processed to remove elements that are es-
sential for production in E. coli but are not relevant for the final purpose (such as antibiotic
resistance gene or origins of replication). For genome engineering applications, this results
in a plasmid that consists of just the homology arms and the internal region with the de-
sired SNPs to be integrated. We hypothesized that the higher numbers of donor molecules
(since total donor mass is held constant and mini-circles are smaller than plasmids) com-
bined with the longer persistence of the mini-circles in cells [17] might lead to higher levels
of HDR. While the total level of gene modification was similar between the experiments
with the three different donors, the mini-circle experiments had markedly lower levels of
HDR (Figure 7-7). Surprisingly, the mini-circle donor performed worse than the parental
3In collaboration with Carol Dickerson and Dr. Steffen Meiler, Georgia Regents University, Augusta GA.
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Figure 7-7: Mini-circle Donor Analysis. n=3 for most samples, n=2 for Nuclease+Mini-
Circle and Nuclease+PreMiniCircle. error bars are s.t.d.
“pre”-mini-circle plasmid.
Truncated guide RNAs have been shown in previous studies to have reduced off-target
effects, but sometimes at a cost of reduced on-target activity. We tested a guide RNA
with a 3 bp truncation compared to the full length guide RNA (Figure 7-8). In contrast to
the substantial decrease in HDR efficiency we observed in the preliminary SMRT analysis
(Figure 7-4), the full-length and truncated guide RNAs performed at statistically indistin-
guishable levels in these experiments (although the mean activities were slightly lower with
the truncated guide RNA for both NHEJ and HDR).
Two different configurations of paired CRISPR nickases were analyzed. In order to
better understand the contributions of each component of the system to the levels of NHEJ
and HDR, each individual guide was analyzed separately as a nickase and as a nuclease in
addition to analyzing the full paired nickase systems (Figure 7-9). Consistent with previous
reports [118], individual nickases can, but do not always, trigger NHEJ and HDR (i.e. the
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Figure 7-8: Truncated Guide RNA Analysis. n=3, error bars are s.t.d.
R-1 guide) even without their paired partner. This phenomenon seems to be highly guide-
strand dependent with no known features being yet able to predict this behavior a priori.
Apart from the aberrantly low levels of NHEJ activity observed for the “R-2 Nuclease
Only” sample, the paired nickases had similar levels of total gene modification activity
as the single nucleases. However, in contrast to the results from the preliminary SMRT
analysis (Figure 7-4), these experiments showed the paired nickases having equal or greater
rates of HDR as the single CRISPR nucleases.
7.4.3 Discussion
High-throughput sequencing analysis allowed a detailed look at the rates of NHEJ and
HDR for a wide variety of nucleases at the HBB locus. While the newer Illumina analysis
pipeline provided similar results as the well-validated SMRT pipeline, there was increased
variability and slight discrepancies between the measurements. Given the marked cost
advantage of Illumina, further refinement of the analysis pipeline should provide a valuable
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Figure 7-9: Paired CRISPR Nickase Analysis. Two different paired CRISPR nickase
configurations were analyzed; the R-2 guide paired with the R-1 guide (upper) and the
R-2 guide paired with the R-7 guide (lower). n=3 for most samples, error bars are s.t.d.
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tool for use in cases where it is acceptable to place one of the PCR primers inside the
homology arms near the nuclease cut site; in cases which require both primers to be outside
the homology arms, SMRT sequencing remains the only available method.
Although the preliminary SMRT analysis pointed to several major performance dif-
ferences—particularly related to HDR rates and NHEJ:HDR ratios—between the different
types of nucleases, these trends were largely not observed in the follow-up Illumina study.
While it is clear that CRISPR systems outperform TALENs and ZFNs, the Illumina anal-
ysis showed no clear differences between CRISPR nucleases, truncated guide strands, and
paired CRISPR nickases. The exact reason for these differences is unclear, but it may be
related to the fact that all SMRT experiments were performed from a single passage of the




The tools created in this thesis represented ‘first-in-class’ developments of new methods
of off-target prediction and analysis of DNA repair outcomes. However, there are several
areas in which these tools could be improved with future work.
8.1 Accurately Predicting CRISPR Off-Target Sites
Although several online tools are now available to search a genome for CRISPR sites with
homology to the intended target sequence [53, 22], none of the tools provides a quantitative
basis for their rankings nor their overall predictive power. Indeed, recent studies have
shown that current online tools routinely do not locate most known CRISPR off-target sites
[119, 22]. The poor performance of current tools is likely due to their simplistic models, but
the current understanding in the field as a whole on the underlying biology of what dictates
the observed performance differences between CRISPR guide strands is still fairly limited,
although single molecule studies have provided some useful insights [111]. However, the
increasing numbers of researchers involved with CRISPR and the tendency of CRISPRs to
cause readily observable off-target effects has led to an accelerating pace of the discovery of
bona fide CRISPR off-target sites; a recent study validated over 100 off-target sites [119],
although it was still unable to divine any broad principles governing CRISPR off-target
activity. The rapid rise in the number of CRISPR off-target sites provides hope that in the
near future there may be a large enough dataset on which to attempt machine learning, even
in the absence of preconceived models of the most important features that distinguish bona
fide off-target sites from other sites with homology to the intended target.
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8.2 Cell-Type-Specific Off-Target Prediction
The intracellular genomic context of a particular off-target location can have a large in-
fluence on what level (if any) of off-target activity occurs. One study found that at two
identical off-target DNA sequences, one site had off-target activity at nearly the same fre-
quency as the on-target site while the other site had no detectable off-target mutagenesis
[21]. Chromatin status, methylation, histone modifications, or other bound proteins are
all factors that can influence the level of nuclease activity at an off-target site, but these
properties are often cell-type dependent. As most nucleases would only need to be applied
clinically in one certain cell type, accurate predictions could greatly enhance the ability to
rationally design nucleases to be less prone to off-target activity in that particular cell as
well as to narrow the focus of off-target assessments on the most appropriate regions.
Databases such as the ENCODE project [32] now provide large amounts of information
about the genomic context in particular cell types. Unfortunately, this is only one side of the
coin—sufficiently large datasets of comparisons of nuclease off-target activity across dif-
ferent cell types must still be performed in order to better understand how different genomic
contexts affect the propensity of a nuclease to cleave that location. However, intermediate
steps in this process could include annotations in the off-target prediction summaries about
known attributes such as whether a site was within a DNAse I hypersensitivity region. Such
information might still provide some utility to end-users even without formal quantitative
algorithms to assess the impact of such factors on off-target activity levels.
8.3 Quantitative Prediction of Off-Target Frequencies
Correlating the rank order of off-target predictions with the observed off-target mutagenesis
has long been a goal in this field. However, even experimental-based off-target character-
ization methods have not had much success in this area (Figure 3-4). In fact, it was only
very recently that any published experimental-based off-target prediction method was able
to achieve any correlation between its predictive ranking and actual observed off-target
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activity [119]. However, there are several challenges in implementing this as a gener-
alized predictive bioinformatic algorithm. As mentioned above, cell-type-specific factors
can play a large confounding role in the exact frequency of mutagenesis at a given off-target
site. Furthermore, compiling data from multiple studies in order to assemble an appropriate
training set would be complicated by different doses, incubation times, and nuclease deliv-
ery methods used in different studies—all of which are factors that affect the on-target:off-
target activity ratios. Given the different downstream applications of nucleases, it seems
unlikely that the field as a whole will adopt more standardized off-target testing conditions
since those may not be as relevant for their particular area of interest. Therefore, unless one
institution or consortium dedicates itself to conducting a large number of off-target inves-
tigations of different nucleases all under similar experimental conditions, it seems unlikely
that computational quantitative prediction of off-target frequencies will occur in the near
future.
8.4 Optimizing Illumina Sequencing of NHEJ vs HDR
Although the short readlengths of Illumina sequencing (compared to SMRT) impose cer-
tain restrictions, the cost-savings available for large scale studies of NHEJ vs HDR makes it
an attractive option to pursue. Current reliable Illumina readlengths are ∼250 bp (although
newer 300 bp chemistries are being further developed). While this is not sufficient to ob-
serve integration of large pieces of exogenous DNA (Figure 6-8) nor in cases where both
PCR primers must be placed outside of the homology arms in order to completely elimi-
nate any non-specific donor amplification—we have not found this to be an issue in K562
cells, but we observed some non-specific amplification of the donor plasmid in recent ex-
periments in hESCs—but can be sufficient in some applications. Specifically, if one PCR
primer is inside the donor homology arms (while the other primer is outside the homol-
ogy arms), then Illumina can provide sequence information about the ∼100 bp flanking the
nuclease target site. In our preliminary investigation, we found that Illumina sequencing
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could provide reasonably accurate readouts (Figure 7-5) at less than 20% of the cost of
SMRT sequencing for large scale analyses. However, the Illumina readout is currently not
as accurate or precise as the SMRT measurements. Because Illumina sequencing reads are
formatted differently than SMRT (uni-directional paired reads from the edges of the ampli-
con rather than providing the full amplicon sequence) and because the Illumina chemistry
is prone to different types of sequencing errors and artifacts than SMRT chemistry, sev-
eral additional changes to the bioinformatics analysis pipeline in order to accomodate these
differences will be needed in order to allow the Illumina approach to provide comparable
results as SMRT. Further optimizations of the experimental protocol are also possible in-
cluding more advanced size selection of the PCR amplicons and variation in the number of
PCR cycles in each of the steps.
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APPENDIX A
EFFECT OF SERUM STARVATION ON PAIRED CRISPR/CAS9
NICKASE ACTIVITY
A.1 Introduction
Although paired Cas9 nickases create indels at very high rates, most measurements have
been made in rapidly dividing cells. The nicks in these cases are typically separated by ∼35
bp, a much larger distance than the typical 4 bp that separates the breaks made by FokI. One
hypothesis was that the indels observed after paired nickase treatment might be generated
by a different method than cannonical NHEJ repair; the nicks might be causing interference
during DNA replication which would lead to deletion of the intervening sequence. In order
to test this hypothesis, we reduced the rate of cell division using serum starvation and
measured the activity of CRISPR nucleases and paired nickases.
A.2 Methods
On Day 0, K562 cells were passaged into media containing 10% FBS (standard treatment)
or no FBS (serum starvation). On Day 1, the K562 cells were nucleofected with Cas9 plas-
mids and plated in fresh media (+/- serum). On Day 4, cells were harvested and genomic
DNA was analyzed by the T7E1 assay to test for indel activity.
A.3 Discussion
Serum starvation had no effect on the activity of Cas9 nucleases but did reduce the activity
of Cas9 nickases (Figure A-1). However, the activity of the Cas9 nickases under serum
starved conditions was still substantially greater than the activity of the Cas9 nucleases.
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Figure A-1: Effect of Serum Starvation on Cas9 Activity. Error bars are s.t.d., n=3. P
value derived from Students’ paired t-test (two-tailed).
Clearly, paired Cas9 nickases are still active in cells undergoing limited cell division, how-
ever the reason for the observed reduction in activity requires further investigation.
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